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Chapter 1  
Human respiratory syncytial virus 
1.1 HRSV history, classification and global burden 
Human respiratory syncytial virus (HRSV) was first isolated in 1956 from a chimpanzee with 
respiratory symptoms characterized by coughing, sneezing and a nasal discharge containing mucus 
and pus. It was identified as a virus and named “Chimpanzee Coryza Agent”. Antibodies against this 
virus were also detected in children and a laboratory worker, suggesting that this virus could also 
infect humans (1). Later, Chanock et al. isolated the same virus from children with symptoms of a 
cold. Since the virus was able to form syncytia in human cells in tissue culture the name of the virus 
was changed to “Respiratory syncytial virus” (2). Soon it became clear that HRSV was a common 
cause of mild to severe respiratory tract disease. 
HRSV is an RNA virus classified in the family of Paramyxoviridae, subfamily Pneumovirinae, genus 
Pneumovirus (3). Characteristics of the Paramyxoviridae are (I) a non-segmented, single stranded, 
negative-sense RNA genome; (II) transcription of the genome occurs through a transcriptional stop-
start mechanism, which results in multiple mRNA molecules; (III) the replication of the virus occurs in 
the cytoplasm of the cell; (IV) virions possess a lipid membrane, derived from the host cell by 
budding of progeny virus; (V) entry in the host cell occurs through a fusion process of the viral and 
cellular membranes. Other viruses, closely related to HRSV, in the pneumovirus genus are: bovine 
RSV (BRSV), ovine RSV, caprine RSV and pneumovirus of mice. HRSV can be divided into two major 
antigenic subgroups, designated A and B, based on in vitro neutralization assays and reactivity with 
monoclonal antibody panels (4). Within each of the two subgroups, several different genotypes have 
been identified which can co-circulate at the same time at the same location. Shifts in dominance 
between the A and B subtypes typically occur every one or two years (5) (Figure 1.1). In contrast to 
other viruses such as influenza A virus, which change quickly due to strong immune pressure, HRSV 
evolves slowly and new strains do not immediately dominate during the following epidemic. An 
example of this is the HRSV B Buenos Aires (BA) strain, which contains a 60 nucleotide duplication in 
4 
the G protein: this strain was first described in 1998 and spread throughout the world rather quickly. 
It wasn’t until 2005 that this strain became the dominant B genotype (6). 
 
 
Figure 1.1 Seasonality of HRSV infections in Belgium. Seasonal frequency of antigen-positive HRSV 
infections (curves) and monthly distribution of typed HRSV-A (white bars) and HRSV-B (black bars) 
infections among hospitalized patients in Belgium (1996 to 2006). Initial letters of months are given along 
the y axis (7). 
HRSV causes seasonal epidemics of respiratory disease during late autumn or winter (Figure 1.1). It is 
globally the most important cause of acute lower respiratory infections in young children and babies, 
especially when premature (8). Typically, HRSV infects at very young age: almost every child has been 
infected during its first year of life, and by the age of two virtually all children have been infected at 
least once and some even twice (9). A prospective study performed by Glezen et al., of children 
infected during the first year of life revealed that 47 % and 45 % of these children were re-infected 
during the second and third year respectively (9). Remarkably, HRSV can infect the neonate, despite 
the presence of maternally derived HRSV-specific serum IgG antibodies in this population. A recent 
study showed that in 2005 HRSV was responsible for over 30 million cases of acute lower respiratory 
tract infections (ALRI) in children younger than five years old (10). Approximately 10% of these 
children required hospitalization due to ALRI caused by HRSV. Moreover, it is estimated that up to 
200,000 children younger than five years old die due to complications caused by HRSV, most of which 
occur in developing countries (10). Furthermore, severe bronchiolitis due to HRSV infection during 
infancy has been associated with an increased incidence of recurrent wheezing and asthma in later 
childhood (11). It is however not clear whether the HRSV infection is the cause of the later asthma, or 
whether children with a genetic predisposition for asthma are more susceptible to severe HRSV 
induced bronchiolitis. Re-infections are common in adults (9). The disease symptoms in adults 
however are less severe than in children, as it mostly manifest as a mild upper respiratory (URT) 
infection (12). Still, it is seen as the second most important cause of adult respiratory disease, after 
influenza infections (13). Several groups are more susceptible to severe HRSV bronchiolitis, such as 
premature born children, children with underlying heart- and/or lung disease, and children with 
immunodeficiency disorders (14). One study estimated the hospitalization rate during the first year 
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of life in HRSV infected children with immunodeficiency as high as 38%, compared to 3% for healthy 
control children (15). Also in immunosuppressed adults, such as leukemia or hematopoietic stem cell 
transplant patients, HRSV is an important cause of morbidity and mortality, with mortality rates 
ranging between 80% and 100% in HRSV infected patients (16). Besides an important cause of infant 
respiratory disease, HRSV is more and more recognized as an important cause of illness in the 
elderly. In this population, HRSV causes pneumonia, bronchiolitis and exacerbation of chronic 
obstructive pulmonary disease; conditions that often lead to hospitalization and excess mortality in 
this age group (17).  
Disease symptoms during a primary HRSV infection can vary strongly among individuals. In most 
young children a primary HRSV infection is restricted to the URT. In 25% to 40% of the cases however 
the infection spreads to the lower respiratory tract (LRT), resulting in bronchiolitis or pneumonia (9). 
These children have symptoms such as coughing, sneezing, rhinorrhea, wheezing and fever. In some 
severe cases of HRSV children experience episodes of apnea (18).  
Currently, no vaccine exists that can inhibit HRSV infection. The only preventive measure currently 
available is a passive immunoprophylaxis therapy. The first developed therapy, named RSV 
Intravenous Immune Globulin (RSV-IVIG, RespGam
TM
, produced by MedImmune) consisted of human 
IgG prepared from donor sera that had been screened for high HRSV-neutralizing titers. These 
antibodies are administered by monthly intravenous infusion, for 4 to 5 months during the HRSV 
season, to children at risk of developing severe HRSV-induced disease. Given prophylactically, RSV-
IVIG reduces the frequency of hospitalization by 55% and the duration of stay in intensive care unit 
by 97% (19, 20). Since 2004 this therapy is no longer being used and is replaced by Palivizumab 
(Synagis
TM
, MedImmune) (21, 22). This new treatment consists of an HRSV F protein-specific 
neutralizing monoclonal antibody that was created by humanizing a mouse monoclonal antibody. 
Even though Palivizumab is comparable in efficiency of reducing HRSV hospitalization as RSV-IVIG, it 
is more effective on a weight basis, allowing administration of smaller volumes. In addition, 
Palivizumab is administered by monthly intramuscular injection rather than an intravenous infusion 
which takes several hours. Due to high costs associated with the treatment, Palivizumab is only given 
to children that have a high chance of developing severe disease upon an HRSV infection, such as 
premature born baby’s or infants with underlying heart or lung disease (23). Table 1.1 gives an 
overview of current and past prophylactic RSV treatments. 
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Table 1.1 Prophylactic RSV treatments 
 
Name Description Application Clinical study results. 
Comments. 
Ref 
RespiGam ® Enriched RSV 
immunoglobulin, 
produced from 
pooled human 
plasma that 
contained high RSV 
neutralizing activity 
Approved in 1996 for 
preterm infants with and 
without CLD. 
Contraindicated for use in 
children with CHD.  
Intravenous infusion (750 
mg/kg). 
 
Reduces incidence of RSV 
hospitalization by 41%. Total 
number of RSV hospitalization 
days reduced by 55%. 
Significant reduction of disease 
severity. 
Drawbacks: large fluid volume 
necessary for infusion. Risk of 
transmitting blood-borne 
infections. 
Withdrawn from the market in 
2004. 
19 
20 
Palivizumab Humanized version 
of the RSV 
neutralizing 
antibody MAb 
1129. The six CDRs 
of the mouse MAb 
were grafted on the 
framework of a 
human IgG1 MAb. 
Approved in 1998 for 
premature born infants 
with CLD or premature 
birth (≤ 35 weeks 
gestational age). 
Approved in 2003 for 
infants with CHD.  
Five monthly intramuscular 
injections (15 mg/kg) 
Significant reduction in RSV 
hospitalization (55% reduction). 
Significant reduction in total 
days of hospitalization and in 
days with increased oxygen 
administration. 
21 
Motavizumab 
 
Derivative of 
palivizumab with 13 
aa changes to try to 
improve its 
biological 
properties.  
Not available on the 
market because clinical 
trials did not reveal an 
improvement over 
palivizumab. 
Five monthly intramuscular 
injections (15 mg/kg) 
No statistically significant 
difference in the duration of 
RSV hospitalization, number of 
patients requiring supplemental 
oxygen and intensive care 
submission between 
motavizumab and palivizumab. 
261
262
263 
MAb=monoclonal antibody; CDR= complementary determining region; CLD=chronic lung disease; CHD=chronic 
heart disease 
1.2 The HRSV virion and proteins 
Human respiratory syncytial viruses are spherical or filamentous particles. Their outer membrane is 
made up of a lipid bilayer which is derived from the host-cell plasma membrane.  The 
transmembrane glycoproteins F, G and SH protrude through this membrane as spikes. The matrix 
protein (M) forms a core lining the inside of the viral membrane. A helical nucleocapsid is located 
within the matrix shell and comprises the viral genome, in association with the nucleoprotein (N), the 
viral polymerase (L) and the phosphoprotein (P) (Figure 1.2). The HRSV genome consists of a single 
negative-sense strand of RNA of 15.2kb in length. The genome encodes ten genes in the order 3’ 
NS1-NS2-N-P-M-SH-F-G-M2-L 5’ (13).  
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The nucleoprotein (N). The viral nucleoprotein is tightly bound to the viral RNA, to form the viral 
ribonucleoprotein (RNP). The N protein functions to stabilize the single stranded RNA molecule and 
most likely it also shields the RNA from host pattern recognition receptors, such as RIG-I and MDA-5, 
which could initiate the host anti-viral response upon detection of cytoplasmic tri-phosphorylated 
RNA or dsRNA respectively (13). The RNP is the template for viral transcription. 
 
The large polymerase (L). The L protein performs RNA synthesis, as well as capping and 
polyadenylation of the mRNA transcripts (25). As the name suggests, this protein is very big: it 
consists of 2165 amino acids.  
 
The phosphoprotein (P). The P protein is a homotetramer and is an essential co-factor of the L 
protein. Besides the L protein, it also interacts with the N and the M2-1 protein (26). During RNA 
synthesis, its function consists of opening the tight structure of the RNP, to allow the L protein to 
reach the RNA for transcription. It is phosphorylated at several sites, hence its name (27). 
 
The matrix (M) protein. The M protein lines the inner side of the viral membrane. It plays a role in 
budding of progeny viruses (28). Upon expression of the viral transmembrane proteins, the M 
proteins tightly assemble at lipid rafts in the membrane, an interaction which is not seen when viral 
glycoproteins are not present (29).  
 
Figure 1.2 Structure of human respiratory syncytial virus particle. The HRSV virion is made up of a lipid 
bilayer with 3 glycoproteins inserted into it: the fusion protein, the attachment (G) protein and the small 
hydrophobic (SH) protein. The matrix protein lines the inner surface of the membrane and surrounds the 
viral ribonucleoprotein (RNP) complex. The viral RNP consists of the viral RNA surrounded by the 
nucleoprotein, and is associated with the viral nucleoprotein and large polymerase. The nonstructural 
proteins NS1 and NS2, and the regulatory proteins M2-1 and M2-2 are not shown. Adapted from (24) 
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The M2 proteins. HRSV encodes two M2 proteins from overlapping reading frames. M2-1 is a 
homotetramer that binds to N and the viral RNA and functions as a transcription elongation factor: 
when absent, transcription is terminated prematurely (30, 31). The second M2 protein, M2-2, 
encoded from a second downstream AUG, is a small, not abundant protein that accumulates during 
infection. It is responsible for a switch from transcription to replication of the viral genome (32). 
 
The nonstructural proteins (NS1 and NS2). Both NS proteins are involved in the inhibition of the host 
IFN response at multiple levels (reviewed in (13)). Mutant strains lacking one or both NS proteins are 
viable, indicating that both proteins are dispensable, however such mutants grow much slower in 
vitro than wild type HRSV and are highly attenuated in vivo (33-35).Besides the direct inhibition at 
several steps of the IFN pathway, the NS1 protein is also involved in an indirect mechanism of IFN 
inhibition, through inhibition of RNA synthesis. Overexpression of NS1 protein in a minireplicon 
system results in inhibition of viral RNA transcription and replication (36), which might serve as a 
safety mechanism of the virus to prevent massive production of viral RNA which could trigger host 
pattern recognition receptors (such as RIG-I, MDA-5 or PKR) and would activate the host IFN 
response. In this way the NS1 is indirectly responsible for inhibition of the host IFN mechanisms. 
 
The small hydrophobic (SH) protein. SH is the smallest of the three transmembrane glycoproteins of 
HRSV: it consists of only 63 amino acids. The monomers aggregate to homopentamers with a pore 
like structure in the membrane. SH pentamers can function as ion channels, however, the exact 
function of this in the HRSV replication cycle is still unclear (37, 38). Mutant viruses lacking SH have 
been developed, indicating that the protein is not essential for virus transcription or replication; 
however these viruses are attenuated in vivo in mice and chimpanzees (34, 39). 
 
The attachment glycoprotein (G). The G protein is a type II transmembrane protein with an N-
terminal transmembrane domain, leaving the C-terminal two thirds of the protein oriented externally 
(13). It is also present in a second, secreted form that arises from transcription starting at a second 
downstream AUG (40-42), which leaves out the N-terminal transmembrane domain. In vitro it was 
shown that this protein functions as a decoy, to catch neutralizing antibodies away from the virion 
(43), however these observation were not confirmed in in vivo studies in mice, and the relevance of 
this finding for HRSV infection in humans is not known. The G protein is characterized by a high 
degree of glycosylation, both of the N- and O-type (44). G is the protein with the highest degree of 
variability among isolates: only 53% of homology is present between subgroups A and B. Also within 
the same subgroup a reasonable amount of variability can be found: 20% between HRSV A isolates 
and 9% between isolates of subgroup B (45). One central region in the G protein, comprising residues 
164 to 176 however is highly conserved. This region overlaps with a region that contains 4 cysteine 
residues which form disulfide bonds, resulting in a cysteine noose (46). The most downstream pair of 
cysteines forms a CX3C motif, which resembles the CX3C motif in the chemokine fractalkine (47). 
Binding of fractalkine with its receptor CXC3R1, expressed on leukocytes, results in activation of the 
leukocytes and trafficking to the lung. Interaction of the G protein CX3C motif with this receptor 
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interferes with CX3CR1 receptor signaling, resulting in less trafficking of leukocytes to the lungs (48). 
In this way the G protein can interfere with the antiviral T cell response. The G protein functions as 
the attachment protein for HRSV since G protein specific antibodies can inhibit attachment of virions 
in vitro, whereas F protein specific antibodies inhibit fusion but not attachment (49). (See below – 
replication cycle). Together with the F protein, the G protein is the major antigenic target to which 
antibodies are directed. Remarkably, G protein specific antibodies are less protective and have less 
neutralizing activity than antibodies targeting the F protein (50).   
 
The fusion protein (F). The F protein, the third membrane protein, is present at the viral outer 
surface as spikes protruding the membrane. F is a type I fusion protein that mediates fusion of the 
viral membrane with the cell membrane, resulting in the release of the viral nucleocapsid in the 
cytoplasm. It is also responsible for fusion of an infected cell with a neighboring cell, the so called 
syncytium formation (51). The F protein is present as homotrimers. Activation of the F protein trimer 
requires cleavage of the inactive F0 precursor by a host furin-like protease to yield the F1 and F2 
chains, which remain linked by disulfide bridges (Figure 1.3). Cleavage occurs at two different sites, 
hereby releasing a 27 amino acid peptide (p27) of which the function is unknown (52). The F1 
polypeptide contains the fusion peptide, followed by a heptad repeat region (HR-A), a globular 
domain, HR-B, a transmembrane domain and a C-terminus. Together with the G protein, the F 
protein is the major target of antibodies. Five major antigenic regions have been located in the fusion 
protein (antigenic site I, II, IV, V and VI) by identifying amino acids that were altered in antibody 
escape mutants (53, 54). Antigenic site III was mentioned in early studies (55), however in later 
studies this site was no longer mentioned as an antigenic region in the fusion protein (54). Sites II and 
IV are the best characterized. Antigenic site II (also called site A) contains amino acids 255 to 275 and 
is the recognition site for palivizumab (55), a humanized monoclonal antibody used prophylactically 
against HRSV. Antigenic site IV (also known as site C) includes residues 422 to 438 (53, 55) and is the 
target site for monoclonal antibodies such as 101F (56) and MAb 19 (55).  
 
 
  
Figure 1.3 Schematic representation of the HRSV fusion protein. Arrows indicate the furin cleavage sites. 
The peptide p27 is released after cleavage. The F1 and F2 fragments which are produced as a result of furin 
cleavage are indicated. CT, cytoplasmic tail; SP, signal peptide; TM, transmembrane region. HR-A and HR-B, 
heptad repeat region A and B. 
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1.3 The HRSV replication cycle 
Attachment. For a long time it was thought that attachment occurred through interaction of the G 
protein with glycosaminoglycans (GAG) (57). The exact cellular receptor though was unknown. 
Although the G protein has been shown to be important for replication in vivo, it was not essential 
for replication in vitro: mutants lacking the G protein are viable in cell culture (58-61). Recently 
however nucleolin was proposed as the cellular receptor for HRSV, through interactions with the 
fusion protein (62). The results suggest that a more complex process of attachment occurs, in which 
both the G and the F protein are involved in two independent binding events to both GAGs and 
nucleolin. The exact mechanism of attachment still needs to be unraveled. 
 
Fusion. Fusion of the viral membrane with the cellular membrane is carried out by the fusion protein 
in a process similar to other Paramyxoviridae (Figure 1.4). Upon attachment, the metastable fusion 
protein is triggered to undergo a series of conformational changes, leading to the formation of a 
stable post-fusion conformation (Figure 1.5) (63, 64). The prefusion form of the F protein is lollipop-
shaped with a stalk consisting of a coiled-coil of HR-B and a globular head in which HR-A is packed. 
During the conformational changes, the fusion peptide (located adjacent to HR-A) is inserted in the 
cellular membrane. The C-terminal coiled-coil of HR-B then dissociates, wraps around the globular 
head and joins the HR-A helices, to form the post-fusion six-helix bundle. These rearrangements 
brings the viral and cellular membrane into proximity, ultimately leading to fusion of both 
membranes (Figure 1.4) and release of the viral nucleocapsid into the cytoplasm. The remainder of 
the viral replication cycle takes place in the cytoplasm. Interestingly, the major antigenic sites II and 
IV, which are present in the pre-fusion form are conserved in the post-fusion conformation 
(Figure 1.5).  
 
Figure 1.4 Model of F-mediated membrane fusion. (A) The prefusion form of the F protein is 
lollipop-shaped with a stalk consisting of a coiled-coil of HR-B (blue) and a globular head in which HR-A 
(green) is packed. (B) During the conformational changes, the fusion peptide (located adjacent to HR-A) is 
inserted in the cellular membrane and the C-terminal coiled-coil of HR-B dissociates. (C) Structural 
rearrangements bring the cellular and viral membranes into proximity. (D) After fusion, the F protein adopts 
the post-fusion conformation consisting of a six-helix bundle made up of the HR-A and HR-B helices. 
Adapted from (63). 
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Figure 1.5 HRSV F protein conformational changes during fusion. (A) Surface representation of a 
prefusion model of the HRSV F protein. Antigenic site II (magenta)  and IV (cyan) are indicated by colored 
outlines. The HR-A and HR-B surfaces are pink and purple respectively. (B) Surface representation of the 
postfusion structure, annotated as in A. Adapted from (65). 
 
Transcription and translation. Transcription is carried out by the viral L protein, with the help of the 
co-factors P, N and M2-1 (reviewed in (3)). The viral genome contains a single polymerase entry site 
at its 3’ end. Between every pair of consecutive genes, conserved gene-end and gene-start 
sequences are present to guide the viral polymerase during the process of transcription. The gene-
end sequence contains several U residues, which leads to polyadenylation of the mRNA transcript. 
Upon completion of the transcript, the mRNA is released. At this point, half of the polymerases 
detach from the template strand, which can then only re-initiate transcription at the polymerase 
entry site, at the 3’ end of the template strand. Only 50% of the polymerases continue along the 
strand for transcription of the more downstream genes. As a consequence, a gradient in mRNA 
transcripts exist, with mRNA of the 3’ end genes being more abundantly present than those at the 5’ 
end (66). An important co-factor in this process of sequential transcription is the M2-1 protein, which 
functions as a transcription elongation factor. Its absence results in preterm dissociation of the 
polymerase from the RNA template, leading to incomplete mRNAs and almost complete absence of 
the more downstream mRNAs (30, 31). Transcription in the presence of M2-1 leads to the production 
of 10 distinct mRNAs (67). Each of these mRNAs is translated into one protein, except for the M2 
12 
mRNA which encodes the M2-1 and M2-2 proteins from overlapping ORFs through a process of re-
initiation of translation (68, 69). The HRSV genome contains one exception to the transcription 
process described above: the transcriptional start sequence of the L gene is 68 nucleotides more 
upstream than the transcriptional stop sequence of the M2 gene. Studies with mini-replicons have 
shown that after transcription of the M2 gene the viral polymerase scans the viral RNA in both the 
upstream and downstream direction to locate the L gene start. This scanning mechanism is thought 
to be a general process that occurs at each gene junction during sequential transcription (70, 71).  
 
Replication. Replication of the viral genome occurs through a full length, positive-sense RNA 
intermediate. To achieve this, the viral polymerase should “ignore” the gene-end and gene-start 
signals, resulting in 1 complete RNA strand. This positive-sense RNA strand subsequently serves as a 
template for the production of a full length, negative sense viral genomic RNA (13). The M2-2 protein 
is thought to regulate the switch from RNA transcription to RNA replication. Recombinant HRSV 
lacking the M2-2 protein show a decrease in RNA replication and an increase in viral mRNA synthesis 
(32). It was suggested that this process is dependent on the intracellular concentration of the M2-2 
protein: early in the infection when M2-2 concentration is still low viral mRNA synthesis 
predominates whereas at later time points during the infection, when the concentration of M2-2 
gradually rises, RNA replication is favored, in preparation for viral assembly and budding (32).  
 
Packing and assembly. The last step in the viral replication cycle is the packing of the viral genome 
and proteins near the cell membrane and budding of progeny viruses. Assembly and budding occur 
at the apical side of polarized cells in filamentous structures (72, 73). The exact mechanism through 
which assembly of progeny virus occurs is not yet completely understood, however, it is clear that 
the M and F proteins play an important role in this process. The M protein associates tightly at lipid 
raft structures in the membrane, only when the viral glycoproteins are present (29). This might be an 
effect of the F protein cytoplasmic tail, since mutant viruses with a mutation in the F cytoplasmic tail 
were unable to attract the viral RNP to the site of assembly (74).  
1.4 The immune response to HRSV infection 
Airway epithelial cells form the main target for HRSV infection in the lungs. Once infected, the virus is 
sensed by these cells and an immune response is started. The immune response to HRSV is complex 
and the viral proteins are capable of interfering with this response at several levels. The immune 
response can be roughly divided into an innate immune response, which is a more general defense 
mechanism independent of the pathogen and an adaptive immune response, which starts off later, 
however is specific for the pathogen.  
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The innate immune response 
The virus is sensed by the immune system through pattern recognition receptors (PRR), which detect 
a variety of pathogen associated molecular patterns (PAMP). To date, three classes of PRRs have 
been identified, including toll-like receptors (TLRs), retinoic acid-inducible gene (RIG)-I-like receptors 
(RLRs), and nucleotide-binding oligomerization domain (NOD)-like receptor (NLRs) (75, 76) and HRSV 
can be recognized by members of all three classes. Binding of HRSV to these PAMPs leads to signaling 
through NF-κB, mitogen-activated protein kinases (MAPKs) and/or members of the interferon 
regulatory factor (IRF) family, resulting in the expression of inflammatory cytokines, chemokines and 
interferons, which activate and/or recruit innate, as well as adaptive, immune cells (77). TLRs are 
expressed on a wide variety of cells, including eosinophils, neutrophils, dendritic cells (DC), 
macrophages and epithelial cells. Several TLRs have been shown to be involved in the immune 
response to HRSV, including TLR2 (78), TLR3 (79), TLR4 (80, 81) and TLR7 (82). While TLR2 and TLR4 
are found on the cell membrane, TLR3 and TLR7 are present in intracellular vesicles, such as 
endosomes.  
TLR4 recognizes the HRSV F protein using a CD14 co-receptor. Binding of the F protein by TLR4 leads 
to NF-κB-mediated secretion of the pro-inflammatory cytokines interleukin (IL)-6 and IL-8 and the 
regulatory cytokine IL-10 (83). TLR4 engagement by the F protein enhances the expression of TLR4 on 
epithelial cells (84). Two single nucleotide polymorphism (SNPs) in the TLR4 ectodomain have been 
associated with an increased risk for severe bronchiolitis and hospitalization in infants (85, 86), 
suggesting a TLR4 response is necessary for inducing protective immunity to HRSV (87). A second 
extracellular TLR which reacts to HRSV infections is TLR2. This TLR forms a heterodimer complex with 
TLR6 (78). Signaling through TLR2/6 in leukocytes results in the production of CCL5, IL-6, and CCL2, 
neutrophil migration and DC activation. 
TLR3 is an intracellular PRR that recognizes double stranded dsRNA. These dsRNA molecules are 
intermediates of the HRSV replication cycle. The TLR3-mediated response channeled through TRIF 
(toll-interleukin (IL)-1 receptor domain-containing adaptor) activates both NF-κB and IRF-3, and 
subsequently drives production of IFN-β, CXCL10, CCL12, and CCL5 (79, 88). By a yet unknown 
mechanism, the HRSV G protein has been shown to inhibit TLR3/4 mediated cytokine production, 
through interfering with TRIF signaling (89). Activation through TLR3 leads to a predominantly Th1 
response; deletion of TLR3 leads to a Th2 response including the production of IL-5 and IL-13 (90). 
TLR7 is present on endosomal membranes and detects single stranded RNA (ssRNA) (91). 
Plasmacytoid DCs (pDCs) are the major cell type expressing TLR7. Signaling of TLR7 through the 
MyD88 adaptor protein leads to activation of IRF7 and production of IFN-α (92). TLR7 is responsible 
for the balance between IL-12 and IL-23 production, which determines the type of immune response 
induced upon HRSV infection: absence of TLR7 results in enhanced IL-23 production (a Th17 
promoting cytokine) and reduced IL-12 production (a Th1 cytokine) (82) resulting in enhancement of 
HRSV-induced pathology. 
RLRs are cytoplasmic viral sensors, present in most cell types including macrophage and conventional 
DCs (cDCs). MDA-5 and RIG-I, two members of the RLR family can sense HRSV infection, which 
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activates NF-κB and IRF3 pathways by complexing with the adaptor MAVS (93). RIG-I is activated by 
5’ triphosphate structure of viral RNA, both single or double strand (94). Scagnolari et al. (95) 
reported that the relative gene expression levels of MDA-5 and RIG-I were significantly higher in the 
HRSV-infected infants than virus-negative infants. HRSV induced RIG-I activation leads to the 
production of IFN-β, IP-10, and CCL5 expression in the airway epithelial cells (96). The HRSV NS1 and 
NS2 proteins interfere with RIG-I induced IFN-β production by decreasing the interaction between 
RIG-I and MAVS (97).  
NLRs are a second type of cytoplasmic PRR. NOD2 was well-known, as a sensor for peptidoglycan 
structures of intracellular bacteria (98) but recent evidence has shown that it can also detect ssRNA. 
NOD2 activated by HRSV ssRNA translocate to the mitochondria where it interacts with MAVS to 
induce activation of both IRF3 and NF-κB (99). HRSV infection of NOD2 knock-out mice results in 
markedly higher body weight loss and severe lung pathology with higher concentrations of pro-
inflammatory cytokines, as well as chemokines, than wild-type counterparts. These results 
demonstrate that, like the RLR receptors, NOD2 can function as a cytoplasmic PRR for HRSV and is 
important for host defense against HRSV infection.  
Activation of PRRs in the epithelial cells or alveolar macrophages induces changes in the cellular 
expression of genes encoding for a variety of factors, including surfactants, cytokines, chemokines, 
and cell surface molecules. In vitro studies have shown that HRSV infection leads to the secretion of 
cytokines and chemokines such as RANTES/CCL5, macrophage chemoattractant protein 1 (MCP-1), 
eotaxin-1/CCL11, IL-9, TNF-α, IL-6, IL-1 and CX3CL1 (fractalkine) (100). In HRSV infected patients 
increased levels of macrophage inflammatory protein (MIP)-1α, RANTES and IL-8 are often found in 
the upper and lower respiratory tract (101). Chemokines identified in the respiratory tract secretions 
of children who experience an HRSV infection include CCL3, MIP-1α, CCL2, MCP-1, CCL11 and CCL5. 
Levels of these chemokines correlate with the severity of HRSV-induced illness, presumably by 
initiating an augmented inflammatory response to HRSV (102). Chemokine expression by HRSV 
infected epithelial cells promotes activation of several types of innate immune cells (including 
neutrophils, eosinophils, NK-cells and monocytes) and their recruitment from the blood to the 
infected tissue. NK-cells are important effector cells in viral clearance by orchestrating cytotoxic lysis 
of infected airway cells. Another major function of activated NK-cells is the production of early IFN-γ 
which primes the subsequent antiviral adaptive Th1-cell and cytotoxic T-lymphocyte (CTL) immune 
response (13). The chemokines CCL5, CCL11 and MIP-1α have been shown to be involved in lung 
histopathology, since blocking of these chemokines in mice resulted in reduced lung histopathology 
(103-105).  
Next to chemokine production, sensing of HRSV through the PRRs also induces the production of 
type I IFNs, of which IFN-α and IFN-β are key members, as well as IFN-λ1, IFN-λ2, and IFN-λ3 (106). 
These cytokines signal through the IFNAR receptor, which activates the Jak/STAT signaling pathway 
resulting in the upregulation of interferon-stimulated genes (ISG). Expression of these genes triggers 
anti-viral functions such as the activation of ribonuclease L which degrades host RNA (107). pDCs are 
the main producers of IFN-α. In addition, epithelial cells are important producers of type I IFNs (108). 
Interestingly, the HRSV NS1 and NS2 proteins are involved in impairing IFN secretion by epithelial 
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cells which inhibits the establishment of an anti-viral state and allows viral replication within infected 
tissues (106, 109). 
Surfactant protein (SP)-A and SP-D may also play an important role in the immune response to HRSV 
infections. These proteins opsonize the pathogen, thereby promoting its uptake by macrophages and 
neutrophils (110). In addition, gene polymorphisms in these proteins have been associated with the 
severity of HRSV-induced disease in infected infants (111, 112). 
The adaptive immune response 
Activation of DCs leads to the initiation of the adaptive immune response, by presenting pathogen 
derived peptides to T cells (discussed in detail in chapter 2). The adaptive immune response can be 
divided in a humoral immune response and a cell-mediated immune response.  
While the CTL response is essential for viral clearance (discussed in detail in chapter 2), HRSV-specific 
antibodies are mainly important in restricting replication and disease upon reinfection with HRSV 
(113). A linear correlation has been found between the ability of HRSV to infect and the level of HRSV 
specific serum antibodies in experimentally infected humans (114). HRSV infection induces 
antibodies to multiple viral proteins; however only F- or G-protein specific antibodies can neutralize 
the virus and contribute to protection (115, 116). HRSV infection induces both serum IgG and 
mucosal secretory IgA production. Secretory IgA is mostly important in protecting the URT which 
cannot easily be accessed by serum IgG antibodies. Although secretory IgA antibodies are short-lived, 
repeated HRSV infections have been shown to induce a sustained IgA response which can protect 
against HRSV infection independently of IgG antibodies. Serum IgG antibodies can more efficiently 
access the LRT and hence are important in providing protection in this compartment (100).  
HRSV disease pathology is clinically characterized by airway hyperreactivity (AHR), increased 
mucus production and inflammation. This is thought to be caused by an altered immune 
environment due to an imbalance in the CD4
+
 Th1 and Th2 response. Indeed, severe acute HRSV 
infections are characterized by a Th2 skewed immune response (254). Recently it was shown 
that IL-17 producing Th17 cells play an important role in the pathogenesis of HRSV-induced 
disease. Increased IL-17 levels were observed in tracheal aspirate samples from children 
hospitalized with severe HRSV-induced disease. In addition, neutralization of IL-17 after an HRSV 
infection in mice led to reduced lung viral load, reduced mucus production and increased CD8+ T 
cell levels (255). These findings demonstrate that IL-17 plays an important role in the 
pathogenesis of HRSV infections. This was an interesting result, since IL-17 production has 
recently been implicated in the development of severe forms of asthma (256). Which again links 
severe HRSV infections with asthma.   
Regulatory T cells (Treg; CD4
+
 Foxp3
+
) play an important role in regulating the adaptive immune 
response upon an HRSV infection (257). Upon HRSV infection Tregs proliferate and rapidly 
accumulate in the lung-draining mediastinal lymph nodes and lungs. Interestingly, in vivo 
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depletion of Tregs in mice prior to HRSV infection results in delayed virus clearance 
characterized by an early lag in the recruitment of HRSV-specific CD8
+
 T cells into the lungs (258). 
Additionally, Treg depletion results in exacerbated disease severity, including increased weight 
loss, morbidity, and enhanced airway restriction, illustrating the importance of this cell type in 
regulating the adaptive immune response. 
IL-10 is an important regulatory cytokine produced by Foxp3
+
 Tregs, although also conventional 
Foxp3
-
 CD4
+
 T cells have been shown to produce this cytokine (259). Protein levels of IL-10 in the 
lung increase following acute HRSV infection, with maximum production corresponding to the 
peak of the virus-specific T cell response. HRSV infection of IL-10-deficient mice results in more 
severe disease compared with wild type mice and an increase in the magnitude of the HRSV-
induced CD8
+
 and CD4
+
 T cells (260). In addition, blocking of the IL-10 receptor during an HRSV 
infection alters the activate T cell subsets, resulting in more IL-17 producing CD4
+
 T cells and a 
decrease in the number of Foxp3
+
 Tregs. These results demonstrate the importance of IL-10 in 
modulating the adaptive immune response to HRSV infections. 
1.5 Animal models for HRSV vaccine studies. 
For evaluating new vaccines or antiviral strategies, an in vivo model is indispensable. Even though 
humans are the only known natural host of HRSV, several animal models are susceptible to HRSV 
replication, such as mice, cotton rats, lambs, ferrets, guinea pigs and several types of non-human 
primates. However, no model can completely mimic the disease observed in humans. The disease 
features, such as viral replication, pulmonary histopathology and immune response, differ between 
the different models and therefore, the choice of the model should depend on the hypothesis under 
investigation.  
Adult mice. 
Mice have the advantage over other animal models that multiple inbred strains are available, 
allowing studies in a homogenous background. Prince et al. (117) first described HRSV infection in 
inbred mice in 1979. Several mice strains were tested for their susceptibility to HRSV growth in the 
nose and lungs. BALB/c mice are the most frequently used inbred strain for HRSV studies, even 
though DBA/2N mice were most susceptible for HRSV growth both in the lungs and in the nose (117). 
Mice are semi-permissive for HRSV infection. In BALB/c mice, a high intranasal inoculum, in the range 
of 10
5
 to 10
7
 PFU is necessary for evoking LRT disease (118). This high viral load, instilled directly into 
the airway does not resemble a natural infection in humans, which originates from a small viral 
inoculum (119). In humans, the virus is first amplified by a couple of rounds of replication in the nose, 
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before progressing to the lower airways. In contrast, due to the high inoculum, in mice the infection 
proceeds immediately to the LRT. This difference in the progression of the viral infection may have 
consequences for the induction of immune responses, which should be taken into account when 
using the mouse as animal model. The HRSV strain used for infecting mice should also be taken into 
account. HRSV-A2 and Long strain are the most commonly used laboratory strains, however the 
clinical isolate Line-19 has been shown to induce substantial mucus production associated with 
airway hyperreactivity upon infection of mice (120). This Line-19 strain infection in mice is therefore 
a useful model for studying HRSV-induced pulmonary pathophysiology. 
Neonatal mice. 
Recently, the neonatal mouse has been introduced as a new model to study HRSV infections. 
Neonatal mice (aged ≤ 7 days) infected with HRSV develop long-term asthma-like symptoms such as 
increased airway hypersensitivity, extensive mucus production, Th2 cytokine and cellular responses 
and airway remodeling (121). A secondary HRSV infection in these mice causes severe lung 
immunopathology, which is not observed when the primary infection occurs in mice older than 7 
days of age. Data from these mouse models closely resemble the data from human epidemiological 
studies (i.e., that the age of initial infection is the major determinant in the persistence of lung 
dysfunction into early adulthood) (122).  
Cotton rats. 
The cotton rat (Sigmodon hispidus) is an interesting model for HRSV because it is highly susceptible 
to HRSV infection and permissive to HRSV replication. The cotton rat is at least 100-fold more 
susceptible to HRSV than the mouse (123). HRSV can be detected in both the upper and lower 
respiratory tract of infected cotton rats at 2 days post infetion. The viral lung titer peaks around the 
5
th
 day of infection and usually becomes undetectable by the 8
th
 day of infection. HRSV infection in 
cotton rats induces symptoms similar to those observed in humans, such as proliferative rhinitis, and 
bronchiolitis (124, 125). Cotton rats have been extensively used to study the development of 
enhanced disease upon formalin-inactivated RSV (FI-RSV) vaccination (see below). Vaccinated cotton 
rats develop severe pulmonary inflammation as observed in FI-RSV vaccinated human infants (124). 
A major disadvantage of the cotton rat model is the limited number of immunological reagents 
available for these animals. 
Perinatal lambs. 
Perinatal lambs, i.e. both term and preterm born lambs, are an interesting model for infant HRSV 
disease, mainly because the lamb pulmonary structure closely resembles that of humans. Both term 
and preterm lambs are susceptible to HRSV infection and develop both URT and LRT disease, with 
symptoms such as coughing, fever, malaise, bronchiolitis, neutrophil infiltration and syncytium 
formation (126, 127). The disease is less severe in term born than in preterm born lambs. HRSV 
readily replicates in the airway epithelium of lambs with peak viral lung titers around day 6 after 
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infection. On this day, a 30-fold increase in viral RNA levels has been observed, compared to day 3 
after infection (126, 127). The larger size of lamb lungs compared to mice lungs makes them a more 
suitable model for studying lung-function following HRSV infection. In addition, since lamb lung 
development is similar to infant lung development, this model is interesting to study the importance 
of the age upon primary HRSV infection (128). As with cotton rats, an important disadvantage of 
lambs as animal model is the limited availability of immunological reagents. In addition, handling and 
housing of larger animals is more complex than small animal models (129). 
Non-human primate models for HRSV. 
Because of their genetic and anatomical relatedness to humans, the non-human primates are an 
interesting model for studying HRSV infections and vaccines. HRSV was first isolated from a 
chimpanzee, before it was recognized as a human pathogen. Chimpanzees permit HRSV replication 
with modest increases (approximately 1 Log10 increase) of viral titers observed in the nasal or 
tracheal secretions (130). Upon intranasal HRSV infection chimpanzees develop URT disease 
symptoms similar to that observed in humans, with symptoms such as rhinorrhea, sneezing and 
coughing (131). No LRT disease has been reported in chimpanzees. HRSV replication has been 
demonstrated in several other non-human primates, such as African green monkeys, Bonnet 
monkeys, owl monkey, rhesus monkey, cebus monkey and squirrel monkey (131-134). However, 
despite their genetic relatedness to humans, all these animals are only semi-permissive to HRSV 
(119) and do not develop clinical symptoms. The African green monkey has been most extensively 
studied. Upon an intranasal and intratracheal infection titers of 10
5
 and 10
3
 PFU per ml can be 
recovered from the lung and nose respectively (135, 136). 
Human challenge model. 
Experimental infection of healthy human volunteers can be used to study the pathogenesis of HRSV 
and to evaluate therapeutics or vaccine candidates. This model replicates features of a natural HRSV 
infection in humans, such as, small inoculum dose, inoculation in the nose (instead of directly in the 
lungs as in the mouse model), an incubation period and URT symptomatic disease. A limitation of this 
model is that the study subjects are not HRSV-naïve, since HRSV is ubiquitously present and every 
adult has been infected at least once, but likely multiple times. Therefore, the URT disease observed 
might be a consequence of the present neutralizing antibodies, and hence this model will not 
completely mimic the course of an HRSV infection in HRSV-naïve infants (114, 137). The human 
challenge model is an important model which can be used for testing new antiviral therapeutics or 
vaccines. 
Models using non-human pneumoviruses. 
BRSV, a relative of HRSV belonging to the same genus, is a natural pathogen of calves. The disease 
observed in cattle is almost identical to that observed in humans, varying from mild URT infections to 
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severe LRT infections with bronchiolitis and pneumonia. This model is of particular interest because it 
can mimic the FI-RSV induced enhanced disease that was observed in the human clinical trials. 
Compared to unvaccinated controls, calves vaccinated with FI-RSV vaccine develop significantly 
greater disease upon a BRSV infection with a Th2 polarized immune response characterized by 
increased levels of IL-4 and IL-5, decreased levels of IFN-γ and a lack of BRSV specific CD8
+
 T cells 
(138-140). Similarly, Pneumovirus of mice (PVM) is a natural rodent pathogen related to HRSV. The 
virus induces severe inflammation which, depending on the size of the inoculum may advance to 
bronchiolitis, pneumonia or even death. The advantage of using this model is that the virus is studied 
in its natural host, allowing robust replication: an infection with less than 100 PFU results in viral 
titers peaking at day 7 post infection at 1 x 10
8
 PFU/g lung (141). 
Studying these viruses in their natural host more closely reflects the pathogenesis of a natural 
infection and has advanced our understanding of pneumovirus pathogenesis in general. These 
models are useful to evaluate vaccine concepts which may be applied to HRSV. 
1.6 A history of vaccine failures 
Formalin inactivated HRSV vaccine 
When HRSV was discovered, in 1956, vaccination against poliomyelitis was introduced all over the 
world. One of the polio vaccines had been developed by Dr. Jonas Salk, and consisted of 
formaldehyde inactivated polio virus (142), a strategy that had previously also been applied to 
influenza virus in the 1940’s when the first influenza vaccines were used clinically. Given the success 
of this vaccine in inhibiting poliomyelitis the same strategy was applied to other viral infections, such 
as HRSV. This resulted in the development of the first HRSV vaccine in 1965 (143). The vaccine 
consisted of formalin-inactivated, in vitro grown HRSV that was concentrated with alum adjuvant for 
intramuscular administration (FI-RSV). From 1965 to 1967 several clinical trials were performed with 
the FI-RSV vaccine, in children of various age (144-147). All trials however had the same negative 
outcome that the vaccine was not strongly immunogenic and poorly protective against a natural 
HRSV infection. FI-RSV recipients experienced enhanced disease during a subsequent natural HRSV 
infection and developed symptoms such as bronchiolitis and pneumonia; whereas control vaccinated 
children mostly developed mild symptoms like rhinitis. In one of the studies up to 80% of the 
vaccinated children required hospitalization versus 5% in the control group (144). Moreover, two of 
the vaccinated children in this study died during a subsequent HRSV infection. Histopathological 
analysis of the lungs of the deceased children demonstrated a strong infiltration of cells in the small 
bronchioles and the presence of numerous eosinophils (144). Analysis of the induced immune 
responses revealed that compared to control vaccinated children, FI-RSV vaccinated children 
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developed a completely different immune response upon a subsequent HRSV infection, including 
poor induction of neutralizing antibodies (148) and an exaggerated CD4
+
 T cell response of Th2 
subset (149). Later, these results were confirmed by animal models mimicking the effects of FI-RSV 
vaccination (reviewed in (150)). Mouse studies confirmed that Th2 type cytokines played an 
important role and that the induction of enhanced disease could be abrogated by depletion of CD4
+
 T 
cells or the Th2 cytokines IL-4 and IL-10 (151, 152). Additionally, the poor stimulation of CD8
+
 T cells 
and as a consequence the lack of an appropriate CD8
+
 T cell memory also contributed to the Th2 
biased immune response (153). The lack of neutralizing antibodies is likely a consequence of 
denaturation of the antigen by the formaldehyde as well as a deficiency in affinity maturation. (154, 
155).  
As a consequence of the enhanced disease observed upon FI-RSV vaccination and due to the fact that 
immunity induced upon a natural HRSV infection is not long lasting, the development of an HRSV 
vaccine has become a slow and difficult process. Requirements for an HRSV vaccine that is both safe 
and effective have been proposed. It is suggested that, (i) the induction of a neutralizing antibody 
response is required for efficacy of the vaccine and (ii) induction of the right type of T cell response 
(i.e. induction of CD8
+
 T cells and avoiding Th2 responses) is required for safety of the vaccine (119).  
Live attenuated HRSV vaccines 
After these fatal results with inactivated vaccines, HRSV vaccine development has focused on live 
attenuated vaccines, since these vaccines induce an immune response that more closely resembles 
the immune response induced upon a natural HRSV infection (156, 157). Intranasal administration of 
a live attenuated vaccine has the advantage of being capable of stimulating both a local and a 
systemic immune response. Additionally, intranasal administration can partly overcome the 
immunosuppressive effects of maternal antibodies (130). The first generation of live attenuated 
HRSV vaccines were produced already in the 1960s by serial passages at a suboptimal temperature 
(cold-passage; cp) (158, 159). Fifty two passages at low temperature (as low as 26°C) resulted in the 
cp-RSV strain, which, due to the lack of a good animal model for HRSV at that time, was immediately 
tested in humans (158). The strain was highly attenuated in adults however, for children it was not 
sufficiently attenuated and symptoms of respiratory tract illness occurred in seronegative children 
(160), and therefore was not an acceptable HRSV vaccine. A different strategy for generating live 
attenuated viruses consisted of passaging the virus in the presence of mutagens, followed by 
identification of mutants with a temperature sensitive (ts) phenotype (160, 161). The first attenuated 
virus generated with this method was clearly attenuated in adults, however loss of its temperature 
sensitivity was observed in seronegative children (160, 161). Therefore, a second ts strain (ts-2) was 
produced which was more stable than ts-1. This ts-2 strain was highly attenuated in primates, 
however it was poorly infectious and only weakly immunogenic in adults and children (162). A 
problem which makes the search for an acceptable live attenuated vaccines difficult, is that only a 
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small window of attenuation exist, often resulting in either under attenuated (cp-RSV and ts-1) or 
over attenuated (ts-2). Loss of stability is another problem for which solutions need to be found. 
The cp-RSV mutant was subsequently subjected to chemical mutagenesis to introduce ts mutations. 
This resulted in several mutants, named cpts530 and cpts248, which were attenuated in mice and 
chimpanzees and which were genetically more stable than previously generated live attenuated 
strains (163). These mutants were subjected to a second round of chemical mutagenesis, to 
introduce additional temperature sensitive mutations. Several candidates were generated 
(cpts530/1009, cpts 248/955, cpts 248/404) which were much more restricted in replication in the 
nasopharynx of mice and chimpanzees and which retained their temperature sensitive phenotype in 
both animal models (164, 165). The cpts248/955 and 530/1009 vaccines were highly attenuated in 
adults and seropositive children. In seronegative children the cpts248/955 vaccine was not 
sufficiently attenuated (166). One candidate, cpts248/404 was shown to be protective in 
chimpanzees (165). This vaccine candidate, after the failed FI-RSV vaccine, that was the first that was 
considered safe enough to be tested in seronegative children less than 2 months of age. The 
cpts248/404 vaccine was immunogenic and was protective against a second dose of the vaccine 
strain. However a mild nasal congestion was observed in these young children, rendering it 
unacceptable for use as a vaccine in the most important target group of HRSV (167). 
Thanks to the development of reverse genetics for HRSV, the so called ‘second generation’ of live 
attenuated viruses could be generated more easily by introducing specific mutations into wild type 
HRSV or by deletion of (fragments of) genes. By introducing the 5 attenuating mutations that were 
present in the cp-RSV mutant into wild type HRSV, the recombinant rA2cp was generated, which is 
used as a basis for other strains (168). Attenuating mutations of strains generated by chemical 
mutagenesis were determined and could be combined to form new combinations of mutations. This 
resulted in the generation of a new strain designated rA2cp248/404/1030ΔSH, of which it was 
suggested that the combined effect of several attenuating elements might result in a strain that is 
more attenuated in humans than the parent cpts248/404 strain (169). The rA2cp248/404/1030ΔSH 
strain contains a total of 5 different attenuating elements: (I) cp which is based on 5 missense 
mutations in the N and L proteins and the F glycoprotein that together confer the phenotype of cp-
RSV and that are considered to be a single attenuating genetic element (168); (II) ts248, a missense 
mutation in the L protein (163); (III) ts404, a nucleotide substitution in the gene-start transcription 
signal of the M2 gene, derived from the mutant cpts248/404 (165, 170); (IV) ts1030, another 
missense mutation in the L protein, derived from the mutant cpts530/1030 (169) and (V) ΔSH, 
complete deletion of the SH gene (34). The rA2cp248/404/1030ΔSH strain was evaluated for its 
safety, immunogenicity and genetic stability in adults and children (171). The vaccine was found to 
be highly attenuated and immunogenic in adults, seropositive children and seronegative children 
older than 6 months. This vaccine was the second live attenuated strain found safe enough to be 
tested in seronegative infants of 1-2 months old. The vaccine was well tolerated and a single dose 
provided substantial restriction of a second dose, indicative of a certain amount of protection. 
However only 44% of the infants had a detectable antibody response after two doses (171), whereas 
high antibody titers were observed in seronegative children older than 6 months. This vaccine was 
22 
recently tested extensively (under the name MEDI-559) in a phase I/IIa clinical trial (trial 
NCT00767416 (172)) for its immunogenicity and for its ability to provide protection against a natural 
HRSV infection in 5 to 24 months old children (173). The trial was finished in august 2012 but the 
results on immunogenicity, protection and stability of the virus have not been communicated. The 
virus that was recovered from children in the first small scale trial did not show any reversions to wild 
type HRSV, which is highly unlikely given the large number of mutations that are present in the 
vaccine strain. However, changes in temperature sensitive phenotype were observed in some 
isolates, but these mutants were not associated with disease and remained attenuated in vivo (171). 
Similar changes were observed in vitro, when the virus was passaged at 35°C (174). Currently studies 
are ongoing to improve the stability of this vaccine (175, 176), and again, questions are being raised 
whether this vaccine will be stable enough for use in young children. 
Another strategy for generating attenuated vaccines involve the deletion of other non-essential 
genes such as NS1, NS2 or M2-2, either on its own or in combination with additional point mutations 
in other genes. Three vaccines have been created with a deletion of the NS2 gene, rA2cpΔNS2, 
rA2cpts248/404ΔNS2 and rA2cpts530/1009ΔNS2 (177), the last two based on observations of 
attenuation of the strains generated through chemical mutagenesis. Since NS2 is involved in the 
inhibition of the host IFN response, deletion of NS2 would be expected to increase IFN signaling and 
response during infection and thereby result in enhanced immunogenicity. The rA2cpΔNS2 virus was 
attenuated in adults and seropositive children, however, since it replicated efficiently in this last 
population it was not tested in seronegative children (177), as it was known from previous studies 
that HRSV strains that replicate efficiently in HRSV-seropositive children can retain reactogenicity for 
HRSV-seronegative children or infants (166). The other two ΔNS2 strains were evaluated in 
seronegative children. Both rA2cpts248/404ΔNS2 and rA2cpts530/1009ΔNS2 were clearly over 
attenuated in seronegative children, and evaluation in the target population of infants was not 
performed (178).   
Strains with deletions of NS1 or M2-2, either separately or the combination of both have been tested 
in monkeys. In contrast to al previously described strains generated through reverse genetics, these 
strains (rA2ΔNS1, rA2ΔM2-2 (179) and rA2ΔM2-2NS2 (180)) do not contain the cp mutations which 
originated from the first cp-RSV strain (158). All three strains were attenuated in monkeys and it will 
be interesting to characterize these vaccines in humans.  
Purified subunit HRSV vaccines 
Since live attenuated vaccines induce an immune response resembling the immune response upon a 
natural infection, they are the best candidate for use in infants. There is however also need for a 
vaccine for older children, adults and elderly who are at risk of severe HRSV infection due to an 
underlying disease or old age. Since several live attenuated vaccine strains have been reported to be 
too much restricted in replication in these populations other strategies are being investigated. The 
most studied strategy, together with the live attenuated vaccine was the production of purified 
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subunit vaccines, consisting of purified HRSV proteins. Several approaches have been developed to 
produce subunit vaccines. A first approach consisted of F protein purified from infected cells. Three 
generations of these proteins were produced, designated PFP-1, PFP-2, PFP-3. The three vaccines 
differ in purification strategy, HRSV strain used for preparation and the adjuvant with which it is 
formulated (Table 1.2).  
 
Table 1.2: overview of the purified fusion protein vaccines, the purification strategy used, the HRSV 
strain used for preparation and the adjuvant with which it was formulated during clinical trials. 
Vaccine HRSV strain used 
for preparation 
Purification strategy used Adjuvant used in 
clinical trials 
PFP-1 wt HRSV Immunoaffinity column Aluminum hydroxide 
PFP-2 wt HRSV Ion exchange chromatography Aluminum hydroxide 
PFP-3 cpts HRSV Ion exchange chromatography Aluminum phosphate 
 
The purified F protein vaccines have been evaluated extensively in clinical trials in healthy adults, in 
institutionalized or ambulatory elderly, in pregnant women and in children older than 1 year, either 
healthy or who had a chronic lung disease (cystic fibrosis or chronic lung disease of prematurity) 
(181-189). PFP-1 and PFP-2 were well tolerated and immunogenic in healthy adults and children over 
12 months of age, as well as in the elderly; however some mild upper respiratory symptoms were 
observed (181, 184, 186, 189). A phase I clinical trial performed in pregnant women, showed that 
vaccination with purified F protein vaccines can induce protective antibodies in the infant, by 
vaccinating the mother during pregnancy. Women were vaccinated with PFP-2 between the 30
th
 and 
34
th
 week of pregnancy (185). The vaccine was well tolerated and immunogenic and during the 
subsequent HRSV season no increase in frequency or morbidity due to respiratory disease was 
observed in children from immunized women. Mean anti-HRSV antibody titers were increased 4 fold 
in children born from immunized mothers compared to children from unimmunized mothers. An 
increase in HRSV neutralizing antibody titer was reported in only 10% of the women and their infants 
at birth, and at 2 months and 6 months of age (185). PFP-3 was evaluated in children with cystic 
fibrosis. The vaccine was safe, well tolerated and immunogenic in this group. A fourfold rise in HRSV 
antibody titer was observed in 67% of the vaccinated children, however, no significant reduction in 
the number of lower respiratory infections between the vaccine or placebo recipients could be 
demonstrated (187). Since no significant protective effect could be attributed to the PFP-3 vaccine, 
the development of these HRSV PFP vaccines is no longer continued. 
A comparable approach, using co-purified F, G and M protein was evaluated in elderly > 65 years of 
age. Several doses were tested, with or without alum as adjuvant. Surprisingly only the highest dose 
(100 µg of vaccine) given without alum adjuvant, induced a fourfold rise in antibody titer in 58% of 
the vaccines (190). Further development of this vaccine has also been suspended (13). 
Another subunit vaccine, called BBG2Na, is a fusion protein expressed in bacteria that consists of aa 
130-230 of the G protein, which contains the central conserved region, fused to the albumin binding 
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domain of streptococcal protein G. This vaccine induced protection against HRSV-A and –B in both 
mice and cotton rats (191, 192) without enhanced lung pathology (193). Evaluation of the BBG2Na 
vaccine in a phase I study in healthy adult volunteers proved the vaccine was safe, well tolerated 
however only mildly immunogenic (194). When BBG2Na absorbed with alum was tested in young 
macaques, there was evidence of an enhanced Th2 response, with IL-13 producing T cells and a 
certain degree of pulmonary eosinophilia (132). Due to adverse events, both in humans and 
macaques, de vaccine was not further developed. 
New technological developments might help the search for a good subunit vaccine. Recently, a post 
fusion form of the HRSV F protein was produced, which forms stable trimers. This post-fusion form of 
the F protein still contains (at least some of) the known antigenic regions, as it is recognized by 
several known monoclonal antibodies (195). Moreover, in rodents it induces neutralizing antibodies 
that are protective against an HRSV infection (65). More research needs to be done, but until now 
these post fusion F trimers seem a promising new vaccine candidate.  
Recently, the crystal structure of the binding site of motavizumab/palivizumab (196) and MAb 101F 
(197) on the F protein have been solved. This new knowledge could be the basis for a new emerging 
vaccine strategy. By building key epitope residues on protein scaffolds, minimalistic subunit vaccines 
can be produced that only contain the neutralizing epitope. The usefulness of this vaccine strategy 
has been explored in an HIV vaccine (198). 
 
In order to elicit an optimal immune response, purified subunit vaccines require co-administration of 
an adjuvant. The adjuvant should be selected carefully, in order to avoid induction of an undesired 
Th2 type immune response. Several studies have been performed for testing different adjuvants in 
animal models. 
Oien and colleagues compared the use of cholera toxin B subunit (CTB) for intranasal vaccination 
with alum as a parenteral vaccine adjuvant, in combination with a chimeric F/G glycoprotein vaccine 
in mice. While both vaccination protocols induced serum antibodies against RSV and protected the 
lower respiratory tract from RSV infection, only intranasal FG/CTB afforded protection of the upper 
respiratory tract (248). A purified F protein vaccine in combination with an adjuvant formulation 
containing caprylic/capric glycerides (CCG) and polyoxyethylene-20-sorbitan monolaurate (PS) was 
tested as intranasal vaccine in BALB/c mice. This vaccine formulation unduced IgG1, IgG2b and IgA 
antibodies which was protective against an RSV challenge (249). The BBG2Na vaccine was tested in 
an adjuvant formulation with dimethyldioctadecylammonium bromide (DDA). This vaccine/adjuvant 
combination was shown to induce a mixed Th1/Th2 immune response that was protective in both 
mice and cotton rats (250). 
Another interesting promising category of adjuvants consists of synthetic oligodeoxynucleotides 
containing unmethylated CpG dinucleotides (CpG-ODN). These compounds have been reported to 
induce a Th1 type immune response (251). Compared with immunization with natural F protein 
adsorbed to aluminum hydroxide (F/AlOH) adjuvant alone, co-administration of F/AlOH with CpG-
ODN resulted in an increase in serum IFNγ and anti-F IgG2a titers, while pulmonary IL-5 levels 
significantly decreased, indicating that the CpG-ODN adjuvant directs the immune response in a Th1 
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direction (252). In addition, administration of CpG during FI-RSV immunization has been shown to 
reduce disease upon a subsequent RSV infection by inducing a more Th1 type immune response 
(253). In addation, Delgado et al. showed that inactivated RSV in combination with a TLR agonist 
treatment (Poly I:C, LPS and polyU) could protect mice from disease exacerbation by RSV (155). 
These interesting observation show that the selection of the adjuvant is critical for the outcome of 
the effects of FI-RSV induced disease exacerbation. 
Live viral vectors as HRSV vaccine 
Several other strategies for the development of an HRSV vaccine have been studied. Most of them 
have only been evaluated in preclinical studies in mice, cotton rats and/or chimpanzees. Different 
live viral vectors, including vaccinia virus (199), parainfluenza virus (PIV) (200), sendai virus (201), 
adenovirus (202-204) and Newcastle disease virus (205), have been tested in animal models. Most of 
them are immunogenic in different animal models and have the possibility of advancing through 
clinical trials. Two of these have been tested in clinical trials: PIV and sendai virus. The PIV vaccine, is 
a chimeric human and bovine parainfluenza virus of type 3, that consists of a bovine PIV backbone 
with the HN and F proteins replaced by those of the human parainfluenza virus which was 
additionally engineered to express the HRSV F protein (136, 200, 206). In African green monkeys the 
vaccine was immunogenic and protective against an HRSV challenge. This vaccine was recently 
evaluated (under the name MEDI-534) in a clinical phase I study in seronegative children 6 to 24 
months of age (NCT00493285; (207)). The vaccine was safe for this population and 50% of the 
vaccinated children had a serum response after 3 administrations of the highest dose (10
6
 TCID50) 
(208). Furthermore, the bPIV3 backbone of this vaccine has already been tested in young infants and 
was found to be safe, immunogenic and stable in this population (209). These results are promising 
and if the stability results of the MEDI-534 are positive this vaccine might advance to clinical testing 
in young infants. Another virus, sendai virus (SeV), which is a murine virus that has not been reported 
to infect humans, has been used as a live vector against human parainfluenza virus type 1, 2 and 3 
(210). A recombinant sendai virus expressing the HRSV F protein (SevRSV) has been studied as 
vaccine against both hPIV-1 and HRSV. In cotton rats, this vaccine elicits HRSV-specific neutralizing 
antibody and T cell responses (211) and is protective against a variety of HRSV A and B subtypes. In 
African green monkey studies, immune responses against SeV or SeVRSV were generated without 
adverse events (212, 213). SeVRSV conferred complete protection against lower respiratory tract 
infection after HRSV challenge. No clinically relevant adverse events were demonstrated after either 
vaccination or challenge in the large animal model. Until now, the SeVRSV vaccine has not been 
tested in clinical trials, however the SeV backbone was well tolerated in adults and children (214). 
Given these promising results, the SeVRSV vaccine might be a good candidate vaccine against HRSV, 
however until now it is unclear whether this vaccine is stable. Compared to live attenuated HRSV 
vaccines this kind of vectors, such as bovine PIV, SeV and also Newcastle disease virus (NDV) have the 
advantage that their native tropism is not human. Therefore these vectors are attenuated in vivo. 
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Also, since the frequency of pre-existing immunity to these viruses is low, the impact of maternally 
derived antibodies to the vaccine will be minimal (119). On the other hand, bovine RSV has also been 
used as a live vector for a recombinant bovine/human RSV vaccine consisting of BRSV expressing 
HRSV F and/or G protein. However, due to host range restrictions, this virus was not able to replicate 
well in chimpanzees (215) and hence did not progress to clinical testing in humans.  
Virus-like particle strategies for HRSV vaccines 
Virus-like particles (VLP) are considered a relatively safe vaccination strategy, as there is no concern 
for viral spread or reversion, which is the case for replicating viruses. One VLP-strategy uses influenza 
virosomes as carrier for foreign proteins. The virosomes resemble empty influenza shells that are 
made up of phospholipids and the influenza hemagglutinin and neuraminidase proteins (216). The 
PEV4 virosome (Pevion biotech), that carries the HRSV fusion protein, induces a neutralizing antibody 
response in mice that is protective against an HRSV challenge (217). Interestingly, also empty 
virosomes were associated with non-specific protection (218). This virosome technology has already 
been tested in clinical trials for other pathogens, giving the PEV4 virosome vaccine a good chance of 
advancing to clinical trials. A similar VLP strategy used virus-like particles consisting of influenza 
matrix protein core and HRSV F or G protein on the surface (219). Vaccination of mice using these 
VLPs induced a strong IgG2a antibody response that significantly decreased lung viral load upon an 
HRSV infection. Another interesting VLP technology uses nanoparticles consisting of HRSV F protein 
(Novavax). The F-protein is engineered to form rosettes (220). These nanoparticles have been tested 
in a phase I clinical trial in healthy adults, where it was found to be safe and immunogenic. On their 
website, novavax reports the nanoparticles to induce functional immunity, however, no details have 
been reported (220, 221). A phase I study in the elderly and a phase II study in healthy women are 
ongoing (222, 223). Both VLP-based strategies show promising results in animal models and healthy 
volunteers; however whether a VLP-based HRSV vaccine would be free from disease enhancement in 
HRSV-naïve infants is unknown. 
Replication defective gene based vectors 
Another vaccination technology of particular interest uses viral derived replication defective gene-
based vectors, for the delivery of a gene encoding the vaccine antigen of interest. In particular 
alphavirus vectors and recombinant adenovirus vectors have been studied as vaccination strategies 
against HRSV. The advantage of these gene-delivery vectors is that the gene expression of the 
vaccine antigen occurs in the host cell in a process that closely resembles natural infection resulting 
in authentic proteins able to elicit both an antibody and a T cell immune response, including CD8
+
 T 
cells. Additionally, these vectors are considered to be safe, as they are not capable of replicating 
(119). Recombinant adenovirus vectors (rAd) are considered an interesting vaccine backbone 
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candidate, in part for its robust production techniques. A rAd vaccine expressing the codon-
optimized soluble F1 part of the HRSV F protein induced a mucosal IgA response in mice, which was 
protective against HRSV challenge (224). rAd have not been used in clinical trials as an HRSV vaccine, 
however rAd expressing HIV envelope proteins have been extensively studied in humans and were 
found to be immunogenic and well tolerated (224, 225). A challenge with the use of rAd of serotype 
5 is the high prevalence of immunity against this viral vector in the human population, which 
dampens immune responses to the vaccine (226). However, children between 6 months and 2 years 
of age are still rAd5-seronegative (227). Therefore, rAd5 vector expressing HRSV proteins might be a 
good vaccine candidate in this age group. For adults, or children under 6 months of age, which still 
possess maternally derived antibodies, other serotypes of rAd can be used, which have a lower 
seroprevelance (228). In an alternative strategy, alphavirus vectors, such as Venezuelan equine 
encephalitis virus (VEE) or Semliki forest virus (SFV) have been used as backbone for replication-
defective HRSV vaccines. Their self-amplifying RNA replicon, which significantly increases antigen 
expression levels, makes these vectors an attractive system. VEE and SFV vectors expressing HRSV F 
or G proteins have been tested in mice and cotton rats and were found to be immunogenic and 
protective against HRSV challenge, and, for the VEE vector, this occurred in the absence of Th2-like 
immunity (229, 230). This technology platform might be a suitable candidate for clinical evaluation in 
the future. 
DNA vaccination 
DNA vaccination has been of great interest as a vaccine platform for various pathogens, due to its 
ability to induce both humoral and cellular immune responses (231). Despite promising results in 
small animal models, first generation DNA vaccines appeared to be only mildly immunogenic in 
humans (232). However, improvements in the vaccine formulation, the route of administration and 
the DNA construct itself have resulted in a new generation of DNA vaccines, which might be a more 
promising strategy (233). Several DNA vaccines, expressing different HRSV proteins have been tested 
in small and large animal models (234-239). Gene-gun immunization is the most popular method for 
administration, since it requires smaller quantities of DNA than conventional immunization methods. 
Gene gun immunization of mice with DNA encoding F or G protein was shown to be immunogenic 
(240) and protective against HRSV (241, 242). However, this method was associated with an 
undesirable Th2-biased immune response and enhancement of disease upon subsequent HRSV 
challenge (243, 244). DNA vaccination in calves using the BRSV F or N protein primed a strong cell 
mediated immune response. This response protected the calves from developing pneumonic lesions 
upon a BRSV infection and significantly reduced viral replication. An additional vaccination with a 
killed-virus vaccine induced high titers of neutralizing antibodies in these calves, which was fully 
protective following BRSV challenge (245, 246).  
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Table 1.3 Overview of RSV vaccination strategies 
 
Experimental approach Preclinical study comments Clinical study comments Ref 
Non-replicating, inactivated virus     
FI-RSV   Not immunogenic and poorly 
protective. Associated with enhanced 
disease upon subsequent RSV infection, 
resulting in two deaths. 
143- 
147 
Live-attenuated and genetically engineered RSV derivatives 
cp-RSV   Highly attenuated in adults. 
Not sufficiently attenuated for 
seronegative children. 
158, 
160 
ts-1   Attenuated in adults. Loss of 
temperature sensitivity in seronegative 
children. 
160, 
161 
ts-2 Highly attenuated in primates Weakly immunogenic in adults and 
children. 
162 
cpts248/955 Replication restricted to 
nasopharynx in mice and 
chimpanzees. 
Highly attenuated in seropositive adults 
and children. Not sufficiently 
attenuated in seronegative children. 
164-
166 
cpts248/404 Protective in chimpanzees. Mild nasal congestion observed in 
seronegative infants < 2 months. Highly 
attenuated in adults. 
165, 
167 
rA2cp248/404/1030ΔSH   Highly attenuated. High antibody titers 
in seronegative children older than 6 
months. Phase II clinical trial performed 
in 2012. Results not yet known.  
171 
rA2cpΔNS2   Attenuated in adults and seropositive 
children, however, replicated efficiently 
in children. 
177 
rA2cpts248/404ΔNS2 and 
rA2cpts530/1009ΔNS2 
  Over attenuated in seronegative 
children. 
178 
rA2ΔNS1, rA2ΔM2-2 and 
rA2ΔM2-2NS2 
Attenuated in monkeys. No clinical studies performed until now. 179 
RSV ΔG Highly attenuated in cotton rats. 
Induces long-lasting protective 
immunity in cotton rats. 
  247 
Live viral vector-based     
BPIV/HPIV3 expressing 
RSV F protein 
Immunogenic and protective in 
African green monkeys. 
Phase I trial in seronegative children  
(6-24 months old): serum response in 
50% of children after 3 doses 
206-
208 
SeV-RSV F protein Protective in cotton rats and 
African green monkeys. Protective 
against HRSV A and B subtypes. 
  211-
213 
BRSV expressing HRSV F 
and/or G 
Limited immune response in 
chimpanzees. 
  215 
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Table 1.3 Overview of RSV vaccination strategies (continued) 
 
Experimental approach Preclinical study comments Clinical study comments Ref 
Subunit vaccines     
PFP-1   Tolerated and immunogenic in healthy 
adults and children > 1 year. Mild upper 
respiratory symptoms. 
186 
PFP-2   Phase II trial in pregnant women: only 
mild effect on antibody levels of babies 
at birth. 
182-
185 
PFP-3   No significant protective effect 
observed in vaccinated children with 
cystic fibrosis. 
187 
F/G/M co-formulation   Phase II trial: immunogenic in healthy 
adults and elderly 
190 
BBG2Na Enhanced Th2 response and 
eosinophilia in young macaques. 
Phase I testing: immunogenic in healthy 
adult volunteers. Phase II trial was 
discontinued due to adverse events. 
191-
194 
132 
Purified RSV post-fusion F Immunogenic and protective in 
rodents. 
  65 
Virus-like particles     
PEV4 influenza virosomes 
containing RSV F protein 
(Pevion biotech) 
High levels of neutralizing 
antibodies. Protective in mice 
and cotton rats. 
Phase I/II trial reported to start in 
2011/2012. 
217 
Influenza matrix protein 
VLPs expressing RSV F or G 
Protective antibody response in 
mice. 
  219 
HRSV F protein rosettes 
(Novavax) 
  
Induces functional immunity in a phase 
I clinical trial in healthy adults. Phase I 
study in elderly and Phase II study in 
healthy women ongoing. 
220-
223 
Replication defective gene based vectors     
Adenovirus expressing RSV 
F1 part 
Induces a protective IgA 
antibody response in mice. 
  224 
Alphavirus vectors 
expressing HRSV F or G 
protein 
Immunogenic and protective 
against HRSV in mice and cotton 
rats. 
  229, 
230 
DNA vaccination     
Gene gun vaccination with 
DNA encoding RSV F or G 
protein 
Induced a Th2 immune response 
and exacerbated disease in 
mice.   
241-
244 
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1.7 Concluding remarks 
The development of an HRSV vaccine has been a high priority for many years. The past decades, 
several different technologies have been studied, and new technologies are still being developed.  
Currently, our knowledge about immune responses to HRSV, and why an HRSV infection does not 
cause long lasting protection, is still not complete. In order to develop a safe and effective HRSV 
vaccine we will need to understand more clearly the immune evasion and immunopathology of 
HRSV. Given the diversity in immune status of different age groups, distinct HRSV vaccines will need 
to be developed for each category. Several strategies have aimed at newborns as their primary 
vaccine target group. However, these often encountered problems due to safety or immunogenicity 
in this young age group. Therefore, it has been suggested, as a short term success, it might be 
interesting to aim at developing a vaccine for the children > 6 months of age, of which a considerable 
number is still HRSV naïve (9). Alternatively, the consequences of herd immunization, or maternal 
immunization need to be further investigated to clarify whether this might form a (partial) solution 
to the HRSV burden. Also, in contrast to other difficult vaccine targets, such as HIV, herpes simplex 
virus or hepatitis C virus, there is a known immune correlate of protection for HRSV, which is the 
neutralizing antibodies to the F protein. Bearing this in mind, it should be possible to come up with a 
safe and effective vaccine that can reduce HRSV disease burden. 
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Chapter 2  
Are CD8
+
 T cells the solution for the  
development of an HRSV vaccine? 
2.1 Introduction 
Human respiratory syncytial virus (HRSV) was first discovered in the 1950s (1) but after decades of 
intensive research, a licensed vaccine against this pathogen is still not available. Since antibodies 
directed against the fusion (F) protein are known to correlate with protection based on 
epidemiological studies (2), most vaccination strategies developed until now focused on inducing a 
humoral immune response against F. The induction of a T cell immune response has received a lot 
less attention in the quest for the development of a safe HRSV vaccine. T cell immunity directed 
against HRSV has not unequivocally been associated with protection against HRSV; in fact it has also 
been associated with worsening of disease. Studies in mouse have associated CD4
+
 Th2 responses 
with increased HRSV pulmonary pathology. Depletion of the Th2-associated cytokine IL-4 prior to 
acute HRSV infection led to decreased lung inflammation and mucus production (3-5). Moreover, a 
Th2 directed immune response is associated with delayed viral clearance in mice (5, 6). In human 
studies sufficient evidence supports a role for CD8
+
 T cells in clearance of HRSV from the lungs (7). 
Therefore a CD8
+
 T cell response is favored over a CD4
+
 Th2 immune response in providing protection 
against an HRSV infection.  
In this chapter we try to answer the question whether a cytotoxic T lymphocyte (CTL) response 
induced by vaccination is a suitable strategy to provide protection against an HRSV infection. First, 
we describe how a CTL response is induced and how these cells can act to protect the host from 
invading pathogens. Additionally, we discuss the factors that have to be kept in mind in the 
development of a CTL based vaccine. Finally, we describe the role of CTLs in controlling HRSV 
infection and the possibilities for CTL based vaccines against HRSV.  
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2.2 Activation, proliferation and memory formation of CD8
+
 T 
cells 
Antigen processing and presentation 
Before going into detail on the possibilities for vaccine induced CD8
+
 T cells in protecting against 
pathogens, we will first focus on the basics of T cell stimulation: how are CD8
+
 T cells activated? Two 
cell types are involved in the activation of T cells; these are (I) an antigen presenting cell (APC) which 
presents a foreign peptide on a major histocompatibility complex (MHC) molecule and (II) a naïve T 
cell expressing the T cell receptor (TCR) and a co-receptor molecule (CD4 or CD8) (8). MHC molecules 
can be divided into two structurally and functionally different classes: class I (MHC I) and class II 
(MHC II) molecules. The function of both molecules is to present short, pathogen-derived molecules 
to T cells, which initiates the adaptive immune response (9).  
Cellular proteins are constantly degraded by the proteasome into short peptides, a process that 
seems to closely follow mRNA translation into protein (10, 11). The same happens to pathogen-
derived proteins in an infected cell, and many pathogens have actually evolved mechanisms to try to 
circumvent this host process. With the help of TAPs (transporters associated with antigen processing) 
these peptides are then transported to the lumen of the endoplasmic reticulum where they are 
loaded onto the peptide binding groove of the MHC I molecule. Proteins from extracellular 
pathogens undergo a different fate: these proteins are internalized into the cell in endosome vesicles 
where they are degraded and loaded on MHC II molecules (9). Noteworthy, through the process of 
cross-presentation, peptides derived from extracellular pathogens can also be presented on MHC I 
molecules (12). Recently it has been shown that presentation of virus-derived antigen on MHC-I 
molecules likely also occurs via cross-presentation throug internalisation of apoptotic infected cells 
by APCs (18). After peptide loading, both classes of MHC molecules/peptide complexes are 
transported to the cell surface, where they present the foreign peptide to T cells (Figure 2.1).  
Both MHC classes are recognized by T cells expressing a specific co-receptor: while MHC II molecules 
are recognized by CD4
+
 T cells, MHC I molecules are exclusively recognized by CD8
+
 T cells. Peptides 
ranging in length between 8 and 11 residues long can bind the MHC molecule in a groove. This 
groove has small pockets which, upon binding of a peptide, are occupied by the side chains of this 
peptide. An MHC I molecule typically has 6 pockets, of which 2 or 3 are important for anchoring the 
peptide to the MHC molecule (9). Since only specific side chains can fill the pockets, each MHC 
molecule is specific for a certain type of peptide. In humans, the genes coding for the MHC molecules 
are called human leukocyte antigen or HLA genes. Many polymorphisms of these genes exist, hence, 
each individual has her/his own specific MHC molecules to which different peptides can bind (13).  
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Figure 2.1 Antigen processing. Viral infection leads to the expression of viral proteins in the 
cytoplasm which are degraded into peptides by the proteasome. Selected peptides are then loaded into the 
endoplasmic reticulum where they are loaded onto newly synthesized MHC class I molecules. The MHC I-
peptide complexes are transported through the golgi apparatus to the cellular membrane. Extracellular 
proteins are taken up by the cell through endocytosis and sequestered into endosomes. MHC class II 
molecules are synthesised in the endoplasmic reticulum and transported through the Golgi apparatus into 
lysosomes which fuse with the endosomes. Enzymes brought into this compartment by the lysosomes 
degrade the engulfed proteins into peptides. Peptides are loaded onto MHC II molecules and transported to 
the extracellular membrane. 
 
Figure 2.2 Activation of CD8+ T cells by dendritic cells results in the formation of memory cells. 
Schematic representation of the phases during T cell proliferation: (A) activation, (E) expansion, (C) 
contraction and memory formation. The number of CD8+ T cells is shown in green. The viral load is shown 
in red. 
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Activation of naïve CD8
+
 T cells 
Dendritic cells (DC) are the main type of APCs that are responsible for the initiation of an adaptive 
immune response. In the lung, DCs reside in the interstitium and constantly sample the lung for 
invading pathogens. DCs are a heterogeneous population of cells represented by two main subsets, 
the conventional CD11c
+
 MHC-II
+
 DC (cDC) and the CD11c
low
/B220
+
 plasmacytoid DC (pDC) (14). In 
addition, cDCs can be further divided into CD11b
+
CD103
-
 cDCs (CD11b
+
 cDCs) and CD11b
-
CD103
+
 cDCs 
(CD103
+
 cDCs). Upon antigen uptake, DCs are activated and migrate to the lung draining lymph nodes 
(LN) where they can encounter antigen-specific T cells. For influenza virus it was shown that CD103
+
 
cDCs are the main cell type that migrates to the LNs and presents antigen on MHC-I molecules for 
priming and activation of CD8
+
 T cells, while CD11b
+
 DCs mainly remain in the lung (15, 16). 
Interestingly, CD103
+
 DCs preferentially present peptides on an MHC-I molecule through cross-
presentation of antigen derived from apoptotic infected cells (17). This is in line with the finding that 
CD103
+
 DCs are not productively infected by influenza (18). In contrast upon an HRSV infection it was 
shown that both CD11b
+
 and CD103
+
 DCs migrate to the draining lymph nodes and in addition, both 
subsets are capable of presenting antigen to CD8
+
 as well as to CD4
+
 T cells (19). Whether the HRSV-
derived antigen presented by CD103
+
 DCs on MHC-I molecules is derived from direct- or cross-
presentation has not yet been clarified. It has been shown that HRSV can directly infect murine and 
human DCs in vitro. However, only low frequencies of DCs are infected in vitro (i.e. 4%) even at a 
multiplicity of infection of >20 (20). The in vivo relevance of this infection of DCs by HRSV remains to 
be established. 
Migration of DCs to the lymph nodes serves to concentrate antigen at a site where virus specific T 
cells can encounter their cognate antigens. When naïve T cells recognize MHC/peptide complexes on 
APCs with high affinity they are stimulated to initiate an immune response; however, antigen alone 
(generally referred to as ‘signal 1’) is not sufficient to efficiently activate CD8
+
 T cells. Indeed, APCs 
also provide a second and third signal required for CD8
+
 T cell activation. Signal two, or the co-
stimulatory signal consists of the binding of B7 (also known as CD80/86), CD70 or OX-40L on the APC 
to CD28, CD27 or OX-40, respectively on the T cell and provides the signal necessary for clonal 
expansion of the T cell (21, 22). Absence of the co-stimulatory signal leads to anergy, for instance, 
when cognate antigen is presented by an epithelial cell. A third signal shapes the overall magnitude 
of the primary response and the formation of memory. This signal consists of cytokines, such as IL-12 
and type I interferons (IFN-α and IFN-β), which impact the CD8
+
 T cell activation and expansion; 
however, requirements for these cytokines are highly pathogen-dependent (23). To avoid tolerance, 
naïve T cells reside in lymphoid tissues, where they only encounter ‘professional’ APCs expressing the 
necessary costimulatory signals (24). Encounter by a naïve CD8
+
 T cell of an APC providing al 3 
stimulatory signals leads to the activation of the CD8
+
 T cell, resulting in proliferative expansion and 
differentiation into effector cells (22, 25). Activated T cells migrate from the LN to the site of 
infection where they can exert their effector functions. The chemokine receptor CXCR3 has been 
shown to be involved in the process of migration to the lungs. CXCR3
-/-
 mice show a decreased 
infiltration of CD8
+
 T cells in the lungs upon viral infection (26). In addition, inhibition of CXCL10, the 
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ligand for CXCR3 results in enhanced disease severity, impaired viral clearance and decreased 
numbers of HRSV specific CD8
+
 T cells in the lungs upon HRSV infection (27). 
Activated CD8
+
 T cells become cytotoxic T cells (CTL) capable of eliminating pathogen-infected target 
cells that express the same MHC/peptide complex on their cell surface (9). The effector functions of 
CTLs include (I) lysis of infected cells through a perforin-dependent release of granzyme-containing 
granules or (II) the induction of apoptosis of infected epithelial cells through Fas-Fas Ligand 
interactions (28). These effector functions can be exerted in the absence of the co-stimulatory 
signals. Activated CD8
+
 T cells produce pro-inflammatory cytokines such as IFN-γ, IL-2 and TNF. In 
addition, IL-10, a regulatory cytokine with anti-inflammatory properties is produced by activated 
CD8
+
 T cells (29). Production of IL-10 occurs at the time of initial influx of effector T cells in the lungs 
with maximum production corresponding to the peak of the virus-specific T cell response (30). This 
cytokine has been shown to be involved in limiting the inflammatory component of the host immune 
response to the pathogen and thereby preventing damage to the host and maintaining critical lung 
function (30, 31). HRSV infection of IL-10
−/−
 mice resulted in more severe disease with enhanced 
weight loss, delayed recovery and greater cell infiltration of the respiratory tract without affecting 
viral load (32). In addition, clinical studies have documented that certain polymorphisms in the gene 
encoding the regulatory cytokine IL-10 are associated with the development of severe bronchiolitis in 
HRSV infected infants (33, 34). Even though effector T cells are the primary source of IL-10 after HRSV 
infection, it should be noted that also other cell types, such as B cells and multiple cell types of the 
innate immune system can produce IL-10 (35). Production of this regulatory cytokine by CD8
+
 T cells 
requires exposure of the T cells in the infected lungs to IL-2 derived from antiviral CD4
+
 effector T 
cells (29) (see below). 
Characteristics of memory CD8
+
 T cells 
After removal of the pathogen, the effector phase is followed by a contraction phase and the 
formation of memory cells (Figure 2.2) (22, 25). Memory CD8
+
 T cells, generated after vaccination or 
after a first encounter with a pathogen have a number of advantages over naïve CD8
+
 T cells with 
respect to clearing a second infection with this pathogen.  
Whereas as few as 100 to 1000 naïve CD8
+
 T cells specific for a given epitope are present in naïve 
mice, the antigen specific memory CD8
+
 T cell population after vaccination or infection is at least 100 
to 500 times larger (36, 37). Next to these changes in absolute number, these epitope-specific 
memory CD8
+
 T cells also possess certain characteristics which distinguish them from naïve CD8
+
 T 
cells. First, they can rapidly produce cytokines such as IFNγ, TNF or IL-2. Also, memory CD8
+
 T cells 
can kill infected target cells immediately, without the need for prior co-stimulation. In addition, these 
memory CD8
+
 T cells exhibit more robust killing capacities due to increased granzyme B expression 
(22). Finally, memory CD8
+
 T cells can reside in peripheral tissues, such as the lung, liver and skin, 
much closer to the site of pathogen invasion compared to the draining lymph node (38). Kimpen et 
al. showed that a secondary HRSV infection in mice induces an accelerated lymphocyte response 
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(both CD4
+
 and CD8
+
) compared to a primary infection, which is also greater in absolute number of T 
cells (39, 40).  
Memory CD8
+
 T cells established after infection or vaccination can be divided in two categories, 
based on the expression of the surface molecules L-selectin (CD62L) and chemokine receptor CCR7. 
Central memory T (TCM) cells which are CD62L
+
CCR7
+
, localize preferentially to lymphoid tissues and 
can circulate throughout the blood, whereas effector memory T (TEM) cells are CD62L
-
CCR7
-
 and 
preferentially localize to the peripheral tissues (38). A recall response upon a secondary encounter 
with the pathogen occurs in three distinct phases, with different memory CD8
+
 T cells involved in 
each phase (38). Antigen-specific tissue resident TEM cells will be the first to respond to the invading 
pathogen, such as a virus and start eliminating virus-infected cells. These TEM cells will rapidly 
proliferate to generate a secondary effector response. The second line of response consist of the 
recruitment of antigen-specific and –nonspecific memory T from the blood to the infected tissue. The 
minor fraction of these cells that are antigen-specific can also proliferate and initiate a secondary 
effector response upon antigen encounter. Finally, the last phase consist of large numbers lymphoid 
resident TCM cells that have been activated by circulating APCs which migrate through the 
bloodstream to the peripheral tissue. Together, these three phases contribute to the rapid control 
and elimination of the invading pathogen. It has been shown that after a primary HRSV infection in 
mice memory T cells reside in both the lungs and the lung draining lymph nodes. 
 
The cytokine IL-2 plays an important role in regulating CD8
+
 T cells both through optimizing effector 
generation and memory differentiation. It affects CD8
+
 T cells during different phases, including 
expansion phase, contraction phase and memory generation. Following viral infection, the primary 
expansion of the CD8
+
 T cell population is about threefold lower in IL-2
−/−
 mice than in IL-2-
competent controls, and this results in less efficient viral clearance by virus-specific CTLs (41). In 
addition, IL-2 treatment of HRSV infected mice results in enhancement of the frequency of IFN-γ-
producing HRSV-specific CD8
+
 effector T cells and increase in numbers of memory T cells. This 
resulted in reduced weight loss and illness after HRSV infection in mice (42). IL-2 also plays a role in 
determining whether an activated CD8
+
 T cell differentiates into either a short-lived effector T cell or 
a long-lived memory T cell. Following initial activation, CD8
+
 T cells upregulate the expression of CD25 
(i.e. the IL-2 receptor α-chain). Some cells only express CD25 during a short period of time, after 
which these cells upregulate CD62L. After the contraction phase, these cells adopt a long-lived TCM 
phenotype. In contrast, cells expressing CD25 for a longer period of time, and hence received strong 
IL-2 signals, differentiate into short-lived effector CD8
+
 T cells, which do not remain after the 
contraction phase (41, 43). Both CD4
+
 and CD8
+
 T cells produce IL-2 during viral infection. It has been 
shown that CD8
+
 T cells respond to IL-2 from both autocrine origin (i.e. produced by CD8
+
 T cells) and 
paracrine origin (i.e. produced by CD4
+
 T cells) (44). 
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2.3 T cell-based vaccines 
The aim of CD8
+
 T cell based vaccines is to present pathogen derived epitopes to the immune system 
in the absence of disease, resulting in the activation of CTLs and the production of a memory 
response which, upon a second encounter with the same antigen results in rapid removal of the 
pathogen. This rapid elimination of the pathogen is a result of the higher number of antigen specific 
T cells and the faster and more robust response of these memory T cells. Because of this mode of 
action, T-cell based immunity can not prevent the infection by the pathogen but rather requires a 
degree of pathogen-derived gene expression before the T cells can recognize the cognate antigen in 
the context of MHC-molecules on the surface of the affected cell. Unlike vaccines that aim at 
inducing a strong antibody response, induction of an effective memory CD8
+
 T cell response by 
vaccination is more complicated. Several factors should be considered when developing a CD8
+
 T cell 
based vaccines.  
 
First, one should bear in mind that the antigen(s) delivered by the vaccine should be presented by an 
MHC I molecule on an APC, either through direct presentation or cross presentation, in order to 
stimulate a strong immune response. For this reason, live vaccine vectors should be preferred over 
recombinant protein vaccine. These vectors can be divided into two categories: (I) replication 
competent vectors, such as live attenuated vaccines or replication competent recombinant vectors 
and (II) replication defective vectors, either recombinant vectors or DNA. Direct presentation would 
require the APC to be infected directly by this vaccine vector. Recently however it was shown that 
CD103+ DC are not easily infected by influenza virus (which likely will also be the case for other 
viruses) and that these cells present foreign peptides through cross presentation rather than through 
direct presentation (18). 
Most vaccines currently in use require repeated administration in order to generate a robust, long 
lasting immune response. Thus, human vaccination will likely require repeated administration with T 
cell vaccines. Classical vaccines boost the immune response by administering the same vaccine, i.e. 
homologous boost. This strategy would not be suitable for generating memory T cell responses, 
especially when using viral vectors, since the robust cellular and humoral immune response to the 
vector would lead to a rapid neutralization and elimination of the vector upon a second encounter. 
This would not lead to the desired boosting of the memory response to the antigen encoded by the 
vector. Therefore, a heterologous prime-boost strategy would be more suited for generating strong 
memory CD8
+
 T cell responses using viral vectors. Of note, the effect of boosting on the T cell 
memory is pathogen dependent an may either be favourable or not (45). For instance, for the chronic 
Lymphocytic Choriomeningitis Virus (LCMV) infection it has been shown that repeated antigen 
exposure does not result in increased number of memory CD8
+
 T cells, rather it drives the CD8
+
 T cells 
into a terminally differentiated state which is unresponsive to re-stimulation with antigen (45, 46). 
The same study showed however that this was not observed for a number of acute infections, such 
as with Listeria monocytogenes, Vaccinia virus or an acute LCMV infection (45).   
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The diversity in human HLA proteins poses another difficulty to the development of CD8
+
 T cell based 
vaccines. For the efficient induction of a T cell response in a broad human population it will be 
necessary to include multiple CTL epitopes matching different haplotypes. This is in strong contrast 
to the situation in most pre-clinical studies, which are often performed in inbred mice strain. Here, 
the haplotype of the population is known and is identical for each mouse. Including a single epitope 
of the pathogen in the vaccine would already be sufficient for efficient CTL induction in inbred mice. 
Therefore, it is usually essential to include complete and as much pathogen-derived T cell antigens as 
possible in the vaccine to be developed. Whereas lots of HRSV CTL epitopes are already known for 
different mice strains (47), human CTL epitopes are still being discovered. Using computer algorithms 
HRSV specific human CTL epitopes specific for different haplotypes are being mapped to the different 
HRSV proteins, which can be of use for designing a human CTL based HRSV vaccine (48, 49). Until 
now, human CTL epitopes for HRSV have been mapped to the F, N, M, M2-1 and SH proteins (50-56). 
Two studies performed in South-Africa revealed that for the epitopes in the N and F proteins which 
are commonly recognized by the HLA subtypes in the South-African population, no variation in these 
epitopes was found in HRSV isolates over multiple years (52, 57). This suggest that immune selection 
of HRSV strains resulting in induction of CTL escape mutations is not common. This however does not 
exclude that immune pressure as a consequence of a potential HRSV CTL vaccine may result in CTL 
escape variants. 
Another point that should be taken in consideration is the immunodominance of the CTL epitopes. 
Indeed, it has been shown that strong immunodominant epitopes elicit high frequencies of 
responding cells and limit the response to subdominant epitopes. Immunodominance in HRSV has 
been extensively studied in a hybrid mouse model. For dominance studies in HRSV, the CB6F1/J 
hybrid mouse model is often used. This mouse strain is the F1 generation of a BALB/c x C57BL/6 
mating and therefore these mice express both H-2
b
 (derived from C57BL/6 background) and H-2
d
 
(derived from BALB/c background) class I MHC molecules. Despite being dominant in the parent H-2
b
 
C57BL/6 strain (58), the D
b
M187-195 epitope is subdominant to the K
d
M282-90 epitope in the H-2
d/b
 
hybrid mouse (59). Additionally, it was shown that mutating the subdominant D
b
M187-195 epitope 
enhanced the response to the dominant K
d
M282-90 epitope, whereas mutation of the dominant 
epitope resulted in a subdominant epitope becoming the dominant one (60, 61). Vaccination can 
change the immunodominance pattern: vaccination with a subdominant epitope of a pathogen 
results in enhanced numbers of primed T cells specific to this epitope which upon subsequent 
encounter with the pathogen, can dominate the response if they outnumber the dominant epitope.  
An advantage of CD8 T cell based vaccines is that the antigen epitope can be derived from any 
internal or external protein of the pathogen, if it can be presented by MHC I molecules. In contrast, 
vaccines that induce antibody responses can exclusively use epitopes derived from external 
pathogen proteins, or pathogen proteins expressed on the surface of the infected cell. 
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2.4 Control of HRSV by CD8
+
 T cells: do mice fool us? 
CD8
+
 T cells with a TCR directed against viral epitopes that are presented in an MHC class I context on 
the surface on infected cells are key for clearing viral infections (62). Clearance of HRSV from the 
infected host is no exception to this paradigm. HRSV-challenge experiments in laboratory mice have 
been instrumental to support this statement. First evidence for the role of CD8
+
 T cells in the 
clearance of HRSV came from adoptive transfer studies. Here, transfer of HRSV primed T cells 
(derived from the spleens of HRSV infected mice) to athymic nu/nu BALB/c mice or immunodeficient 
gamma irradiated mice, results in clearance of HRSV from the lungs by day 15 after HRSV infection, 
whereas without T cell transfer, the virus remains present beyond day 15 after infection (63). 
Clearance can be achieved by transfer of either CD4
+
 or CD8
+
 T cells separately, or by the 
combination of both. However CD4
+
 T cell are less efficient in clearing HRSV than CD8
+
 T cells. 
The role of CD8
+
 T cells upon an HRSV infection is however still somewhat controversial since it is not 
completely clear whether they are in part also responsible for the lung damage observed upon an 
HRSV infection. The answer to this question is not clear cut, as the effects of the CD8
+
 T cells differ in 
mice and in humans. CD8
+
 T cells from an HRSV-specific CD8
+
 T cell line transferred to gamma 
irradiated mice were responsible for rapid clearance of the virus from the lungs of persistently 
infected mice, however, this was associated with augmented and sometimes lethal respiratory 
disease (64). The amount of lung damage correlated with the number of cells transferred: lower 
numbers of CTLs transferred produced less severe disease. Also in normal, immunocompetent mice, 
transfer of HRSV specific CTLs was associated with clearance of HRSV from the lungs and was again 
accompanied by acute and sometimes lethal respiratory disease (64). Depletion studies, performed 
by Graham and colleagues confirmed that T lymphocytes are responsible for both viral clearance and 
lung pathology and that CD8
+
 T cells appear to be the important mediator of illness (65). Depletion of 
the CD8
+
 lymphocyte population during primary infection resulted in modest illness and early 
recovery. Also in rechallenge studies, mice in which CD8
+
 T cells were present (but CD4
+
 T cells and 
HRSV specific antibodies were absent) experienced severe illness. These results suggest that in mice 
CD8
+
 T cells are important for viral clearance, however also are responsible for the lung pathology. 
These findings in mice are in strong contrast with results observed in humans where there is no clear 
evidence that CD8
+
 T cells play a role in lung pathology (66). The most important target group of 
HRSV are very young infants (younger than 6 months of age). Little is known about immune 
responses elicited in these young children, although it is generally accepted that the infant immune 
system is still developing and reacts differently and mostly less effective to a variety of infections 
than does the adult immune system (67). Infant immune responses are mainly biased in the Th2 
direction, which, for HRSV infections, is considered as unwanted. It has however been shown that a 
CD8
+
 T cell response can be found in infants experiencing severe disease due to HRSV. Activated, 
HRSV-specific CD8
+
 T cells with an effector phenotype could be found in the blood and BAL of these 
infants (66). No correlation could be found between the severity of disease and the magnitude of the 
CD8
+
 T cell response in these infants, which suggests that the disease is not caused by a strong CD8
+
 T 
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cell response, as seen in mice (66). Furthermore, in timing, the peak of the CD8
+
 T cell response does 
not coincide with the peak of disease severity. In a study performed by Lukens et al. (7) the kinetics 
of the HRSV viral load in the lungs and the CD8
+
 T cell numbers in the blood were followed daily, 
during hospitalization of infants. They observed that peak viral load occurred early after 
hospitalization or even before hospitalization, with a peak of disease severity 2-3 days after 
admission. In contrast, the levels of CD8
+
 T cells in the blood peaked around day 11-15 after onset of 
the primary symptoms, which correlates with the recovery from disease and not with the peak of 
disease symptoms (7). Moreover, reports have demonstrated that fatal cases of HRSV infections are 
characterized by high viral titers and near absence of pulmonary infiltration of T cells or the cytokines 
they produce (68). Taken together, all these studies demonstrate that CD8
+
 T cells play a role in viral 
clearance and that they are not the cause of the observed lung pathology, which is in contrast to the 
observations in mice. 
An intriguing feature of HRSV infection is the susceptibility of previously infected individuals to 
reinfection with antigenically closely related viruses or the identical virus strain (69). In a human 
challenge model, almost 50% of adults with high levels of circulating neutralizing antibodies could be 
re-infected with HRSV of the same serotype within two months of natural infection (70). These 
observations suggest that the duration of protective immunity to challenge HRSV infection is short-
lived and that the formation of a long-lived memory T cell response (CD4
+
 and/or CD8
+
) after HRSV 
infection is lacking. Little is known about the formation of a proper memory CD8
+
 T cells in humans. 
One study reported that memory CD8
+
 T cells are present in healthy elderly people, however in 
smaller numbers compared to influenza specific CD8
+
 T cells (71). This is an indication that a memory 
response does exist, however is not effective at preventing reinfections (at least in the elderly). There 
was a tendency towards lower numbers of HRSV specific CD8
+
 T cells with increasing age, which 
might explain the poor protection against HRSV reinfection and the increased risk to develop an 
HRSV-related severe illness in this population. With respect to the formation of a memory response, 
Braciale and colleagues studied the response to the M282−90 epitope, the major target of CD8
+
 T cells 
(72) in BALB/c mice upon HRSV infection (73). By comparing tetramer staining of M282−90 specific T 
cells with functional assays they found that a large number of M282−90 specific T cells expanded and 
infiltrated into the lungs upon HRSV infection, only half of these possessed effector activity. These 
cells were impaired in cytokine synthesis, ex vivo cytolytic activity as well as development of memory 
cells in the lung. It was suggested that the impaired effector phenotype was due to defective TCR 
signaling. The same discrepancy between tetramer staining and intracellular IFN-γ production was 
found for the subdominant F85-93 epitope. These results suggest that in BALB/c mice, an HRSV 
infection can suppresses T cell effector function and the establishment of a long lived lung memory 
response through its effect on TCR dependent signaling. Later, these results were questioned by an 
different group, who found that the impairment of the CD8
+
 T cell response is not typical for HRSV 
but rather specific for the lungs (74): the same effect was observed in the lungs after influenza 
infection. It is not known whether such impairment of CD8
+
 T cells in the lungs is also present upon 
HRSV infection in humans and whether or not this could contribute to the absence of long-lasting 
protection to HRSV.  
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2.5 The role for CD8
+
 T cells in protecting against vaccine 
induced enhancement of disease 
The first HRSV vaccine trials, using formalin inactivated HRSV (FI-RSV) vaccine had a fatal outcome, 
with vaccinated children experiencing more severe disease than unvaccinated controls, upon HRSV 
infection. In experimental mouse models, this vaccine-associated enhancement of disease can be 
mimicked and such a model has been used to try to recapitulate and understand the unfortunate 
outcome of the clinical use of FI-RSV. Analysis of the induced immune response upon vaccination 
with FI-RSV vaccine revealed that the vaccine efficiently primed B cells and CD4
+
 T helper 2 cells, but 
only weakly primed a CD8
+
 memory response (75, 76). This is an expected consequence of the use of 
an inactivated vaccine, since it is generally assumed that antigen from injected inactivated vaccines 
can only be processed in the MHC I presentation pathway via cross-priming, which is usually far less 
efficient than direct-priming, when the antigen is present and processed for MHC I presentation from 
within the cell, for example when the antigen is delivered by a life viral vector. In mice, the same 
enhancement of disease after an HRSV challenge was observed when the mice had been vaccinated 
with vaccinia virus expressing HRSV G protein (vacv-G) (77). Similar to the FI-RSV vaccine trial, the 
immunity induced by vacv-G vaccination consisted of only a memory CD4
+
 T cell response, with no 
detectable memory CD8
+
 response. This was in contrast to vaccination with vaccinia expressing other 
HRSV proteins (F, N or M2): these mice developed both CD4
+
 and CD8
+
 memory T cell responses, and 
did not show any enhancement of disease upon HRSV infection. Interestingly, immunization with 
vacv-G in which the CD8
+
 T cell epitope of the M2.1 protein was inserted resulted in the formation of 
both a memory CD4
+
 and a memory CD8
+
 immune response (78). These mice were devoid of 
enhancement of disease upon HRSV infection. These results were further confirmed by studies in 
CD8
+
 T cell deficient mice (beta 2 microglobulin knock-out mice): priming with Vacv-F in these mice 
results in enhancement of disease, presumably due to the absence of CD8
+
 T cells; an observation 
that was not found in wild type mice primed with vacv-F upon HRSV infection. In another study, vacv-
F immunized mice develop enhanced disease, characterized by pulmonary eosinophilia, when CD8
+
 T 
cells were depleted by anti-CD8 antibodies (79). Together, these studies show that a CD8
+
 memory 
response plays an important role in preventing enhanced disease that is associated with certain 
vaccines upon HRSV infection. In addition, this ameliorating effect by HRSV-specific CD8+ T  cells is 
dose-dependent: the ability of CD8
+
 T cells to control enhanced disease depends on the number of 
CD8
+
 T cells present in the lungs before or early after HRSV infection: reducing the number of HRSV-
M2 specific CD8
+
 T cells on day 3 after HRSV challenge to 2 x 10
4
 cells per lung resulted in 
enhancement of disease, whereas 8 x 10
4
 HRSV-M2 specific CD8
+
 T cells present in the lung on day 3 
after HRSV challenge was sufficient to inhibit disease enhancement (80).  
Given the observation that enhancement of disease due to FI-RSV vaccination is characterized by the 
absence of CD8+ T cells, and that this enhancement of disease can be abolished when sufficient CD8+ 
T cells are present before the HRSV infection it is clear that a vaccination strategy that induces a CD8
+
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memory T cell response is desired for maximally avoiding the possibility of enhancement of disease 
upon a subsequent HRSV infection. 
2.6 CD8
+
 T cells as a correlate of protection in HRSV vaccines 
Even though most vaccination strategies aim at inducing a protective antibody response, several 
studies have been performed to investigate the possibility of CD8
+
 T cells to provide protection 
against HRSV. In a study by Voges and colleagues, recombinant sendai virus (a Respirovirus) 
expressing HRSV F protein (SeV F) or soluble HRSV F protein (SeV sF) were used as vaccine (81). These 
recombinant sendai viruses induced both an antibody response and a CTL response to the HRSV F 
protein and protected against an HRSV challenge 3 weeks after vaccination. The CD8
+
 T cell 
component induced by SeV F and Sev sF vaccination provided protection against an HRSV challenge 
in B cell deficient MB1 mice, 3 weeks after vaccination. These data show that CTLs are sufficient to 
provide protective immunity against HRSV, shortly after vaccination. The formation of memory T cells 
and the protection at later time points were not examined. Instead of using a complete HRSV 
protein, several studies used only a CTL epitope of the HRSV M2-2 protein. A DNA plasmid containing 
a minigene encoding the HRSV M282-90 CD8
+
 T cell epitope was used for DNA vaccination in BALB/c 
mice. Intradermal injection with this plasmid induces an M282-90 specific CD8
+
 T cell response that 
provided significant reduction in viral load upon HRSV challenge 3 weeks later (82). Intranasal 
administration of this DNA in nanoparticles composed of chitosan could also induce a protective 
M282-90 specific CD8
+
 T cell response (83); however, HRSV challenge was performed only 14 days after 
the last vaccination and the memory response induced by this DNA vaccine was not assessed. 
For the induction of a long-lasting memory response, a peptide encoding this same M282-90 CD8
+
 T cell 
epitope was formulated with different adjuvants. Upon administration of the M282-90 peptide with an 
enterotoxin-based adjuvant LTK63, the CD8
+
 T cells remained detectable in the spleen more than 100 
days after vaccination (84). Unfortunately, resistance to HRSV afforded by this vaccine is 
accompanied with enhanced weight loss upon an HRSV infection. Alternatively, a fusion protein 
consisting of the M282-90 epitope fused to the carrier protein DsbA (disulphide bond isomerase) of E. 
coli and the fusion peptide of measles virus F1 protein can induce CD8
+
 T cells which remained 
detectable in the spleen until at least 123 days after vaccination (85). These CD8
+
 T cells possessed ex 
vivo cytolytic activity, but the ability to protect against an HRSV challenge 123 days after vaccination 
was not examined. In contrast to the previous study mentioned, this last vaccine did not prime for 
enhanced weight loss upon an HRSV infection. It is unclear why one vaccine causes weight loss while 
the other does not. Simmons et al. (84) believe that the excessive TNF production during viral 
infection, which is partly driven by IFN-γ producing CTLs can have detrimental consequences, such as 
the observed weight loss. This could be influenced by the adjuvant used in the first study, which 
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indicates that the selection of an appropriate adjuvant may be crucial when inducing a CTL response 
by peptide vaccination. 
A recent study tried to answer the question whether memory CD8
+
 T cells induced by vaccination can 
still provide sufficient protection long after the vaccination. A vaccine termed TriVax, which consists 
of a peptide representing the immunodominant M282-90 CD8
+
 T cell epitope, the Toll-like receptor 
agonist poly(I·C), and a costimulatory anti-CD40 antibody, was used as a T cell vaccine (86). The 
vaccine efficiently induced HRSV specific effector and memory CD8
+
 T cells in BALB/c mice. It was 
reported that vaccinated mice were protected against HRSV infection, as they efficiently cleared 
HRSV four days after challenge; however, it should be noted that challenge HRSV infection was 
performed only six days after vaccination, which is at the moment when CTL numbers are increasing, 
due to vaccination. Protection against HRSV challenge by memory T cells was only partial: an HRSV 
challenge 42 days after TriVax vaccination could reduce the viral lung titer 4 days after challenge by 
only 1 Log10.  
To explore the possibilities of inducing a CD8+ T cell response against HRSV using a live viral vector, 
we created a recombinant influenza virus carrying the HRSV F85-93 CTL epitope in the NA stalk 
(PR8/NA-F85-93 virus). Infection of mice with this virus showed that an HRSV specific CTL response was 
efficiently induced and upon an HRSV challenge 4 weeks after the vaccination these CTLs were 
capable of reducing the HRSV replication in the lungs of the mice (87). When postponing the HRSV 
challenge until 50 days after the vaccination we also observed a reduction of the viral lung titer by 1 
Log10.  
These results demonstrate that CD8
+
 T cells induced by vaccination can contribute to protection 
against an HRSV infection. However, more studies will need to be performed to sort out how a long-
lasting memory response could be achieved and whether CD8
+
 T cells alone can provide sufficient 
protection 
2.7 Conclusions 
After the failure of the formalin inactivated HRSV vaccine, it became clear that the development of a 
safe and effective HRSV vaccine would likely require a long path to success, which today still has still 
not reached an endpoint. Sufficient evidence is present that supports the role for CD8
+
 T cells in viral 
clearance in humans. In addition, the studies summarized here suggest that induction of a CD8
+
 
memory T cell response is necessary to avoid the induction of a harmful Th2 CD4
+
 memory response 
that is responsible for enhancement of disease during an HRSV infection. Furthermore, the formation 
of a long lasting T cell memory response after an HRSV infection is lacking. Therefore, we believe that 
induction of a CD8
+
 T cell memory response will be essential for effective protection against HRSV. 
Several strategies for the induction of CD8
+
 T cells against HRSV by vaccination have been explored. 
58 
These studies have learned us that not the induction of a T cell response per se is a challenge, but 
rather the formation of long-lasting protective CD8
+
 memory response. Therefore, in order to 
develop a safe and effective HRSV vaccine, a better understanding of the formation of memory 
response to HRSV CTL epitopes will be necessary. Ideally, an HRSV vaccine should be administered to 
the infant as early as possible. Since the potential use of a non-replicating HRSV vaccine is still being 
held back by the early studies that showed that a formalin-inactivated vaccine caused an abnormal 
and pathologic immune response, a replicating vaccine is currently the best option. Live attenuated 
vaccines eg. against rotavirus, measles virus, mumps virus and rubella virus are already routinely 
being used in early childhood vaccination programs and offer opportunities for the acceptance of a 
potential live attenuated HRSV vaccine to be included in the early childhood vaccination program. 
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Chapter 3  
Recombinant influenza viruses as live viral vector 
vaccines 
3.1 Influenza virus 
The classification, nomenclature and global burden of influenza viruses 
Influenza viruses belong to the family of the Orthomyxoviridae, members of which are characterized 
by a segmented, negative-sense, single stranded RNA genome. They are divided into three genera, 
influenza A, B and C, based on antigenic differences in the nucleoprotein (NP) and the matrix protein 
(M). Influenza A viruses are further categorized based on the subtypes of membrane glycoproteins 
hemagglutinin (HA) and neuraminidase (NA). Until now 17 HA subtypes (H1-H17) and 9 NA subtypes 
(N1-N9) have been reported (1). The last HA subtype (HA17) was only recently discovered in an 
influenza A virus isolated from yellow shouldered bats in Guatemala (2). While all of these subtypes 
can be found in their natural reservoir, aquatic wild birds, only 3 HAs (H1, H2 and H3) and 2 NAs (N1 
and N2) are capable of circulating in humans. Sporadically, there have been cases reported of human 
infection with an avian H5N1 virus but until now these viruses have not been reported to transmit 
form one person to another.  A common nomenclature is used for naming different influenza virus 
isolates. This name consists of the subtype, the species of origin (if not human), the place of origin, 
the isolate number, the year it was isolated, and for influenza A viruses, the HA and NA subtype. For 
example A/Puerto Rico/8/34 (H1N1) is isolate number 8 of a human influenza virus, isolated in 
Puerto Rico in 1934 and it has a subtype 1 HA and subtype 1 NA glycoprotein (3). 
Influenza is an important cause of respiratory infections. Yearly epidemics, caused by influenza A and 
B viruses result in 3-5 million clinical infections and 250.000-500.000 fatal cases (4). In humans, 
influenza virus infects the respiratory tract leading to disease which is characterized by symptoms 
such as fever, aching muscles, headache, malaise, cough, sore throat and rhinitis (5). Most people 
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recover within one or two weeks, without the need for medical treatment, however in risk groups, 
such as very young children, the elderly, immunocompromised people or people with other 
infections, influenza infection can lead to severe pneumonia and even death. 
Antigenic variation of influenza viruses 
Due to the constant pressure by neutralizing antibodies, and thanks to the error-prone viral 
replication machinery, point mutations occur in the influenza HA and NA, resulting in virus which can 
evade existing antibodies. This change, called antigenic drift, is the reason why influenza vaccine 
composition has to be adapted yearly. A second method through which change arises in influenza 
viruses occurs when a person is simultaneously infected by two different viruses. Due to the 
segmented nature of the influenza viral genome, exchange of gene segments can occur between 
these two viruses. This rearrangement of genes is called antigenic shift, and can result in a new 
pandemic when an antigenically distinct virus arises that can transfer between humans and to which 
little or no protective immunity is present in the human population (6, 7). These variations are 
interesting when using influenza as a viral vector for vaccination, because antigenically unrelated 
strains can be used for priming and boosting vaccinations. 
The influenza virion structure 
Influenza virions are spherical or filamentous particles with the spherical particles in the order of 100 
nm of diameter and the filamentous often in excess of 300 nm in length. The lipid bilayer of the viral 
particle is acquired from the apical cell membrane during the process of budding and is covered with 
three membrane proteins (Figure 3.1). These proteins are the large glycoproteins HA and NA, present 
in a four to one ratio, and the smaller transmembrane channel protein M2, which is present at 
approximately 1 M2 protein per 10 to 100 HAs. HA is present as homotrimers and is important during 
the first steps of the influenza infection cycle. First, it is responsible for the binding to the host cell 
through the binding of sialic acids on carbohydrate side chains of cellular glycoproteins. Second, after 
the virion is taken up into the cell in an endosome, HA mediates fusion of the viral and endosomal 
membranes, to release the viral genome in the cell cytoplasm (8, 9). NA is present as homotetramers 
(10, 11) and possesses sialidase activity, which, upon the budding of a new virus particle, is used to 
cleave terminal sialidase activity which is essential for the spread of newly formed virions. NA 
removes sialic acid residues form both viral and host glycoproteins, to prevent the newly formed 
virus particles from aggregating to each other or to the cell membrane (12, 13). Additionally, NA is 
shown to be responsible for degradation of mucins in the respiratory tract, allowing binding of the 
virus to the respiratory epithelium (14). The M2 protein forms homotetramers that act as an ion 
channel (15, 16). It has a small ectodomain, consisting of only 23 amino acids, which are highly 
conserved among different influenza A viruses from different hosts.  
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  Figure 3.1 The influenza A virion. 
 
The inner side of the lipid bilayer is lined by a shell formed by the matrix 1 protein (M1). The M1 
protein is one of the most abundant proteins present in the viral particle. It is responsible for the 
shape and structure of the virion (17). Within the matrix core there are the nuclear export protein 
(NEP; formerly known as nonstructural protein 2) (18) and the viral RNA genome (vRNA) that is 
surrounded by numerous nucleoproteins (NP) and is associated with the heterotrimeric RNA 
dependent RNA polymerase (RdRp) consisting of two basic and one acidic subunit (PB1, PB2 and PA) 
(17). Together, the vRNA, NP, PB1, PB2 and PA form the viral ribonucleoprotein complex (RNP). The 
nonstructural protein 1 is only expressed in the infected cells and is not included in the virion. It 
counteracts the interferon-induced host immune response (19). Several other non-structural 
accessory proteins have been described for influenza A viruses, such as PB1-F2, N40 and PA-X. PB1-
F2 is present in some, but not all influenza isolates. It is located in the mitochondria and multiple 
functions for this protein have been described: (1) The protein can induce apoptosis in a cell type-
dependent manner, (2) PB1-F2 is able to promote inflammation, and (3) finally it up-regulates viral 
polymerase activity by its interaction with the PB1 subunit (20, 21). PB1 N40 represents an N-
terminally truncated version of the PB1 protein which lacks transcriptase function but is still able to 
interact with the other subunits of the RdRp complex. The function of PB1 N40 is still unclear (22) 
although this protein appears to be nonessential for viral replication. Via a mechanism of ribosomal 
frameshifting, a second protein, termed PA-X, is encoded from the PA gene segment. This protein 
comprises the endonuclease domain of the viral PA protein with a different C-terminal domain and 
functions to repress cellular gene expression. In a mouse model, PA-X acts as a virulence-modulating 
factor to decrease pathogenicity (23). Intriguingly, PA-X and PB1-F2 exert opposite effects on 
pathogenesis. Presumably, the two proteins work together to optimally modulate host immunity 
(24). Recently, two other N-terminally truncated forms of PA, which were named PA-N155 and PA-
N182, have been described. These N-truncated PAs did not show polymerase activity when 
expressed together with PB1 and PB2; however, mutant viruses lacking the N-truncated PAs 
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replicated more slowly in cell culture and had lower pathogenicity in mice than did wild-type virus 
(25). 
The influenza genome structure and its transcription and replication 
The influenza A viral genome consists of eight negative sense RNA strands. The segments are 
numbered in decreasing order of size. These segments encode minimum 10 proteins but some 
strains encode 11 or 12 proteins. The segments 1, 4, 5 and 6 each encode a single protein: PB2, HA, 
NP and NA. Segment 2 encodes the PB1 protein in all influenza viruses. In some influenza A viruses 
this protein also encodes two accessory proteins: PB1-F2 (20, 21) and PB1 N40 (22) from overlapping 
reading frames. Segment three that encodes PA from the full length mRNA also encodes up to 3 
accessory proteins via ribosomal frameshifting (PA-X) (23) or through alternative start codons (PA-
N155 and PA-N182) (25). Segment seven encodes two proteins: M1 is encoded from the full length 
mRNA, whereas the M2 protein is encoded by a spliced mRNA. The 8
th
 segment also encodes two 
proteins in the same way as the M segment: NS1 is produced from full length mRNA whereas NS2 is 
produced from a spliced mRNA.  
The 5’ and 3’ ends of each vRNA segment form a helical hairpin, which is associated with one RdRp 
complex; the remainder of the vRNA is covered with NP molecules. The negative sense coding 
sequence of the viral genome is flanked at both the 3’ and 5’ end by a noncoding region. The 
ultimate 13 nucleotides on the 5’ end and 12 nucleotides on the 3’ end are highly conserved among 
viral strains and among the different vRNPs (26-28). These sequences are partly complementary and 
base-pair to form a short double stranded RNA stretch (29) which serves as the promoter for the viral 
RdRp (30, 31). Even though they are not translated, these non-coding sequences are indispensable 
for the virus; besides sequences involved in transcription of the genome, these regions also contain 
packaging signals, for the incorporation of the vRNPs in the newly formed virion (32). The viral vRNA 
serves as template for both the transcription and replication of the viral genome, processes which 
are performed by the viral RdRp complex, built up of PB1, PB2 and PA. mRNA transcripts contain a 5’ 
CAP structure and a 3’ poly-A tail. This CAP is ‘stolen’ from a cellular pre-mRNA, by the viral RdRp and 
serves as primer which is subsequently elongated to positive sense mRNA (33). The production of the 
poly-A tail occurs through stuttering of the RdRp at a poly U stretch at the 5’ end of the vRNA (34). 
The process of viral replication also uses the negative sense vRNA as template. For replication the 
vRNA is copied by the viral RdRp complex into a positive sense complimentary RNA strand (cRNA). 
This cRNA is a complimentary copy of the complete vRNA, including non-coding regions at both ends 
of the vRNA. In contrast to mRNA, this cRNA is not capped nor does it contain a poly-A tail. The cRNA 
in turn serves as template for the production of a new full length vRNA, again produced by the viral 
RdRp complex (1). These vRNA molecules are then covered by NP molecules and attach to one viral 
RdRp complex, which is essential for its incorporation in progeny virions. Understanding of the 
transcription and replication process was crucial for the development of reverse genetics systems for 
the generation of recombinant viruses form plasmid DNA. 
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3.2 Reverse genetics techniques for the generation of 
recombinant influenza viruses 
The RNP transfection method 
For using influenza virus as a vaccine vector, reverse genetics techniques have been developed, 
allowing the production of recombinant influenza viruses which contain foreign proteins or epitopes. 
Several generations of techniques have been developed. In 1989 it was discovered that the vRNP, 
consisting of vRNA complexed with NP proteins and a viral polymerase complex is the minimal 
essential unit necessary for the production of viral proteins and vRNA (35). This discovery soon led to 
the first reverse genetics technique: the RNP transfection method (32). A foreign gene, flanked by 
the 5’ and 3’ non-coding regions of the influenza A NS gene, under control of a T7 promoter was 
incubated with the purified NP, PB1, PB2 and PA proteins and the T7 RNA polymerase. This led to the 
in vitro transcription of the gene into viral like RNA and the assembly of vRNPs. These RNPs, 
containing the foreign gene sequence were transfected into cells co-infected with influenza helper 
virus, to provide the remaining vRNPs. The recombinant RNA is amplified, expressed, and packaged 
into progeny virus particles, which can be passaged several times. The drawback of this system is that 
a mixture of helper virus and recombinant virus is obtained and selection is needed for the 
production of pure, recombinant virus. Without selection, the recombinant virus is usually lost after 
several passages (32). A more advanced system, first described by Neumann and colleagues, no 
longer made use of in vitro transcription of vRNA. Instead, the vRNPs were reconstituted in cells by a 
DNA-dependent RNA polymerase I (Pol I) driven system (36). Pol I is abundantly present in cells and 
transcribes ribosomal RNA, which, like vRNA does not contain a cap or a poly A tail. The gene of 
interest, present in a DNA plasmid between the Pol I promoter and terminator, was transfected to 
cells and subsequently transcribed to vRNA by the Pol I. Packaging of the vRNA into vRNPs still 
required the polymerase and NP proteins. Provision of these 4 essential proteins occurred through 
the infection with a helper virus or by transfection of plasmids expressing these proteins, under 
control of a DNA-dependent RNA polymerase II (Pol II) driven promoter. For generation of 
recombinant influenza virus a helper virus was still required. Nevertheless, selection was still 
required for the isolation of pure recombinant virus. At that time, selection systems for only six of 
the eight RNA systems had been described. For two of the influenza genes, PB1 and PA, it was not 
possible to generate a genetic mutant at that time (reviewed in (37)). As selection techniques were 
elaborative, a new, selection-free method would be an advantage. 
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A plasmid only system 
A breakthrough in the generation of recombinant influenza viruses came in 1999, with the 
development of the first, “plasmid only” rescue system for influenza. This first generation of plasmid 
only reverse genetics consisted of 17 plasmids: 8 plasmids containing the viral genome and 9 
expression plasmids for the production of the viral proteins (38, 39). The expression plasmids used 
the pol II promoter for mRNA and protein expression, resulting in 9 viral proteins. The M1 and M2 
proteins were synthesized form different plasmids. NS1 protein was not produced, since it is a non-
structural protein that is not necessary to generate new progeny virus. To generate influenza vRNA, 
the positive sense sequence of the influenza gene segments was cloned behind a Pol I promoter. Two 
different methods used either the Pol I terminator (38) or the hepatitis delta virus ribozyme (39) for 
generating the correct 3’ end. The latter contains autocatalytic activity, which splices the RNA 
transcript at a defined site. After transcription by Pol I, these vRNA fragments contain the exact 3’ 
and 5’ viral ends that are recognized by the influenza polymerases and NP proteins which assemble 
to vRNPs. The aggregation of all viral proteins and the vRNPs near the membrane results in budding 
of recombinant progeny virus. Even though this system required the introduction of 17 plasmids into 
the same cell, high viral titers, up to 10
7
 PFU/ml culture supernatant could be recovered (37). With 
this new system, for the first time, virus could be generated starting from “scratch”, i.e. only DNA. In 
contrast to previous systems, now virus with changes in any of the 8 segments could be produced, 
including PB1 and PA, at least if the introduced mutations or changes did not affect important steps 
in the viral replication cycle. This system was easy to use, since only molecular cloning, DNA 
purification and transfection techniques were needed. Additionally, the need for selection could be 
circumvented, since no helper virus was used and hence only pure recombinant virus is generated. In 
fact, the minimal number of plasmids necessary for the generation of influenza virus was 12: only 
PB1, PB2, PA and NP were necessary as expression plasmids (38). Upon transfection of these 12 
plasmids, a first round of transcription would be performed by the cellular Pol II resulting in the 
expression of PB1, PB2, PA and NP. The presence of these 4 proteins ensures further transcription 
and expression of the other viral proteins. However, expression of more than these 4 proteins from 
expression plasmids increased the viral titer that could be recovered.  
The eight-plasmid system 
In 2000 Hoffmann and colleagues described a new influenza A virus reverse genetics system, 
combining the Pol I and Poll II transcription units in one, ambisense Pol I/Poll II cassette (40). This 
system consisted in 8 plasmids carrying each one of the influenza gene segments which provide both 
the vRNA and the viral proteins from the same plasmid. In these plasmids negative sense vRNA was 
produced under control of a human Pol I promoter and murine Pol I terminator. This transcription 
unit was in turn flanked by a truncated immediate early Poll II promoter of human cytomegalo virus 
and a polyadenylation signal from bovine growth hormone (bgh) in the opposing direction of the Pol I 
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unit, such that positive sense mRNA was produced by Pol II (Figure 3.2). As Pol I terminator, only a 
truncated form of 33 bp of the murine Pol I terminator was used, as it was observed that nucleotide 
sequences in the full length 174 bp terminator could interfere with Pol II driven protein expression. 
(40). Interestingly, two different types of mRNA are produced with this system. A first mRNA species 
is transcribed by the cellular Poll II polymerase and contains sequences of the pol I promoter and 
terminator in its non-coding regions. A second type of mRNA is produced by the viral polymerases, 
from the negative sense vRNA, which in turn was produced by the Pol I polymerase. This second 
mRNA species does not contain additional 3’ and 5’ non-coding regions. 
 
Figure 3.2 Schematic representation of the pol I/pol II transcription system for the synthesis of 
vRNA, mRNA and viral proteins. The cDNA of each of the eight viral gene segments, together with its 5’ and 
3’ non coding regions (NCR) is inserted between the human pol I promoter (Pol I) and murine pol I 
terminator (T). This pol I transcription unit is flanked, in the opposite orientation, by the human 
cytomegalovirus pol II promoter (Pol II) and the bovine growth hormone gene polyadenylation signal (pA). 
Upon transfection of eight plasmids to a human cell line, transcription from the pol I promoter results in 
negative vRNA transcripts, which contain the viral NCRs. Pol II transcription yields positive sense mRNA that 
has a 5’ CAP and a 3’ poly-A tail. This mRNA is translated into at least 10 viral proteins. 
Variations of the plasmid only system 
Later, multiple systems have been reported which reduced the number of plasmids that need to be 
co-transfected. For example, in 2005, Neumann. et al. reported a 3 or 4 plasmid system consisting of 
1 plasmid containing all 8 Pol I transcription cassettes combined with a plasmid containing the PB1, 
PB2 and PA Pol II expression cassette and a third plasmid containing the NP Pol II expression cassette 
(41). Alternatively, the Pol I cassettes could be separated on two plasmids, one carrying the HA and 
NA gene sequence and the other carrying the other 6 gene sequences. This system would be ideal for 
rapid generation of new vaccine strains. It has the advantage over the eight plasmid system that 
70 
fewer plasmids need to be transfected, which is required for the transfection of cell types such as 
Vero cells that have been approved for the production of vaccines but are difficult to transfect (42). 
An ultimate reduction in the number of plasmids resulted in a one-plasmid system, in which the pol 
I/pol II ambisense cassettes for PB1, PB2, PA and NP were combined with the Pol I cassettes of HA, 
NA, M and NS into one large plasmid (43). A major drawback of these 3-, 4- or 1-plasmid systems is 
that these systems use large plasmids, up to 23.6 kb in size, which are susceptible to intraplasmid 
recombination. This is most likely a consequence of the large number of repetitive structures present 
in these plasmids. Growth of large plasmids at room temperature (41), or the use of low copy 
number plasmids (43) have been reported to overcome this problem, however this makes it more 
difficult to produce these plasmids. For this reason the eight plasmid system, which uses smaller 
plasmids is currently still widely being used for the rapid production of recombinant influenza 
viruses.  
Due to the species specificity of the Pol I promoter there is a restriction on the cell line that can be 
used for recombinant virus production with the plasmid-only based systems. The first systems that 
possessed a human Pol I promoter used HEK293T cells, as these cells are easily transfectable (38). 
However, these cells do not support multiple rounds of influenza replication, because they detach 
upon addition of high concentrations of trypsin to the cell culture, which is required for the cleavage 
of the HA protein, to generate infectious virus particles (44). In contrary, MDCK cells are commonly 
used to grow influenza virus, however, these cells have a very low transfection efficiency, which is 
undesirable when multiple plasmids need to be transfected into a single cell. Additionally, MDCK cells 
do not support transcription from a human Pol I promoter, making these cells not suitable for 
generation of recombinant influenza virus from plasmid only rescue system. Therefore, combination 
of these cell types in coculture was used to increase the yield of influenza viral titer (40). In this 
coculture, transfection of plasmids resulted in recombinant virus produced by a single round of virus 
growth in HEK cells, which after addition of trypsin was capable of replicating to high titers in MDCK 
cells. Plasmid-based transfection systems were also adapted to multiple cell types, by changing the 
Pol I promoter used. Cell types used, other than human cell lines, include monkey cells (Vero) (39, 
41), canine cells (MDCK) (45) and avian cells (CEF, QT6) (43, 46). One study reported the generation 
of recombinant influenza virus using the human Pol I promoter in MDCK cells (47). This is the only 
exception to the species specificity of the Pol I promoter that was reported. To overcome the species 
specificity, a universally applicable plasmid-based reverse genetics system was designed using the 
bacteriophage T7 promoter for the expression of vRNAs instead of the Pol I promoter (48). This 
system is dependent on the expression of the T7 polymerase in the cells, which can be achieved by 
transfection of a plasmid expressing the T7 polymerase. Even though this system is still dependent on 
transfection of multiple plasmids, it allows the production of recombinant influenza virus in cell types 
from multiple species. 
Next to the systems mentioned here, also reverse genetics 8 plasmid and 7 plasmid systems have 
been constructed for the generation of influenza B virus and influenza C virus respectively (49, 50). 
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A plasmid-free reverse genetics system 
Recently, Chen et al. reported the generation of a plasmid-free reversed genetics system (51). By 
PCR, using primers that contain the sequence of the pol I promoter and terminator, they generated 8 
PCR amplicons consisting each of 1 viral gene flanked by the pol I promoter and terminator. Similarly 
4 pol II PCR amplicons were generated containing the 3 polymerase genes and NP flanked by the pol 
II promoter and bgh poly A site. Transfection of these 12 PCR products into co-cultured 
HEK293T/MDCK cells resulted in detectable, albeit low levels or viable influenza A virus. This plasmid 
free system may be interesting when cloning difficulties are encountered. A drawback of this system 
is that internal primers in the influenza genes are needed to generate PCR amplicons. This requires 
sequence information, which may not always be available for new viral strains. 
3.3 Applications of the reverse genetics system 
A new strategy for the production of influenza vaccines 
The plasmid based reverse genetics systems have become a useful tool for generating recombinant 
influenza viruses, which can be used for several purposes. By site-directed mutagenesis in a gene of 
interest, the function of a specific gene or a gene domain can be elucidated. Also for the generation 
of new vaccine strains this system has proven to be useful. Two different types of influenza vaccine 
are currently licensed and used for the prevention of seasonal influenza infection. Inactive influenza 
vaccines that are delivered by an intramuscular injection have been popularly used world-wide for 
the prevention of annual influenza epidemics. Alternatively, live vaccines are given by an intranasal 
route and have the advantage to stimulate a broader immunological response than the inactive 
vaccines providing cross-protective immune responses (52, 53). The production of both vaccines 
requires a reassortant vaccine strain that matches the current infection. The classical method for 
generating such a reassortant strain is based on the co-infection of a circulating strain with a high 
growth laboratory strain such as A/Puerto Rico/8/34 or with a live attenuated master strain and the 
selection of the reassortant of a particular 6:2 ratio, that possesses the NA and HA gene from the 
circulating strain and the other six genes from the master strain (54). The method is very laborious 
and time-consuming and may not meet the tight schedule for the production of a vaccine in a short 
period of time (55). In contrasts, the reverse genetic approach allows direct generation of the 6:2 
recombinant vaccine strains without the need for selection, which can be achieved in a few weeks 
(56, 57).  Until now seasonal influenza vaccines continue to be produced via the classical way. 
However, during the 2009 so called swine flu or Mexican flu pandemic, caused by the 
A/California/07/2009 H1N1v virus, reverse genetics has been successfully used, alongside the 
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classical reassortant based method, in an attempt to rapidly produce a vaccine before the pandemic 
reached its peak (57). In the end, both vaccines were manufactured and used for prevention of the 
swine flu pandemic. Due to biosafety concerns, classical reassorting techniques cannot be used for 
the generation of vaccine strains against highly pathogenic avian influenza viruses (HPAIV), as these 
vaccine viruses would still contain the polybasic cleavage site in HA, which is characteristic for HPAIV, 
and is responsible for their pathogenicity (57, 58). Removing a stretch of basic amino acids from the 
cleavage site of HA results in attenuation of the HPAIV (59) which is suited for use as a vaccine strain 
(58, 60). Several of this avian influenza vaccine strains have been used as seed strain for the 
production of avian flu vaccines (57) which have been tested in human clinical trials (61, 62). 
Influenza as a recombinant viral vector vaccine for other pathogens  
In addition, plasmid based reverse genetics systems have become interesting for the use of influenza 
as a recombinant viral vector expressing foreign proteins or peptides to induce immunity against a 
variety of diseases. Influenza is particularly interesting as viral vaccine vector, for several reasons. 
First, since no DNA intermediates are produced during viral replication, there is no fear for 
integration of viral DNA in the host genome, which could result in adverse mutations or cancer. 
Second, influenza is known to induce a strong humoral and cellular immune response, which is a 
requirement for a good vaccine. Another advantage of influenza vectored vaccines is that they may 
be used frequently. As a consequence of its continuously evolving NA and HA genes, changing in 
these proteins in the vaccine vector would result in a new vaccine, to which no immunity is present. 
A practical advantage of the use of influenza as viral vector, is the availability of large scale 
production, in embryonated chicken eggs. Additionally, since live attenuated influenza vaccines are 
already being used in the human population, it is not unlikely that other influenza vector based 
vaccines would be accepted for human use. And finally, the reverse genetics plasmid based systems 
have made influenza an easy to manipulate vector, as changes only need to be introduced in DNA 
plasmids. With the advent of reverse genetics techniques, several recombinant influenza viruses 
expressing foreign peptides or proteins have been created (for a review, see (63, 64). These have 
been used for providing protection in experimental animal models against a wide range of infectious 
diseases such as HIV (65, 66), tuberculosis (67, 68), or malaria (69-71) and even as an anti-tumor 
therapy (72, 73). Several different strategies have been used, with differences in the protein used to 
insert the foreign sequence and differences in the length of the insertion, and in the way the foreign 
sequence is expressed, leading to differences in attenuation of the resulting recombinant virus. 
Indeed, it has been shown that most of the insertions result in a virus that is viable, however, 
attenuated in vitro and/or in vivo, compared to the wild type virus. The foreign proteins or peptides 
are expressed either as fusions to one of the influenza proteins, or as a separate open reading frame 
in a bicistronic gene, or even as a completely independent genome segment. The proteins most 
frequently used for insertion of foreign sequences are HA, NA and NS and will be discussed in more 
  73 
detail. Determining the regions that allow insertion of foreign sequences, without affecting the 
protein function, has been critical for the construction of recombinant viruses.  
 
Hemagglutinin 
The influenza HA forms mushroom-shaped trimers on the surface of the virion. These consist of a 
globular head and a stem. HA is known for its induction of neutralizing antibodies and the antigenic 
structure of different HA molecules has been extensively studied. Five antigenic regions, named A to 
E, have been mapped to the HA protein (74, 75) (Figure 3.3). Antigenic site A is centered around a 
protruding loop containing residues 133 and 137 and 140–146; site B is centered on a loop of 
residues 155–160 and an α-helix at residues 186–197; site C comprises the surface around the 
bonded cysteine residues 52 and 277; site D is located near the interface between monomer 
subunits; and site E is near the bottom of the globular domain between sites A and C. Since HA is the 
major antigenic protein of the influenza virus, this protein is of particular interest for the insertion of 
foreign epitopes for the induction of antibody responses.  
Figure 3.3 Model of influenza HA antigenic structure. The antigenic sites A–E in are indicated with special 
colours and labels. Adapted from Mochizuki et al. (76). 
 
Foreign B cell epitopes have been inserted with success into sites B and E, resulting in antibody 
mediated protection against pathogens such as HIV (65, 66), Pseudomonas aeruginosa (77) and 
Plasmodium falciparum (71). The HA protein was not only successful for the induction of B cell 
responses; also introduction of foreign cytotoxic T lymphocyte (CTL) epitopes into antigenic site B or 
E induced an effective immune response against the foreign epitope (70, 71, 78, 79). A recombinant 
influenza virus carrying a CTL epitope of the rodent malaria parasite Plasmodium yoelii in its antigenic 
site E was shown to induce a CD8+ T cell response that was protective against P. yoelii (70). This was 
the first report showing that a recombinant influenza virus can induce a protective T cell response 
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against a heterologous pathogen. Besides small B- and T-cell epitopes, also large polypeptides have 
been expressed as fusion proteins with HA. For example, Li and colleagues succeeded in fusing a 
fragment of 140 amino acids, representing the receptor binding domain of Bacillus anthracis PA 
protein to the HA protein, resulting in a functional HA and a recombinant virus which remained 
stable after multiple passages. The foreign protein was fused behind the fusion peptide of HA at the 
N-terminus of the HA1 domain; a region known to allow large insertions. Immunization of mice with 
plasmids encoding the recombinant HA and the recombinant virus induced protective antibody 
responses against both influenza and Bacillus anthracis (80). 
 
Neuraminidase 
The NA is the second major glycoprotein that forms spikes on the viral membrane. The gene 
encoding NA is 1,413 nucleotides long and codes for a protein of around 470 amino acids (11); 
however, differences in length occur between different subtypes and even within viruses belonging 
to the same subtype. NA is present as mushroom-shaped, homotetramers on the virion (11). It is 
built up of 4 different parts, which are, (I) a short highly conserved cytoplasmic tail, (II) a hydrophobic 
transmembrane domain, (III) a stalk region and (IV) a globular head which possesses the enzymatic 
activity (10). The stalk, the cytoplasmic domain and transmembrane domain are not essential for the 
neuraminidase to be active: globular head domains separated from the rest of the protein is still 
enzymatically active (81). The sequence of the stalk region is highly variable between viruses of 
different subtypes. Additionally, differences in stalk length due to deletions or insertions are 
frequently found in nature (82, 83). For example, deletions of about 20 amino acids in the stalk of NA 
are characteristic for the adaptation of influenza viruses from aquatic birds to domestic poultry, such 
as chickens (84, 85). These observations led to the idea that the stalk of NA might tolerate the 
insertion of additional, foreign sequences, which was confirmed by Castrucci and coworkers (86). 
Later, Luo and colleagues described that insertions of up to 41 amino acids in the stalk of NA did not 
abolish the formation of infectious progeny virus (87). Soon, this resulted in the development of the 
first influenza viral vector expressing a foreign epitope in NA. This vector, constructed by Castrucci 
and colleagues contained a CTL epitope of the lymphocytic choriomeningitis virus (LCMV) and 
protected mice against an otherwise lethal LCMV infection (88). Additionally they showed that 
insertions of up to 58 amino acids into the stalk are tolerated by NA, opening windows for insertions 
of large foreign epitopes; however, until now only short T cell epitopes have been reported as 
insertions into the NA stalk for generating influenza viral vectors. T cell epitopes inserted in the NA 
stalk have been reported to protect against a variety of infectious diseases, such as malaria (69), 
LCMV (88), Chlamydia (89), Herpes (90) and others. Additionally, recombinant influenza viruses 
expressing a foreign epitope in the NA stalk have been reported as an attractive candidate for anti-
tumor vaccines. A recombinant influenza virus expressing a CTL epitope of the proto-oncogene HER-2 
was shown to specifically induce CTLs against this tumor associated gene (72). Another study, which 
used a recombinant influenza viral vector expressing a CTL epitope of β-galactosidase in the NA stalk, 
showed that CTLs induced by this vector mediated the regression of established pulmonary 
metastasis in mice (91) and tumor clearance (92). Using a recombinant influenza virus containing the 
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OVA-derived K
b
-SIINFEKL epitope in the neuraminidase stalk, Dolan and colleagues demonstrated 
that this epitope is rapidly presented at the cell surface by MHC-I molecules: the first peptide-MHC 
complexes were detected already 3h after infection (93). 
HA is the major antigenic protein of influenza viruses, and substantially less antibodies are directed 
to the NA. This might explain why insertions in the stalk of NA has been almost exclusively limited to 
T cell epitopes (reviewed in (63)) and little insertions of foreign B cell epitopes for the induction of an 
antibody response have been reported. One study using the NA stalk for the insertion of the Flag 
epitope showed that this region is not suited for the induction of B cell responses. Mice immunized 
with the Flag expressing virus did not mount a detectable antibody response (94). Different 
approaches have been used for the insertion of larger foreign protein fragments into the NA gene 
segment. A first approach expresses a foreign protein from a bicistronic gene segment using a 
duplication of the NA 3’ noncoding region (95, 96). In contrast to the strategies described earlier, this 
approach does not produce a fusion protein, but rather results in the production of 2 separate 
proteins: a wild type influenza NA protein and a reduced but significant expression of a foreign 
protein. These recombinant influenza viruses harboring a bicistronic NA gene fragment however 
show a reduced growth rate in vitro, which correlated with reduced expression of NA protein in 
infected cells (95). These recombinant viruses have been shown to effectively induce both B- and T-
cell mediated immune responses to the foreign protein in mice (96). A similar strategy uses an 
internal ribosomal entry site (IRES) for the expression of a second protein (97). A last approach uses 
the foot and mouth disease virus (FMDV) 2A protease recognition site, between the foreign 
sequence and the NA sequence (98, 99). Upon translation, this sequence is self-cleaved, resulting in 2 
separate proteins. This strategy has also been used for the generation of a reporter influenza virus, 
carrying the enhanced green fluorescent protein (eGFP) sequence in the NA gene segment (100).  
 
Non-structural protein 1 
A last gene that is commonly used for the insertion of foreign sequences is the influenza NS gene 
segment. This gene codes for the NS1 protein from collinear mRNA and the NEP protein from a 
spliced mRNA (101, 102). NS1 has a length of 230-237 aa, depending on the strain. The NS1 protein 
can be divided into three domains: an N-terminal RNA binding domain (aa 1 – 73) (103), a larger 
effector domain (aa 74 – 207) and a short C-terminal tail (23 to 30 aa in length). Full-length NS1 
proteins are present in the cell as homodimers (104). NS1 is not a structural component of the virion 
but is present in very high levels in the infected cells. The non-structural NS1 protein is a non-
essential accessory protein that has multiple functions during the viral infection cycle. The major 
function of the NS1 protein consists of antagonizing the anti-viral state in the host by inhibiting the 
production of IFN-α and IFN-β and the antiviral effects of IFN-induced proteins. Additionally, NS1 also 
plays an import role in other aspects of the viral replication cycle, such as RNA replication, viral 
protein synthesis and general host-cell physiology (reviewed in (105)). The second protein, encoded 
from a spliced mRNA of segment 8 is the 121 aa long NEP (previously referred to as NS2). This 
protein, as the name says, is involved in the export of newly synthetized vRNP complexes from the 
nucleus (106). NEP consists of an N-terminal domain (aa 1-53) which binds to Exportin 1 (also known 
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as Chromosome Region Maintenance protein 1 (CRM1)) and a C-terminal domain (aa 54-121) that 
binds to influenza M1 protein, which in turn is bound to the vRNPs  (107). Recent studies have 
suggested that NEP may have multiple functions during the influenza virus replication cycle. In 
addition to nuclear export of vRNPs, it has been demonstrated that NEP contributes to the viral 
budding process through interaction with a cellular ATPase. Furthermore, studies have demonstrated 
that NEP is involved in regulating the accumulation of viral RNA species, which might lead to a switch 
from viral transcription during early viral replication to the production of genomic vRNPs later in the 
replication cycle (reviewed in (108)). The NS gene is of particular interest for the insertion of foreign 
epitopes or proteins, because of several reasons. First, due to the small size of both NS1 and NEP, 
large sequences can be inserted in the gene segment (109). Second, since NS1 is non-essential, 
deletion of this gene (by replacing it with foreign sequences) does not affect the viability of the virus 
in vitro in IFN deficient systems (110). The same is true for truncations of NS1. In fact, viruses with 
NS1 deletions or truncated NS1 proteins are attenuated and replicate less efficiently in vivo (111); 
which might be an advantage, if one aims at constructing a live attenuated influenza viral vector. 
Mice infected with influenza viruses lacking (a part) of the NS1 protein, experience reduced or no 
illness as a results of a more robust host IFN response. As a consequence of this strong host immune 
response,  T and B cell responses are efficiently induced (112, 113) which are effective in providing 
protection against a subsequent influenza challenge (111). Influenza viruses possessing a C-terminally 
truncated NS1 have been studied extensively for their potential as live attenuated influenza vaccine, 
for instance against highly pathogenic avian influenza viruses (114). Another advantage of the NS 
gene for inserting foreign sequences is that a functional NEP, which is essential for virus replication, 
can still be produced even when NS1 is changed, by introducing a FMDV 2A autoproteolytic cleavage 
site in between both coding sequences. Alternatively, NEP production is not affected when foreign 
sequences are inserted between nucleotides 57 and 528 of the NS gene, which corresponds to the 
NS1 coding region which is not present in NEP, due to splicing of the mRNA. For the expression of 
foreign epitopes or proteins from the NS gene similar strategies have been used as for the expression 
of foreign proteins from the NA gene (see above). These include fusions to the NS1 protein (115), 
insertion a caspase recognition site (109) or the FMDV 2A autoproteolytic cleavage site (116) 
between NS1 and the foreign protein, or alternatively, the insertion of an overlapping stop-start 
codon (UAAUG) between both coding sequences (117). A recombinant influenza virus which 
expresses a truncated NS1 protein (125 amino acids) fused to the FMDV 17-amino-acid self-cleaving 
2A site and the 137 C-terminal amino acids of the HIV-1 Nef protein, was able to induce HIV-specific 
immune responses. Even though the virus was highly attenuated in vivo (it did not replicate in the 
mouse respiratory tract) it induced significant Nef-specific B cell and CD8+ T cell responses (116). The 
same approach, using a virus with a truncated NS1 protein of 125 aa expressing the Mycobacterium 
tuberculosis ESAT-6 protein (95 aa) was shown to induce a CD4+ Th1 immune response which was 
protective against M. tuberculosis in mice and guinea pigs (67, 68). The immune response could be 
enhanced by administering a booster vaccination with an influenza virus of a different subtype than 
the priming vaccination. Insertion of GFP in the NS gene results in the generation of a reporter virus 
which can be used to follow the course of in influenza infection in vivo and in vitro (109, 118). 
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Another interesting application uses recombinant influenza viruses for the expression of biologically 
active molecules, such as cytokines (117, 119). Kittel et al. generated a recombinant influenza virus 
with a truncated NS1 (aa 1-125) that encodes interleukin 2 (IL-2) in a bicistronic reading frame (117). 
Upon infection of mice with this virus, IL-2 is expressed and acts as an adjuvant enhancing the 
immunogenicity of the virus. This approach resulted in an enhanced CD8
+
 T cell immune response to 
the viral antigens. Similarly, the IL-2 coding sequence was added to the NS1 gene of the cold adapted 
influenza strain which is currently being used for the generation of live attenuated influenza vaccines 
(LAIV) (54, 120). The expression of IL-2 from this enhanced the immunogenicity of this LAIV in mice, 
resulting in enhanced mucosal IgA production and an enhanced CD8
+
 T cell response. This might form 
an interesting strategy for the improvement of the immunogenicity of LAIVs. The expression of 
immunomodulatory cytokines from a virus lacking the NS1 protein (delNS1) has also been shown to 
be an interesting anti-cancer tool. One of the functions of NS1 is to inhibit PKR. As a consequence, 
delNS1 viruses can no longer replicate in normal, PKR expressing cells, but are still replication 
competent in PKR-deficient cells. Activated ras, which can be found in malignant tumor cells, induces 
an inhibitor of PKR (121). Hence, cells expressing ras are permissive for delNS1 viruses, resulting in 
lysis of these tumor cells. This delNS1 virus was shown to repress tumor growth in a SCID mouse 
model (122). The oncolytic effect could be further enhanced by the expression of biologically active 
IL-15 from the NS gene (73). This immunomodulatory cytokine is known to activate tumor specific 
CTLs and NK cells (123), and the delivery of this cytokine specifically in tumor cells through a delNS1 
virus might provide an interesting anti-tumor strategy. 
 
Influenza with additional gene segments 
A different strategy for creating recombinant influenza viruses is by adding an extra gene segment 
carrying a foreign gene to the virus. In fact, the first report of a reverse genetics technique using the 
RNP transfection method, generated such a virus expressing the chloramphenicol acetyltransferase 
(CAT) gene instead of the NS genes (32). Crucial for the generation of these recombinant viruses is 
the characterization of packaging signals required for incorporation of the influenza gene segments 
in the virion (124). Even though the process of packaging was not completely understood at that 
time, Luytjes et al. succeeded in incorporating a foreign gene in the influenza virion, by flanking the 
non-viral CAT sequence with the viral non-coding regions of the NS gene segment (32). Shortly after 
this first recombinant virus, Enami et al. reported the creation of the first influenza virus carrying 9 
instead of the normal 8 gene segments (125). This 9
th
 segment can be of use for generating bivalent 
vaccines against 2 pathogens, or against 2 different influenza strains, for instance, by incorporating 
an additional HA gene of a second influenza strain as was demonstrated by Gao et al. (126). Stability 
of the resulting recombinant viruses remains an important factor. For example, for the 8-segment 
influenza virus carrying the CAT coding sequence it was reported that CAT activity dropped after as 
little as 3 passages (32). In contrast, the 9-segment virus produced by Enami et al. stably replicated. 
This is most likely explained by the fact that the 9-segment virus has a selective advantage over the 
same virus with only 8 segments, because it carried an extra NS1 gene, which complemented for the 
loss of function of NS1 in the parental, 8-segment virus (125). 
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3.4 Conclusion 
Influenza viruses are capable of inducing strong and long lasting humoral as well as cellular immune 
responses. Therefore, manipulated influenza viruses expressing selected antigens from a foreign 
pathogen have the potential to elicit humoral and cellular immune responses to this pathogen. This 
was made possible by the development of reverse genetics techniques. The generation of 
recombinant influenza virus relies on the expression of the polymerase and NP proteins, in the 
presence of the viral RNA genome. The plasmid only rescue systems form an attractive platform for 
manipulating influenza virus genes and generating recombinant viruses. These systems have been 
used for the generation of recombinant influenza viruses expressing a variety of B and T cell epitopes 
or polyproteins derived from foreign pathogens. Protection has been shown in several cases. For the 
efficient induction of a T cell response, a live viral vector, such as a recombinant influenza virus, is an 
ideal vehicle, since it delivers the T cell epitope inside the cell, a perquisite for its processing and 
presentation on the cell surface. It should be noted, that a prime/boost vaccination strategy might be 
necessary in most cases for induction of a strong long lasting immune response. In this respect, 
priming with recombinant influenza virus expressing malaria antigens, followed by a boost with 
recombinant vaccinia virus expressing the same antigen, provided the first evidence of such a 
strategy in animal models (70, 127). Alternatively, as a result of the constantly occurring antigenic 
drift, influenza strains with different antigenic characteristics, which do not cross-protect could be 
used for prime/boost vaccination strategies. Recombinant influenza viruses with truncated or 
deleted NS1 proteins form an even more attractive strategy for the use of influenza as recombinant 
viral vector for foreign epitopes. Indeed, as a result of their decreased anti-IFN effect, these viruses 
induce a potent immune response in the host, with minimal morbidity, due to in vivo attenuation. 
The time between the emergence of a new (possible pandemic) influenza strain and the availability 
of a vaccine is crucial in the fight against a possible new influenza pandemic or epidemic. With the 
development of reverse genetics techniques for influenza viruses it has now become faster and 
easier to develop such vaccine strains for the production of vaccines. The limitations of the 8 plasmid 
system, which are, the transfection of multiple plasmids into one cell and the use of a cell line not 
approved by the FDA for vaccine production (HEK293T cells) has already been tackled. By reducing 
the number of plasmids for transfection to 3 or even 1 it is possible to have high yield of recombinant 
influenza virus in the FDA approved Vero cell line (42). The reverse genetics system has already been 
used for the production of a vaccine strain against the 2009 Mexican flu, and will likely be used more 
frequently in the future for the production of influenza vaccine viruses. 
Highly pathogenic H5N1 viruses are lethal to human and embryonated chicken eggs and therefore, 
vaccines against these viruses cannot be produced by traditional methods. The reverse genetics 
system made it possible to replace the cleavage site of the HPAIV HA protein with that of less 
pathogenic avian strains. These viruses are now safe to be handled by human and are no longer 
lethal, when produced in embryonated chicken eggs (128). 
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Aims and objectives 
Infection with respiratory syncytial virus (RSV) is a major cause of severe pneumonia and 
bronchiolitis in new-born babies. Preventive measures available for this pathogen consist of monthly 
injections with monoclonal antibodies directed against RSV. However, due to its high cost, this 
treatment is only routinely being applied to children having an increased risk of developing severe 
RSV-induced disease. In addition, the protection provided by this treatment is partial and only 
temporary (1). Therefore, there is an urgent need for effective preventive measures against RSV. A 
vaccination that protects infants from becoming infected with RSV would be an ideal solution. 
Strategies for vaccine development explored in the past mainly involved the use of live attenuated 
RSV or subunit vaccines. However, these vaccines were not suitable as a vaccine for use in infants 
because they were either not sufficiently attenuated or did not provide a significant level of 
protection (2). Therefore, the main aim of this thesis is to explore novel strategies for developing a 
safe and effective RSV vaccine. 
The level of RSV neutralizing antibodies has been shown to correlate with protection against RSV 
infection in experimentally infected adults (3). In addition, high levels of maternally derived 
antibodies correlate with protection in infants (4) and passive administration of antibodies reduces 
the risk of acquiring severe RSV-induced disease (1). Therefore, the first approach explored in this 
research aims at inducing a significant level of RSV neutralizing antibodies (Chapter 4). To achieve 
this, selected peptides of the RSV fusion protein were genetically fused to virus-like particles 
consisting of Hepatitis B virus core protein monomers, which results in the presentation of the 
peptide in a highly repetitive manner to the immune system. 
An increasing number of data supports the rationale that, for an efficient vaccine against RSV, the 
induction of a T cell immune response will be mandatory. In RSV infected infants, the increase in RSV 
specific CTLs coincides with convalescence, indicating a role for CD8
+
 T cells in clearing the virus from 
the lungs (5). Moreover, reports have demonstrated that fatal cases of RSV infections are 
characterized by high viral titers and near absence of pulmonary infiltration of T cells or the cytokines 
they produce (6). In addition, the induction of a CD4
+
 Th2 immune response by vaccination has been 
shown to lead to exacerbation of disease upon a subsequent RSV infection (7). The induction of a 
CD8
+
 T cell response has been shown to redirect this harmful response to a more balanced immune 
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response in mice (8). Therefore, the second vaccine approach described in this research explored the 
possibility of inducing an RSV specific CTL immune response by using a recombinant influenza virus 
that expresses an RSV CTL epitope. The protective efficacy of this vaccine against an RSV infection 
was evaluated in vivo in BALB/c mice (Chapter 5). 
Since the recombinant influenza virus is a live, replicating virus used as vaccine vector a last aim of 
this research was to develop a safe variant of this vaccine that is harmless to the mice, yet still 
potently induces immunity against an RSV infection. We explored the use of passive anti-M2e 
antibody treatment prior to infection with the recombinant influenza virus (Chapter 5). In addition, 
two strategies for developing an attenuated variant of the influenza virus were assessed (Chapter 6). 
Moreover, one of these attenuated viruses was engineered to express GFP protein in the infected 
cells. The possibility to use this virus as an in vitro and in vivo reporter virus was examined (Chapter 
6). 
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4.1 Introduction 
Despite decades of research, there is currently no licensed safe and effective HRSV vaccine available. 
Throughout the years, several different approaches have been developed, however, none were 
successful, due to different reasons. First attempts, with formalin-inactivated whole HRSV as a 
vaccine, were only poorly protective and even resulted in exacerbated disease upon a subsequent 
HRSV infection (1). Later attempts with subunit vaccines consisting of purified F protein (PFP-1, PFP-2 
and PFP-3) or the conserved central domain of the G-protein fused to the albumin-binding domain of 
streptococcal G-protein (BBG2Na) were discontinued for several reasons. The PFP-3 vaccine was 
tested in a clinical phase III trial in children 1 to 12 years of age with cystic fibrosis, but even though 
the vaccine was well tolerated and induced an increase in neutralizing HRSV antibodies, this response 
was not associated with significant protection (2). A clinical phase III trial with the BBG2Na vaccine 
had to be stopped due to unexpected adverse events (3). A different strategy consisted of the 
production of live, attenuated virus vaccines by cold-adaptation and chemical mutagenesis of the 
virus. The initial live attenuated viruses were further modified through genetic engineering, by 
deletion of non-essential genes or adding additional attenuating mutations. One such virus, 
rA2cpts248/404/2030/ΔSH (MEDI-559) is currently being tested in a phase I/IIa trial in 5 to 24 
months old children (4).  Despite the fact that MEDI-559 has been shown to be immunogenic in a 
small scale trial in infants and has an acceptable safety profile (5), stabilization of the temperature 
sensitive phenotype seems to be difficult, due to the emergence of additional mutations (4). A 
difficult challenge regarding the development of a live attenuated vaccine remains to find a balance 
between under- and over-attenuation, resulting either in an unfavorable safety profile or 
in insufficient protection. Recent progress in the development of an HRSV vaccine include the use of 
chimeric viruses and replication-competent and –incompetent vectors (Table 1.3; reviewed in (6)). 
Due to problems with stability, safety and potency in the above mentioned attempts, the search for 
an HRSV vaccine is still ongoing. 
Antibodies induced upon an HRSV infection are mostly short lived and are poorly protective against 
reinfections. Despite the defective natural immunity induced by an HRSV infection, neutralizing 
antibodies play an important role in protecting against an HRSV infection. In animal models, HRSV F- 
and G-protein can induce long lived protection through neutralizing antibodies (7, 8). In human, high 
titers of HRSV neutralizing antibodies tend to correlate with protection of adults against an 
experimental HRSV challenge (9), although the level of preexisting antibodies is not fully predictive of 
susceptibility to HRSV infection. Also in children the amount of HRSV neutralizing antibodies inversely 
correlates with susceptibility to severe HRSV infection (10, 11). The observation that neutralizing 
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antibodies can provide a substantial protection against HRSV infections was a rational for the 
development of a prophylactic treatment consisting of an IgG preparation containing high levels of 
HRSV neutralizing antibodies derived from human donors (Respigam) (12), which can substantially 
reduce HRSV incidence in high risk children. Nowadays this treatment is replaced by a humanized 
monoclonal antibody treatment Palivizumab (also known as Synagis; Medimmune, Gaithersburg, 
Maryland, USA)(13). Efficacy studies with Palivizumab have shown that a high level of circulating 
antibodies is sufficient to prevent lower respiratory illness in infants (13) (Table 1.1). 
Together with the attachment G-protein, the fusion F-protein is a major glycoprotein expressed as a 
homotrimer at the surface of the HRSV particle. The F-protein is responsible for the fusion of the viral 
membrane with the host cell membrane. Each F-monomer is expressed as an inactive precursor, 
which needs to be cleaved at two sites by a host furine protease to liberate the so called fusion 
peptide (14) (see chapter 1, Figure 1.3). After insertion of the fusion peptide in the host membrane, 
the metastable pre-fusion form is activated and a series of conformational rearrangements leads to 
fusion of the viral membrane with the host membrane (15, 16). After fusion, the F-protein acquires a 
highly stable post-fusion conformation, which is characterized by a 6-helix bundle (see chapter 1, 
Figure 1.4). Neutralizing antibodies have been mapped to three major antigenic regions in the fusion 
protein: antigenic site I, II and IV, by identifying amino acids that were altered in in vitro selected 
antibody escape mutants (17). Sites II and IV are the best characterized. Antigenic site II (also called 
site A) contains amino acids 255 to 275 and is the recognition site for palivizumab (18), the 
humanized monoclonal antibody used prophylactically against HRSV. More recently the structure of 
motavizumab, a more potent derivative of palivuzumab, in complex with a synthetic peptide 
revealed that the peptide that corresponds to residues 254 to 277 (NSELLSLINDMPITNDQKKLMSNN) 
forms the recognition site for this monoclonal antibody. However, modeling suggested that besides 
this peptide, the antibody also binds to other residues which are present on an adjacent monomer in 
the F-protein trimer, indicating that this antibody recognizes a quaternary epitope (19). Antigenic site 
IV (also known as site C) includes residues 422 to 438 (17, 18) and is the target site for monoclonal 
antibodies such as 101F (20) and MAb 19 (18). For these two antigenic sites (site II and IV) it has 
recently been shown that they are present in both the pre- and the post-fusion conformation of the 
F-protein (21) and that the well-characterized monoclonal antibodies that bind to these regions, such 
as palivizumab/motavizumab and 101F can bind to both conformations. Whether the pre-fusion or 
the post-fusion state is the better vaccine candidate is still being discussed (21-23). 
There is an increasing interest in the use of VLPs as vaccines for different pathogens. Currently, 
licensed VLP-based vaccines for human use are available against Hepatitis B virus and human 
papilloma virus (24, 25). VLPs consist of structural proteins without the incorporation of a viral 
genome. VLPs mimic infectious viruses but are not capable of performing multiple rounds of 
infection as infectious viruses, yet they retain the superb antigenicity of viruses, thereby potentially 
yielding safer vaccines (24). As potential immunogens that mimic the optimally spaced array of 
repetitive elements characteristic of virus surfaces, VLPs can elicit strong humoral response by 
efficiently cross-linking the immunoglobulin receptors of B cells. Interaction of B-cells with VLPs, 
therefore, efficiently induces antibodies against the highly repetitive and orderly displayed viral 
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capsid proteins. Thus, we believe that a VLP expressing fragments of the HRSV fusion protein might 
be an attractive strategy for designing an effective HRSV vaccine.  
We explored a vaccination strategy against HRSV that is based on the induction of humoral immunity 
to small peptide-epitopes instead of complete HRSV G- or F-proteins. Since small peptides on itself 
are only poorly immunogenic, the peptides were presented at the surface of a virus-like particle 
(VLP) consisting of Hepatitis B virus core protein (HBc) monomers. HBc VLPs have been extensively 
evaluated by our research group, for the development of a universal influenza vaccine based on 
linking the ectodomain of the influenza A virus M2 protein (M2e) to the HBc monomer (26-29). By 
linking short peptides of the HRSV fusion protein to HBc, we aim at inducing a protective, antibody 
response directed against specific epitopes of the HRSV fusion protein. 
4.2 Results 
Selection of the epitopes 
The fusion protein (F-protein) of HRSV is highly conserved between isolates of the HRSV A and B 
subgroups. Up to 91% of the amino acid sequence is identical between HRSV A and B isolates, 
rendering this protein a good candidate for the selection of epitopes that can induce cross-protective 
immunity against HRSV A and B subtypes. The selection of epitopes was mainly based on previously 
described neutralizing epitopes, categorized into three antigenic sites (17). Additionally, since the 
VLPs will be produced in E. coli the peptides were selected based on the absence of glycosylation 
sites. Known glycosylation sites are: Asn27, Asn70 and Asn500. 
A first peptide that was selected is the sequence from amino acid (aa) 260 to 298 of the HRSV fusion 
protein. This highly conserved region contains antigenic site II (18) and forms the recognition site for 
two known neutralizing antibodies (47F and L4) (30, 31). Furthermore, this region also contains the 
residues that are substituted in mutants that are resistant to neutralization by Palivizumab 
antibodies (32, 33). Structural data confirm that this region lies at the outer surface of the protein 
and is easily accessible to antibodies in the post-fusion state. Based on homology models with the 
parainfluenza virus type 3 F-protein pre-fusion state it is suggested that this region is also accessible 
to antibodies when it is in the pre-fusion state (21).  
The HBc carrier protein 
To render the peptides immunogenic they were coupled to virus-like particles consisting of 
monomers of the hepatitis B virus (HBV) core (HBc) protein. This is a well-characterized carrier 
protein that has been successfully used for a variety of antigens (34-36); one such example is the 
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fusion of the influenza A virus M2 ectodomain (M2e) to the HBc monomer, which has been 
extensively studied by our research group (27-29, 37). HBc is a 183 amino acid long structural protein 
(Figure 4.1 A), that assembles into dimers which form the viral capsid of the HBV particle. The N-
terminal part of HBc (amino acid residues 1-140) represents the assembly domain, as this region is 
necessary to form dimers that can self-assemble into capsids. The carboxy-terminal part (residues 
150-183) of HBc is a protamine-like domain that is arginine-rich and binds the viral genome in the 
HBV particle (38). Upon expression of HBc in E. coli, this domain can bind to host RNA, which can 
function as an adjuvant to stimulate the immune response into a, for an HRSV vaccine desired, Th1 
direction (39). However, since particles containing the C-terminal part are more complex to 
characterize and to purify, we also explored two shorter, C-terminally truncated particles consisting 
of either 149 aa (HBc-S) or 163 aa (HBc-I). An extra cysteine was engineered at the C-terminus of 
these shorter particles, to ensure stability of the particle, which in the full length protein is 
accomplished by the C-terminal cysteine at position 183. A similar approach to display M2e from an 
HBc-I based VLP has been reported recently by our group (68). 
 
 
 
Figure 4.1 Structure of hepatitis B core. (A) Primary structure of hepatitis B core (HBc) protein. (B) 
Structure of an HBc monomer, residues 1-142. (Adapted from pdb file 1QGT). (C) Structure of an HBc dimer 
(pdb 1QGT). (D) Cryo-electron microscopy picture of an HBc particle.The major immunodominant region 
(MIR) is indicated in red (panel A and B); The cysteines at position 61 that form a disulfide bridge are 
indicated in blue (panel A and C) 
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The 3-dimensional structure of a HBc monomer is made up of alpha-helices that are connected by 
loops (Figure 4.1 B) (40). HBc dimers are characterized by a central bundle of 4 helixes that are 
connected by a disulfide bridge between the cysteine residues at position 61 in each monomer 
(Figure 4.1 C). The loops that connect the anti-parallel helices within an HBc monomer are oriented 
distal from the inner capsid core and thus are located at the top of the spikes that are formed by the 
bundle of 4 helixes in each HBc dimer. The tips of these spikes are known to be very immunogenic 
and hence form the major immunodominant region (MIR) of the VLP (Figure 4.1 B). Insertion of 
heterologous epitopes in these loops or replacement of parts of the loop by heterologous epitopes 
usually does not interfere with particle formation and has been exploited to create highly 
immunogenic recombinant VLPs (41, 42). Besides the MIR, we also explored addition of peptides at 
the N-terminal part of the HBc monomer. Because of the repetitive pattern in which the epitopes are 
presented, optimal stimulation of B-cells can be obtained both in T-cell dependent and independent 
manner (43).  
Expression system 
For heterologous expression of HBc in E. coli, the HBc coding sequence was cloned into the pLT32h 
vector, behind the PL promotor of bacteriophage λ. Expression was performed  in E. coli B. strain 
(BL21 CodonPlus) bacteria that stably contain the repression plasmid pICA2. At low temperature, 
protein expression is blocked by the temperature sensitive λcI857 repressor, present on the pICA2 
plasmid. Protein expression can be achieved by raising the cultivation temperature to 42°C, which 
inactivates the λcI857 repressor. Additionally, expression may also be achieved at low temperature, 
by the addition of isopropyl-β-D-1-thiogalactopyranisid (IPTG). This molecule inhibits the expression 
of a lacI
q
 repressor from the Lac promotor. This leads to the activation of the expression of an anti-
repressor of cI857, from the pN25/O2 promotor hereby no longer inhibiting expression of the HBc 
protein from the PL promotor (44). 
Analysis of protein expression 
A first series of three expression vectors was produced using the aforementioned F260-298 peptide. This 
epitope was cloned into the loop of the HBcS, HBcI and the full length HBc protein (HBcL), replacing 
amino acids 78-82, hereby aiming to produce particles with the F260-298 sequence protruding from the 
tips of the spikes of the VLPs (Table 4.1, n° 1-3).  
For expression and purification, these three plasmids were each transformed to pICA2 BL21 E. coli. 
Protein expression was induced either at 28°C by the addition of IPTG or by raising the culture 
temperature to 42°C. After fractioning the bacteria by sonication, the soluble fraction was separated 
from the insoluble pellet fraction by centrifugation. Analysis of the induced HBc fusion proteins 
containing the F260-298 epitope, either by western blot or by SDS-PAGE revealed that al the protein 
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was present in the insoluble pellet fraction (Figure 4.2). No difference was observed between the 
two induction methods. Since re-solubilizing the protein is a difficult process with low success rate, 
we searched for a new strategy that would yield more soluble protein. No expression was observed 
for the HBcL-F260-298-Loop construct, but this was due to a technical issue. We could later confirm 
expression of this construct.  
 
Table 4.1 Overview of the HBc constructs 
 
 
Figure 4.2 SDS-PAGE and western-blot analysis show that chimeric HBc particles expressing F260-298 
in the loop precipitate upon sonication. Plasmids carrying HBcS-F260-298-Loop (1), HBcI-F260-298-Loop (2) or 
HBcL-F260-298-Loop (3) were transformed to BL21 E. coli and protein expression was induced using IPTG or 
enhancement of the growth temperature to 42°C. Not induced bacteria transformed with HBcS-F260-298-Loop 
were included as negative control. Protein expression was analyzed by SDS-PAGE (A) or western blot (B). (S 
= soluble fraction; P = pellet, insoluble fraction) 
 
Number Name of the construct Epitope used 
Position of the 
epitope in HBc 
HBc variant 
used 
1 HBcS-F260-298-Loop F 260 - 298 Loop Short 
2 HBcI-F260-298-Loop F 260 - 298 Loop Intermediate 
3 HBcL-F260-298-Loop F 260 - 298 Loop Long 
4 N-F260-298-M2e-HBcS F 260 - 298 N-terminus Short 
5 N-F260-298-M2e-HBcI F 260 - 298 N-terminus Intermediate 
6 N-F260-298-M2e-HBcL F 260 - 298 N-terminus Long 
7 N-F234-303-M2e-HBcI F 234 - 303 N-terminus Intermediate 
8 N-F234-485-M2e-HBcI F 234 - 485 N-terminus Intermediate 
9 N-F420-441-M2e-HBcI F 420 - 441 N-terminus Intermediate 
10 HBcI-F420-441-Loop F 420 - 441 Loop Intermediate 
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Next, the same F260-298 epitope was fused behind the first methionine of all 3 versions of the HBc 
protein. The ectodomain of the influenza A virus M2 protein (M2e) was added between the F260-
298 epitope and the HBc sequence, in an attempt to enhance the solubility of the expression 
fusion protein (Table 4.1, n° 4-6). Fusion of this epitope to HBc had proven in the past to result in 
a soluble fusion product upon expression in E. coli (28). Analysis of the expressed fusion products 
however revealed that again all the protein was present in the insoluble pellet fraction 
(Figure 4.3). The addition of M2e to the fusion product did not result in more soluble protein. 
 
Figure 4.3 SDS-PAGE analysis shows that chimeric HBc particles expressing F260-298 at the N-terminus 
of M2e-HBc precipitate upon sonication. Plasmids carrying N-F260-298-M2e-HBcS (4), N-F260-298-M2e-HBcI (5) 
and N-F260-298-M2e-HBcL (6) were transformed to BL21 E. coli and protein expression was induced using 
IPTG or enhancement of the growth temperature to 42°C. Not induced bacteria transformed with HBcS-F260-
298-Loop were included as negative control. Protein expression was analyzed by SDS-PAGE. (S = soluble 
fraction; P = pellet, insoluble fraction) 
Comparison of different sonication buffers 
Until now, sonication of all bacteria was performed in a sonication buffer (50mM TRIS, 25mM NaCl, 
1mM EDTA – pH 8.0; Table 4.2, n° 1) that has been used in the past for sonication of M2e-HBc VLPs. 
Since optimizing of sonication conditions might result in more soluble protein we tested sonication 
buffers with different salt concentration or at a slightly higher pH (pH 8.5) (Table 4.2, n° 1-4). 
The expression of the fusion proteins HBcI-F260-298-Loop and N-F260-298-M2e-HBcI was induced by 
addition of IPTG. A control construct, containing three copies of the M2e from the 
A/Chicken/Vietnam/35/2004 (H5N1) strain at the N-terminus of HBc was used as positive control. 
Analysis of the expressed fusion proteins, either by western blot or SDS-PAGE revealed the HBcI-F260-
298-Loop and N-F260-298-M2e-HBcI VLPs are present in the pellet fraction under all tested conditions 
(Figure 4.4). In contrast, for the control construct, a large fraction of the expressed protein was 
present in the soluble fraction. 
 
 
  99 
Table 4.2 Overview of the used sonication buffers. 
N° Buffer name pH Buffer composition 
1 TRIS Buffer 1 8.0 50 mM TRIS 1 mM EDTA 50 mM NaCl 
2 TRIS Buffer 2 8.0 50 mM TRIS 1 mM EDTA 25 mM NaCl 
3 TRIS Buffer 3 8.0 50 mM TRIS 1 mM EDTA 5 mM NaCl 
4 TRIS Buffer 4 8.5 50 mM TRIS 1 mM EDTA 25 mM NaCl 
5 Piperazine buffer 10.0 20 mM Piperazine 1 mM EDTA 50 mM NaCl 
6 MES buffer 6.0 50 mM MES 1 mM EDTA 10 mM NaCl 
7 Diethanolamine buffer 8.5 50 mM Diethanlolamine 1 mM EDTA 25 mM NaCl 
 
 
Figure 4.4 SDS-PAGE analysis shows that chimeric HBc particles expressing F260-298 precipitate upon 
sonication using different sonication buffers. Plasmids carrying N-F260-298-M2e-HBcI (A) and HBcI-F260-298-
Loop (B) and N-(VN_M2e)2-HBcI (C) were transformed to BL21 E. coli and protein expression was induced 
using IPTG. A control construct, containing three copies of the M2e from the A/Chicken/Vietnam/35/2004 
(H5N1) strain at the N-terminus of HBc was used as positive control (C). The buffer used for sonication is 
mentioned above the figure: (1) 50mM TRIS, 5mM NaCl, pH 8.0; (2) 50mM TRIS, 25mM NaCl, pH 8.0; (3) 
50mM TRIS, 50mM NaCl, pH 8.0; (4) 50mM TRIS, 25mM NaCl, pH 8.5; Protein expression was analyzed by 
SDS-PAGE. (S = soluble fraction; P = pellet, insoluble fraction) 
Searching for new epitopes 
After analyzing in silico models of the HRSV fusion protein we noted that the chosen epitope only 
consist of a fragment of a structural domain of the complete protein. This may have prompted 
misfolding of the protein, which might be an explanation for the insolubility of the VLPs. Therefore, 
we continued by selecting three new epitopes; this time taking into account the different structural 
domains of the F-protein. 
A first epitope that was selected contains the sequence of amino acid residues 234 to 303. This 
epitope is slightly longer than the previously used epitope, however, in contrast to the first epitope, 
this epitope forms one structural domain within the F-protein, which might facilitate proper folding 
of the protein. As a second option, we chose to attach almost the complete F-protein sequence to 
HBc (F234-485). This sequence contains most of the known antigenic regions of the F-protein, which 
might result in high immunogenicity of the VLP. The coding sequence of both peptides, followed by 
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an M2e sequence, was inserted at the N-terminus after the first methionine of HBcI (Table 4.1, n° 7 & 
8). As third option we chose again for a short peptide of the HRSV F-protein: the region from aa 420 
to 441 (F420-441) which contains antigenic site IV (45), the target site of several monoclonal antibodies 
such as MAb19 (18) and 101F (20). This peptide is highly conserved among isolates of HRSV and does 
not contain any glycosylation sites. This F420-441 sequence, followed by the M2e sequence was 
inserted at the N-terminus of the HBcI protein (Table 4.1, n° 9). Analysis of the produced proteins, 
upon expression in BL21 E. coli again revealed that the first two constructs (N-F234-303-M2e-HBcI and 
N-F234-485-M2e-HBcI) did not result in any soluble fusion protein (Figure 4.5 & Figure 4.6). Analysis of 
the expressed proteins of the third new construct (N-F420-441-M2e-HBcI) however revealed that a 
small fraction of the protein was in the soluble fraction upon induction with IPTG (Figure 4.7). 
 
Figure 4.5 SDS-PAGE analysis shows that chimeric HBc particles expressing F234-303 precipitate upon 
sonication using different sonication buffers. Plasmid carrying N-F234-303-M2e-HBcI  was transformed to 
BL21 E. coli and protein expression was induced using IPTG. The buffer used for sonication is mentioned 
above the figure: (1) 50mM TRIS, 5mM NaCl, pH 8.0; (2) 50mM TRIS, 25mM NaCl, pH 8.0; (3) 50mM TRIS, 
50mM NaCl, pH 8.0; Protein expression was analyzed by SDS-PAGE. (S = soluble fraction; P = pellet, 
insoluble fraction) 
 
Figure 4.6 SDS-PAGE and western-blot analysis show that chimeric HBc particles expressing F234-485 
at the N-terminus precipitate upon sonication using different buffers. Plasmid carrying N-F234-485-M2e-HBcI 
was transformed to BL21 E. coli and protein expression was induced using IPTG (A  & C) or enhancement of 
the growth temperature to 42°C (B & D). The buffer used for sonication is mentioned above the figure: (1) 
50mM TRIS, 5mM NaCl, pH 8.0; (2) 50mM TRIS, 25mM NaCl, pH 8.0; (3) 50mM TRIS, 50mM NaCl, pH 8.0; (4) 
PBS. Protein expression was analyzed by western blot and SDS-PAGE. (S = soluble fraction; P = pellet, 
insoluble fraction) 
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Figure 4.7 Western-blot analysis shows that a small fraction of chimeric HBc particles expressing 
F420-441 at the N-terminus is present in the soluble fraction. (A) Plasmids carrying N-F420-441-M2e-HBcI, N-
F260-298-M2e-HBcI (as negative control) and  N-(VN_M2e)2-HBcI (+) were transformed to BL21 E. coli and 
protein expression was induced using IPTG. Sonication was performed in buffer 1 (50mM TRIS, 5mM NaCl, 
pH 8.0). (B) Plasmids carrying N-F420-441-M2e-HBcI and  N-(VN_M2e)2-HBcI (+) were transformed to BL21 E. 
coli and protein expression was induced using IPTG. The buffer used for sonication is mentioned above the 
figure: (1) 50mM TRIS, 5mM NaCl, pH 8.0; (2) 50mM TRIS, 25mM NaCl, pH 8.0; (3) 50mM TRIS, 50mM NaCl, 
pH 8.0; (4) PBS. Protein expression was analyzed by western blot. (S = soluble fraction; P = pellet, insoluble 
fraction) 
 
Given the relative success we had with the F420-441 epitope we also cloned this epitope into the 
immunodominant loop of HBcI (Table 4.1, n° 10). Unfortunately, for this construct we did not 
observe any protein in the soluble fraction after sonication (Figure 4.8). Since the best result was 
observed with N-F420-441-M2e-HBcI when a sonication buffer of pH 8.5 was used, we hypothesized 
that a change of pH in the sonication buffer might result in more soluble protein. To test this 
hypothesis we sonicated bacteria, that expressed either the F420-441 epitope at the N-terminus in 
sonication buffers consisting of different buffering agents (Table 4.2, n° 4-7). However, the change in 
pH did not result in condition in which the majority of the protein is present in the soluble fraction 
(Figure 4.9).  
 
Figure 4.8 Western-blot analysis of chimeric HBc particles expressing F420-441 in the loop. Plasmids 
carrying HBcI-F420-441-Loop, and N-(VN_M2e)2-HBcI (+) were transformed to BL21 E. coli and protein 
expression was induced by enhancing the growth temperature to 42°C or by the addition of IPTG, or both 
(indicated in the figure). Sonication was performed in buffer 1 (50mM TRIS, 5mM NaCl, 1 mM EDTA, pH 
8.0). Protein expression was analyzed by western blot. 
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Figure 4.9 Western-blot analysis of chimeric HBc particles expressing F420-441 at the N-terminus. 
Plasmid carrying N-F420-441-M2e-HBcI was transformed to BL21 E. coli and protein expression was induced by 
enhancing the growth temperature to 42°C. Sonication was performed in different sonication buffers, 
indicated in the figure: (1) 50mM TRIS, 5mM NaCl, 1 mM EDTA, pH 8.0; (4) 50mM TRIS, 25mM NaCl, 1 mM 
EDTA, pH 8.5. (5) 20mM Piperazine, 50mM NaCl, 1 mM EDTA, pH 10.0; (6) 50mM MES, 10mM NaCl, 1 mM 
EDTA, pH 6.0; (7) 50mM Diethanolamine, 25mM NaCl, 1 mM EDTA, pH 8.5; Protein expression was analyzed 
by western blot. 
 
Since no condition could be found in which the fusion of an epitope of the HRSV F-protein to HBc 
VLPs resulted in soluble particles, a possible solution might be to search for different carrier proteins, 
which might result in a more soluble fusion product.  
4.3 Discussion 
Since humanized monoclonal antibodies directed to the HRSV F protein are a known correlate of 
protection and are capable of reducing HRSV-associated hospitalization (13), we thought that 
inducing an antibody response through vaccination might be a feasible strategy for preventing, or at 
least reducing disease incidence caused by HRSV. Earlier studies using purified F protein to induce an 
antibody response by vaccination were discontinued, because the proteins were not immunogenic 
enough to induce a strong antibody response in humans, which correlated with protection (2). 
Therefore, any novel strategy should be capable of inducing a strong immune response. We 
hypothesized that coupling of an HRSV fusion protein epitope to VLPs made up of the HBc monomers 
would be a good candidate vaccine. VLP vaccines generally consist of one or more structural viral 
proteins, without the presence of a viral genome. Hence these particles cannot replicate, and form a 
potentially safer vaccination strategy.  
HBc monomers aggregate to form VLPs which have been shown to be very immunogenic, because of 
the highly repetitive pattern in which the foreign antigen is presented to the immune system, which 
allows both T-cell dependent and T cell independent stimulation of the immune system. These VLPs 
have been used with success in our lab, for the production of a universal influenza vaccine (27, 29, 
37, 46), by coupling the influenza M2e to HBc. Applying the same strategy to HRSV epitopes seemed 
straightforward with little difficulties. However, the opposite turned out to be true. We experienced 
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difficulties in producing VLPs that did not precipitate. Upon separation of the soluble fraction from 
the precipitated fraction, after sonication, most of the VLPs containing HRSV derived peptides were 
present in the insoluble fraction whereas only a minor fraction of control M2e-VLPs precipitated. 
Having a soluble VLP is necessary for further purification processes, especially if one wants to 
produce this vaccine on a large scale. From the performed experiments it cannot be concluded 
whether VLPs are directly produced in insoluble inclusion bodies or whether the VLPs precipitate 
during sonication. We tried if changing the buffer solution in which the sonication was performed 
would change the outcome. Buffers with different pH were tested, however, this did not result in any 
VLP product that was highly soluble. When looking into the structure of the F protein, we realized 
that the first chosen peptide might experience difficulties to fold properly, since the peptide was only 
a part of a structural domain. Therefore we tried coupling several different fragments of the HRSV F 
protein to HBc. A variety of fragments, ranging from peptides of only 20 aa in length to almost the 
complete F protein were coupled to HBc; however, again this did not resolve the solubility problem. 
M2-VLPs are highly soluble, since most of these proteins were always present in the soluble fraction, 
after sonication. This brought us to the idea that fusion of insoluble HRSV peptides to the soluble 
M2e peptide, which in turn is fused to HBc might enhance the solubility of the VLPs. But again this 
did not result in any highly soluble VLP product. Also, changing of the position of the peptide in the 
HBc monomer to the N-terminus instead of insertion in the MIR did not change the solubility of the 
VLP product. 
It remains unclear why VLPs with HRSV proteins precipitate so easily and the difference with M2e-
VLPs is remarkable. The hydrophobicity of the selected peptides might play an important role in 
determining the solubility of the HBc VLP. When examining the hydrophobicity, using the Kyte & 
Doolittle prediction method (47) (Protscale, http://web.expasy.org/cgi-bin/protscale/protscale.pl) we 
noticed that, with the exception of some N-terminal amino acids, the M2e sequence is hydrophilic. 
Most of the HRSV F protein derived peptides however show some degree of hydrophobicity. The 
largest fragments used (F234-485 and F234-303) show alternating hydrophobic and hydrophilic regions. 
Also the F260-298 peptide contains several hydrophobic regions. These hydrophobic regions might be 
involved in the precipitation of the VLPs expressing these peptides. The smallest peptide (F420-441) 
however is mostly hydrophilic, with only a small hydrophobic sequence. This is comparable to the 
situation of M2e, but still this F420-441 peptide does not result in soluble VLPs. Therefore, other 
mechanisms might be involved in determining the solubility of the produced VLPs.  
When inserting peptides or larger antigen fragments in HBc it is essential that these foreign 
sequences fold properly. A native folding of the inserted sequence is of utmost importance for the 
induction of a humoral immune response through vaccination. Especially when inserting foreign 
fragments in the HBc MIR, the structure of this loop might impose difficulties: the N- and C-terminal 
ends of the MIR are in close proximity and the same would be needed for the foreign sequence in 
order for it to fold properly. Insertions at the N-terminus require less stringent structural 
specifications, since the foreign sequence is only attached to HBc with its C-terminus. Nevertheless 
misfolding of the foreign sequence is still possible. From the experiments performed it is not possible 
to conclude whether the foreign sequences were folded properly and it is not excluded that 
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improper folding is the reason for the insolubility of the VLPs. Insolubility of the VLPs has been 
reported for other epitopes (48, 49). Additionally, the length of the epitope does not seem to be of 
importance, as epitopes of less than 10 residues long have generated insoluble VLPs.  
It has been reported that it is possible to purify the VLPs from the inclusion bodies using urea for 
denaturation followed by a refolding step. Purifying the HBc VLPs carrying HRSV F protein peptides 
from the inclusion bodies might be a solution for generating soluble HRSV peptide-VLPs (50). 
Alternatively, if the insolubility arises already during translation, than codon harmonization might 
improve folding (51). It is known that folding of a polypeptide occurs co-translationally and the speed 
of translation may influence the folding: increasing translation rate may result in fewer proteins that 
are correctly folded (52). In addition, the translation-elongation rate varies during the process of 
translation: because of differences in the number of genes present for each tRNA, certain codons are 
‘slow’ while other are ‘fast’ (53, 54). Moreover, the available tRNA pools are different between 
species causing the same protein to be synthesized at a different rate in bacteria compared to 
eukaryotes (55). Therefore, the process of sequence harmonization changes the mRNA codons 
(without affecting the aa sequence) based on the available expression-host tRNA pools, to mimic the 
translation rate of the protein in the original organism (51). This was shown to result in more 
efficient folding of a luciferase, when expressed in bacteria.  
As an alternative to the genetic fusion of heterologous protein sequences to HBc, chemical fusion 
might be used. Using a modified HBc particle that has been engineered with an acceptor lysine 
residue in the MIR, synthetically produced peptides can be linked to the particle (56). This strategy 
can overcome folding difficulties observed in the genetic fusion strategy. Controlling the number of 
peptides that become chemically linked to a HBc particle however is difficult and therefore this 
strategy is less suited for possible clinical applications. 
Besides hepatitis B virus, other viruses have been used for producing VLPs expressing heterologous 
epitopes such as tobacco mosaic virus (57), alfalfa mosaic virus (58, 59), cowpea mosaic virus (60, 61) 
and potato virus X (62). VLP vaccines have been described for HRSV. In one study VLPs were 
constructed using Newcastle disease virus NP, M and hemagglutinin-neuraminidase (HN) proteins, 
with the ectodomain of HN replaced by the HRSV G protein ectodomain (63). These particles induced 
a robust HRSV specific antibody response which was protective in mice upon an HRSV infection. Two 
different groups studied the potential of an alfalfa mosaic virus expressing HRSV G protein derived 
epitopes (64, 65). These vaccines induced high levels of serum G protein specific antibodies in mice 
and in non-human primates, that were protective against an HRSV challenge. A novel virus-like 
particle based vaccine platform uses a modified alphavirus (Alphavax, North Carolina, USA). In 
contrast to previously described VLP vaccines, these Alphavax particles do not express heterologous 
antigen on the particle surface but rather carry a modified viral RNA genome that carries the coding 
sequence of the heterologous antigen (66). Therefore these particles are commonly referred to as 
VRPs (virus replicon particles). Vaccination with these VRPs results in abundant expression of the 
heterologous antigen in the infected cell, which induces both an antibody and a T cell immune 
response. Due to the absence of structural genes – these genes have been replaced by the coding 
sequence of the heterologous antigen – these VRPs can not replicate in vivo and are considered safe. 
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Such VRPs have been developed for different pathogens and phase I clinical trials have been 
conducted with success with vaccines against influenza, cytomegalo virus, HIV as well as cancer. 
Alphavax particles carrying the HRSV F protein have been shown to induce antibody and T cell 
immunity which is protective against an HRSV infection in mice and cotton rats (67).  
These examples suggest that VLP-based vaccine has potential as an HRSV vaccine strategy. Future 
research on the use of VLPs for HRSV vaccines, whether based on HBc or other viral proteins, might 
result in the development of a potent and safe HRSV vaccine. 
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4.4 Materials and methods 
Construction of expression vectors. 
For expression of recombinant fusion proteins, the pL-promotor driven pLT32H (44) expression 
plasmid containing the HBc sequence was used. The selected HRSV epitopes (see Table 4.1) were 
amplified from HRSV-derived cDNA using PCR techniques and subsequently inserted either in the 
immunodominant loop or at the N-terminus of HBc, using classical restriction digest and ligation. 
For cloning into the loop, the selected epitope was inserted in frame between the BstXI and NheI 
restriction site, replacing amino acids 78-82 of the HBc sequence. For N-terminal fusions, the 
corresponding HRSV epitopes were inserted between the NdeI and ClaI restrictions sites, replacing aa 
1-4 of the original HBc sequence. For M2e-HBc fusions to an HRSV epitope, the corresponding HRSV 
epitopes was fused in frame with the M2e-HBc sequence after the initial methionine, using fusion 
PCR. The resulting fusion product was subsequently cloned into the pLT32H vector, using the NdeI 
and HindIII restriction sites.  
Expression of chimeric HBc proteins. 
For expression of the chimeric HBc proteins, the pLT32H-HBc plasmids carrying an HRSV epitope 
were transformed to BL21 Codon Plus bacteria (Stratagene) containing the transcription regulatory 
plasmid pICA2. A 3ml preculture grown over night at 28 °C in Luria broth medium was diluted 40x in 
15ml fresh medium. The cultures were re-incubated at 28°C until an OD at 600nm was reached 
between 0.6 and 0.8. At this point, the expression of the chimeric proteins was induced either by the 
addition of 1 mM isopropyl 1-thio-β-d-galactopyranoside (IPTG), or by raising the culture 
temperature to 42°C. After 4h of incubation the bacteria were pelleted by centrifugation (6000 × g, 
10 min, 4 °C). The bacterial pellet was resuspended in the desired sonication buffer, in 1/15 of the 
initial culture volume and sonicated. Bacterial debris was pelleted by centrifugation (20,000 × g, 1 h, 
4 °C). The supernatant and pellet fraction were loaded separately on a 12% SDS-PAGE gel. The 
proteins on the gel were either stained directly with coomassie brilliant blue solution or transferred 
to nitrocellulose membrane and detected using an anti-hepatitis B-core IgG polyclonal antibody 
(HBP-023-9 Gentaur).  
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5.1 Abstract 
Human respiratory syncytial virus (HRSV) is the leading cause of lower respiratory tract infections in 
infants worldwide. Despite decades of research there is still no registered vaccine available for this 
major pathogen. We investigated the protective efficacy of a recombinant influenza virus PR8/NA-F85-
93 that carries the HRSV CD8
+
 T cell epitope F85-93 in its neuraminidase stalk. F85-93-specific CTLs were 
induced in mice after a single intranasal immunization with PR8/NA-F85-93 virus, and these CTLs 
provided a significant reduction in the lung viral load upon a subsequent challenge with HRSV. To 
avoid influenza-induced morbidity, we treated mice with M2e-specific monoclonal antibodies before 
PR8/NA-F85-93 virus infection. Treatment with anti-M2e antibodies reduced the infiltration of immune 
cells in the lungs upon PR8/NA-F85-93 infection, whereas formation of inducible bronchus associated 
lymphoid tissue was not affected. Moreover, this treatment prevented body weight loss, yet still 
permitted the induction of HRSV F-specific T cell responses and significantly reduced HRSV 
replication upon challenge. These results demonstrate that it is possible to take advantage of the 
infection-permissive protection of M2e-specific antibodies against influenza A virus to induce 
heterologous CD8
+
 T cell mediated immunity by an influenza A virus vector expressing the HRSV F85-93 
epitope. 
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5.2 Introduction 
Human respiratory syncytial virus (HRSV) is the most important cause of acute lower respiratory 
infections in babies, especially when premature, and young children (1). Almost every child has been 
infected before the age of two years and will very likely be re-infected several times more with HRSV 
during its further life (2). It is estimated that each year over 30 million infections with HRSV result in 
acute lower respiratory infections (ALRI) in children younger than five years (3). Approximately 10% 
of children in this age group suffering from ALRI due to HRSV require hospitalization. Moreover, it is 
estimated that up to 200,000 children younger than five years die due to complications caused by 
HRSV, most of which occur in developing countries (3). Furthermore, severe HRSV infection during 
infancy has been associated with an increased incidence of recurrent wheezing in later childhood (4). 
Also in the elderly, HRSV causes pneumonia, bronchiolitis and exacerbation of chronic obstructive 
pulmonary disease, conditions that often lead to hospitalization and excess mortality in this age 
group (5).  
Despite the disease burden caused by HRSV, no licensed HRSV vaccine is currently available. The 
development of a safe vaccine is difficult, since natural HRSV infections occur at very young age and 
do not provide long lasting protective immunity. The inability of natural infections to evoke 
protective immunity in the absence of significant antigenic drift, might in part be attributed to the 
ability of HRSV to evade the host immune response at different levels (reviewed in (6)). The main 
mechanism for evasion of the host innate immune response by HRSV is the inhibition of type I 
interferon (IFN) production and IFN-associated genes. The HRSV genome encodes two non-structural 
(NS) proteins, NS1 and NS2, that collaborate to suppress both the synthesis and the function of type I 
IFN, through the transcription factors IFN regulatory factor 3 (IRF-3) and signal transducer and 
activator of transcription 2 (Stat-2) (7, 8). This suppression of the type I IFN response contributes to 
the inhibition of CD8
+
 and CD4
+ 
T cell responses (9, 10). 
A clinical trial with a formalin-inactivated HRSV virion-based vaccine (FI-RSV) in the 1960’s did not 
evoke protective immunity but led to enhanced disease upon infection (11). A possible explanation 
for this adverse response could be that the FI-RSV vaccine strongly skews the immune response in an 
undesired allergic-like Th2 direction, which leads to enhanced infiltration of eosinophils and 
neutrophils into the lungs upon HRSV infection, causing severe lung damage. Such a strong Th2 
response blunts the CD8
+
 T cell response, thereby compromising viral clearance from the lungs (12). 
Since that fatal trial, it is generally believed that HRSV vaccines that induce a strong Th2 biased 
immune response should be avoided.  
Past attempts to produce an HRSV vaccine focused mainly on inducing neutralizing antibody 
responses. However, it has been suggested that an antibody response might not be sufficient for 
protection (as reinfections occur throughout life) and that a vaccine that elicits both an antibody and 
a T cell response might be more effective (13). Multiple reports have consistently demonstrated that 
fatal or severe lower respiratory tract HRSV infections are characterized by high viral titers and near 
absence of pulmonary infiltration of T cells or the cytokines they produce (14). Moreover, a possible 
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role for T cells in the clearance of HRSV is supported by the observation that viral clearance from the 
lungs occurs once a potent T cell response is induced (15, 16). Mouse studies have indicated that 
both CD8
+
 and CD4
+
 T cells are essential for the clearance of HRSV (17, 18). In addition, CD8
+
 T cells 
have been shown to mediate protection in animals immunized with several candidate HRSV vaccines, 
such as BCG-RSV (19). 
Therefore, we hypothesized that priming for an HRSV CD8
+
 T cell response might be an attractive 
strategy for an HRSV vaccine. These primed CD8
+ 
T cells could promote rapid clearance of the virus 
from the lungs and potentially prolong HRSV-specific T cell memory. It has been shown that priming 
for an HRSV K
d
M282-90-specific CD8
+ 
T cell memory response abrogates the induction of an 
undesirable Th2 response in a model of FI-RSV primed mice (12, 20, 21). However, Ruckwardt et al. 
reported that an augmented response to the dominant K
d
M282-90 epitope exacerbated illness upon 
HRSV infection, whereas mutating the dominant K
d
M282-90 epitope enhanced the response to the 
subdominant D
b
M187-195 epitope with significantly less illness upon HRSV infection (22). Moreover, 
also CD8
+
 T cells specific for the subdominant K
d
F85-93 epitope can reduce lung eosinophilia if the total 
number of F85-93-epitope specific CD8
+ 
T cells is increased early after HRSV infection (23).  These 
results suggest that a vaccination strategy that induces an immune response to a subdominant HRSV 
cytotoxic T lymphocyte (CTL) epitope, such as the K
d
F85-93 epitope, could contribute to viral clearance 
without exacerbating illness.   
Here, we used a recombinant influenza virus as a live viral vector for mucosal delivery of the HRSV 
K
d
F85-93 CTL epitope. Influenza virus is an interesting vaccine vector candidate because it induces both 
humoral and cellular immune responses (24) and because it can be modified by reverse genetics (25). 
We produced recombinant A/Puerto Rico/8/34 influenza virus carrying the HRSV F85-93 CTL epitope in 
the stalk of the neuraminidase and tested its protective efficacy against HRSV in BALB/c mice. We 
show that F85-93-specific CTLs are induced in the mice upon a single intranasal immunization with 
PR8/NA-F85-93 virus and that these CTLs were associated with a significant reduction in the lung viral 
load upon HRSV challenge. We further optimized the vaccination strategy by passive administration 
of IgG2a monoclonal antibodies directed against the extracellular domain of influenza matrix protein 
2 (M2e) to suppress morbidity associated with PR8/NA-F85-93 virus infection.  
5.3 Results 
Generation of recombinant influenza viral vector for delivery of an HRSV 
F CTL epitope.  
To evaluate whether a recombinant influenza virus harboring an HRSV CTL epitope can provide 
protection against HRSV, we used a reversed genetics system for PR8 influenza (25) to generate the 
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following: (i) a virus containing the H-2
d
-restricted F85-93 CTL epitope (KYKNAVTEL) of the HRSV fusion 
protein (PR8/NA-F85-93 virus); (ii) a virus with an H-2
d
-restricted CTL epitope (IYSTVASSL) of the 
influenza virus hemagglutinin HA518-526 (PR8/NA-HA518-526 virus). These F- and HA-derived CTL epitopes 
were cloned in the neuraminidase (NA) coding sequence as replacements of part of the NA-stalk by 
replacing amino acids (aa) 65 to 71 with a 15-aa sequence containing the CTL epitope extended with 
the 3 naturally flanking amino acids both C- and N-terminally (Figure 5.1 A). Both viruses could be 
rescued and were further subcloned by two rounds of limiting dilution. The presence of the epitope 
in the viral genome was confirmed by RT-PCR followed by sequence analysis (Figure 5.1 B). 
 
 
 
Figure 5.1 Characterization of recombinant PR8/NA-F85-93 and PR8/NA-HA518-526 influenza viruses. 
(A) Schematic representation of wild type and mutant neuraminidases. CT, cytoplasmic tail; TM, 
transmembrane domain. (B) RT-PCR of a NA fragment containing the insertion site of the epitope: a band 
shift from 170 to 207 bp is seen when the epitope is inserted. (C) Neuraminidase activity assay on live, 
purified virus. Fluorescence of the cleaved MUNANA substrate was measured every 2 min during 3 h. (D) 
Plaque phenotypes of the PR8/NA-F85-93 and PR8/NA-HA518-526 influenza viruses do not differ from the wild 
type virus plaques in an MDCK plaque assay. (E) In vitro growth kinetics. MDCK cells were infected with a 
multiplicity of infection of 0.001 of wild type PR8, PR8/NA-F85-93 or PR8/NA-HA518-526 virus. A sample was 
taken at 0, 4, 8, 12, 24 and 48 h post infection. The viral titer in the samples was determined by TCID50 
assay.  
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To test whether insertion of the epitopes affects the activity of the NAs in vitro, we performed a 
neuraminidase activity assay on whole, purified virus (Figure 5.1 C). The number of virions was 
normalized by using equal amounts of hemagglutination units of the three viruses that were 
compared. Both PR8/NA-F85-93 virus and PR8/NA-HA518-526 hydrolyzed the MUNANA substrate at a 
slower rate than NA from wild type PR8 virus, suggesting a lower specific activity of both mutant NAs. 
The activity of NA-F85-93 was 40% of the activity of the wild type NA, whereas the activity of NA-HA518-
526 was even lower (15% of the activity of wild type NA). In a plaque assay the plaques of wild type 
PR8, PR8/NA-F85-93 and PR8/NA-HA518-526 virus were similar in size (Figure 5.1 D). 
To determine the in vitro viral growth kinetics, MDCK cells were infected with a multiplicity of 
infection of 0.001 of wild type PR8 virus, PR8/NA-F85-93 virus, or PR8/NA-HA518-526 virus. At various 
times after infection the viral titer in the supernatant was quantified by TCID50 assay. The growth 
kinetics of PR8/NA-F85-93 virus and PR8/NA-HA518-526 virus resembled that of wild type PR8 virus 
(Figure 5.1 E). 
 
 
 
Figure 5.2 PR8/NA-F85-93 virus infection induces F85-93 specific CTLs in mice. BALB/c mice (6 per 
group) were infected with 5 x 10
3
 PFU of PR8/NA-F85-93 or PR8/NA-HA518-526 virus. Spleens were isolated 10 
days post infection and stimulated with HRSV F85-93 peptide (panels A, B and C)  or influenza NP155-163 
peptide (panel D). After restimulation with HRSV F85-93 peptide IFNγ production in splenic F85-93-specific CD8
+
 
T cells was determined with (A) ELISPOT assay and (B) flow cytometry. (C) Representative dot plots showing 
IFNγ positivity in splenic CD8
+
 T cells, after restimulation with HRSV F85-93 peptide. (D) Splenocytes were 
restimulated with influenza NP155-163 peptide. The percent of NP155-163 specific CD8
+
 T cells was determined 
by flow cytometry.  
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PR8/NA-F85-93 virus infection induces HRSV F85-93-specific cytotoxic T 
lymphocytes.  
We next investigated whether F85-93-epitope specific CTLs can be retrieved from mice that had been 
exposed to PR8/NA-F85-93 virus. BALB/c mice were immunized with 5 x 10
3
 PFU of PR8/NA-F85-93 virus 
or, as a control, PR8/NA-HA518-526 virus, and spleens were isolated 10 days later. F85-93-peptide specific 
IFNγ ELISPOT analysis and intracellular cytokine staining illustrated that F85-93-epitope specific CTLs 
were induced in mice that had been exposed to PR8/NA-F85-93 virus but not in mice that had been 
exposed to PR8/NA-HA518-526 virus (Figure 5.2 A-C). No significant difference in response to the 
influenza specific NP155-163 epitope was detected (Figure 5.2 D). 
To compare the pathogenicity of PR8/NA-F85-93 and PR8/NA-HA518-526, we infected BALB/c mice with 
10
3
, or 10
4
 PFU of wild type PR8 virus, or 10
2
, 10
3
, or 10
4
 PFU of PR8/NA-F85-93 or PR8/NA-HA518-526 
virus. Interestingly, both PR8/NA-F85-93 and PR8/NA-HA518-526 virus caused less morbidity than wild 
type PR8 virus (Figure 5.3 A-C). A tenfold higher inoculum dose of PR8/NA-F85-93 and PR8/NA-HA518-526 
was needed to cause morbidity resembling that caused by wild type PR8 virus (approximately 30% 
bodyweight loss). PR8/NA-HA518-526 was slightly more pathogenic than PR8/NA-F85-93 (Table 5.1). 
Splenocytes were isolated 14 days after infection with these different doses and cellular responses 
were analyzed using an F85-93-peptide specific IFNγ ELISPOT assay. We observed F85-93-epitope specific 
CTLs in mice that had been exposed to PR8/NA-F85-93 virus. The number of spots, reflecting the 
number or F-epitope specific T cells, correlated with the viral dose used for inoculation (Figure 5.3 D). 
Interestingly, the number of IFNγ spots after infection of mice with as little as 100 PFU of PR8/NA-F85-
93 was similar to that after infection with 1 x 10
6
 PFU of HRSV. This is most likely due to the fact that 
PR8/NA-F85-93 virus is able to replicate in mice, whereas the mouse is far less permissive for HRSV. 
 
Table 5.1  Survival of BALB/c mice infected with different doses of 
PR8/NA-F
85-93
 or PR8/NA-HA
518-526
 or with wild type PR8 virus 
 Virus  Infectious dose 
(PFU) 
No. of survivors/ 
total number 
Wild type PR8 10
3
 3/3 
 
10
4
 0/3 
PR8/NA-F85-93 10
2
 4/4 
 
10
3
 4/4 
  10
4
 3/6 
PR8/NA-HA518-526 10
2
 4/4 
 10
3
 4/4 
  10
4
 2/6 
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Figure 5.3 PR8/NA-F85-93 virus induces F85-93-specific CTLs in a dose dependent manner. BALB/c mice 
were infected with (A) 1 x 10
2
 (n=4), 1 x 10
3
 (n=4) or 1 x 10
4
 (n=6) PFU of PR8/NA-F85-93 or (B) 1 x 10
2
 (n=4), 1 
x 10
3
 (n=4) or 1 x 10
4
 (n=6) PFU of PR8/NA-HA518-526 virus or (C) 1 x 10
3
 (n=3) or 1 x 10
4
 (n=3) PFU of wild 
type PR8 virus. Bodyweight was recorded daily (mean +/- SD; the PBS group is the same for all 3 graphs). (D) 
Splenocytes were isolated 14 days post infection and ex vivo restimulated for 12 h with the F85-93 peptide. 
IFNγ secreting cells were quantified by ELISPOT. Control groups received PBS or 1 x 10
6
 PFU of HRSV. (Bars 
represent the average number of spots and SD) 
Immunization with PR8/NA-F85-93 virus reduces HRSV replication in 
challenged mice.  
Next, we evaluated the ability of the PR8/NA-F85-93 virus to protect mice against an HRSV challenge. 
Eight-week-old BALB/c mice received a single intranasal immunization with PR8/NA-F85-93 virus, 
PR8/NA-HA518-526 virus, HRSV, or PBS. Ten days after the immunization, the spleens of the mice were 
isolated and splenocytes were stimulated for 12 h with the F85-93 peptide (KYKNAVTEL) for IFNγ 
ELISPOT analysis. F85-93-epitope specific CD8
+
 T cells were activated in mice exposed to PR8/NA-F85-93 
and to a lesser extent in HRSV-exposed mice, but no F85-93-epitope specific splenocytes were 
observed in the control groups (PR8/NA-HA518-526 and PBS) (Figure 5.4 A). Four weeks after 
immunization, the mice were challenged with 1 x 10
6
 PFU of HRSV-A2. Lung homogenates were 
prepared four days after infection and the HRSV titer was determined by plaque assay. The mice that 
had received the PR8/NA-F85-93 virus as a T cell vaccine had a significantly lower HRSV lung titer than 
the control groups (PR8/NA-HA518-526 and PBS). Median lung titer was 19- and 31-times lower than in 
mice immunized with PR8/NA-HA518-526 or PBS, respectively, indicating that the induced CTLs reduced 
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HRSV replication in the challenged mice (Figure 5.4 B). Remarkably, we repeatedly observed that 
mice that were vaccinated with PR8/NA-HA518-526 generally had a lower pulmonary HRSV titer than 
PBS treated mice. This could indicate that influenza induces a pathogen independent immune 
response that can reduce HRSV replication. 
 
 
Figure 5.4 Immunization with PR8/NA-F85-93 virus reduces HRSV replication in challenged mice. 
BALB/c mice were infected with the indicated viruses or with PBS and then challenged intranasally with 1 x 
10
6 
PFU of HRSV-A2. (A) Spleens were isolated 10 days after infection, restimulated ex vivo with the F85-93 
peptide, and the number of F85-93-epitope specific splenocytes was counted by IFNγ ELISPOT assay. (B) Lung 
HRSV titers were determined by plaque assay 4 days after HRSV challenge. Statistical significance was 
determined by using a two-sided Mann-Whitney U test; ** p < 0.01. 
Anti-M2e antibodies reduce infiltration of immune cells in the lungs 
after PR8/NA-F85-93 challenge without impairing iBALT formation. 
We investigated whether we could reduce the morbidity induced by the PR8 vector but retain F85-93-
specific CD8
+
 T cell induction and protection against HRSV infection. We previously described a 
universal influenza A vaccine based on M2e (27), and recently reported that this vaccine prevents 
morbidity, but in accordance with the infection permissive nature of M2e-based immune protection 
(28), it allows the induction of cross-reactive T cells upon challenge with influenza virus (29). Here, 
we used passive transfer of monoclonal antibodies directed against M2e one day before infection 
with the PR8-based CTL-delivery vectors to diminish the morbidity caused by the influenza viral 
vector. To better understand the effect of intranasal instillation of anti-M2e antibodies on an 
influenza infection, we first characterized the immune response in the lungs of the mice by 
examining bronchoalveolar lavage (BAL). Mice were treated with 1 µg IgG2a anti-M2e antibodies or 
control antibodies directed against the ectodomain of the NB protein of influenza B (anti-NBe) and 
24 h later they were challenged with 5 x 10
3
 PFU of PR8/NA-F85-93 virus. Mice treated with polyclonal 
anti-PR8 mouse serum and mock challenged mice (anti-NBe treated, PBS challenged) were included 
as controls. BAL fluid was collected five days after influenza infection. Mice treated with anti-NBe 
showed a strong infiltration of immune cells in the lungs (Figure 5.5 A). This infiltration was 
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significantly less in anti-M2e treated mice. Infiltration of all cell types was strongly reduced in anti-
M2e treated mice compared to anti-NBe treated mice, except for resident alveolar macrophages 
(Figure 5.5 B-C). These effects were reflected in the viral lung titer five days after influenza infection: 
viral lung titer in anti-M2e treated mice was significantly lower than in anti-NBe treated mice. 
However, anti-M2e immunity is not neutralizing in contrast to the polyclonal post-PR8 challenge 
serum (Figure 5.5 D). Infection with influenza virus is known to induce the formation of inducible 
bronchus associated lymphoid tissue (iBALT). These tertiary lymphoid structures can contribute to 
protection by promoting T- and B-cell mediated immune responses (30). Therefore, we also 
investigated if iBALT is still formed after PR8/NA-F85-93 challenge in mice pretreated with anti-M2e 
antibodies. Germinal center formation, a prime hallmark of iBALT, was analyzed on day 26 after 
infection with PR8/NA-F85-93. By flow cytometry we determined the number of IgM
-
/IgD
-
 B cells 
expressing GL7 and Fas. Interestingly, iBALT formation in anti-M2e treated mice was comparable to 
that in anti-NBe treated mice (Figure 5.5 E). These results show that by combining the PR8/NA-F85-93 
virus with anti-M2e pre-treatment, we can eliminate the disadvantages of the vaccine virus (i.e. lung 
inflammation and substantial viral replication) without preventing the formation of iBALT.  
 
Figure 5.5 Anti-M2e antibodies reduce infiltration of immune cells in the lungs after PR8/NA-F85-93 
challenge without impairing iBALT formation. Mice were immunized with anti-M2e antibodies or control 
anti-NBe antibodies 1 day before infection with PR8/NA-F85-93. Mice treated with polyclonal anti-PR8 mouse 
serum and mock challenged mice (anti-NBe treated, PBS challenged) were included as controls. (A) The 
total number of cells in the BAL fluid was determined on day 5 after influenza infection. Bars represent 
average + SD. (B-C) BAL cellular composition determined by flow cytometric enumeration of eosinophils 
(CD3ε
-
  CD11c
-
  MHC-II
-
 CD11b
med
 SSC
hi
 CCR3
+
), neutrophils (CD3ε
-
  CD11c
-
  MHC-II
-
 CD11b
hi
 SSC
med
 CCR3
-
), 
resident alveolar macrophages (AM) (CD3ε
-
 CD11c
+
 autofluo
hi
 CD11b
lo
), recruited AM (CD3ε
-
 CD11c
+
 
autofluo
med
 CD11b
+
), dendritic cells (DC) (CD3ε
-
  CD11c
+
 autofluo
lo
 MHC-II
hi
), CD4
+
 T cells (CD3ε
+
  CD4
+
) and 
CD8
+
 T cells (CD3ε
+
  CD8
+
). Bars represent the number of cells + SD. (D) Influenza lung viral titer was 
determined by plaque assay 5 days after PR8/NA-F85-93 challenge. (E) Formation of iBALT was analyzed by 
counting the number of Fas
+
GL7
+
 IgM
-
 IgD
-
 B cells in the lungs 26 days after challenge. Bars represent 
average + SD; Bdl. = below detection limit. Statistical significance was determined by using a two-sided 
Mann-Whitney U test; ** p < 0.01. 
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Treatment with anti-M2e antibodies prevents PR8/NA-F85-93-induced 
morbidity but still allows the induction of F85-93-specific CD8
+
 T cell 
responses that reduce HRSV lung viral load. 
We next investigated whether anti-M2e treatment followed by a PR8/NA- F85-93 infection still allows 
the induction of F85-93-specific CD8
+
 T cell responses that are capable of reducing HRSV lung viral load. 
Mice received a single intranasal dose of 1 µg of an anti-M2e antibody or irrelevant control anti-NBe 
antibody followed 24 h later by an intranasal influenza virus infection (PR8/NA-F85-93 or PR8/NA-
HA518-526). Mock immunized mice received anti-NBe antibodies followed by administration of PBS. As 
shown in Figure 5.6 A, anti-NBe treated mice displayed up to 25% weightloss after infection with 
PR8/NA-F85-93 or PR8/NA-HA518-526.  
 
Figure 5.6 Treatment with anti-M2e antibodies prevents PR8/NA-F85-93-induced morbidity but still 
allows the induction of F85-93-specific CD8+ T cell responses and reduced HRSV lung viral load. Mice were 
immunized with anti-M2e antibodies or control anti-NBe antibodies 1 day before infection with PR8/NA-F85-
93 or PR8/NA-HA518-526, and 7 weeks later they were challenged with 1 x 10
6
 PFU of HRSV-A2. (A) Bodyweight 
after PR8/NA-F85-93 or PR8/NA-HA518-526 infection. Graph shows average relative body weight +/- SD. (B) One 
day before HRSV challenge, splenocytes were isolated and restimulated ex vivo with F85-93 peptide for 12 h. 
Percentage IFNγ positive CD8
+
 T cells was determined by flow cytometry. (C) Lung HRSV titers were 
determined by plaque assay 5 days after HRSV challenge. Statistical significance was determined by using a 
two-sided Mann-Whitney U test; * p < 0.05; ** p < 0.01. 
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In contrast, mice receiving anti-M2e lost very little weight after infection, and both anti-M2e treated 
groups differed significantly from the corresponding groups that received anti-NBe treatment (two-
way ANOVA p<0.0001). Fifty days after the primary infection with the PR8 vectors, the CTL memory 
response in the spleen was analyzed by flow cytometry. F85-93-epitope specific CTLs were induced in 
the PR8/NA-F85-93 infected groups after anti-M2e treatment or anti-NBe treatment (Figure 5.6 B). 
Although anti-M2e antibody treatment almost completely prevented body weight loss upon PR8/NA-
F85-93 infection, the induction of F85-93-epitope specific CTL responses was only partially affected. Fifty 
one days after the immunization, mice were challenged with HRSV and the viral lung titer was 
determined five days later. In anti-NBe treated mice, viral lung titer was reduced in the PR8/NA-F85-93-
infected group relative to the PR8/NA-HA518-526-infected group. A significant reduction in viral lung 
titer was also observed in anti-M2e treated PR8/NA-F85-93-infected mice, compared to anti-M2e 
treated mice that had been vaccinated with PR8/NA-HA518-526. As in previous experiments, in all 
groups the lung viral titer was lower than in the PBS immunized group. These results demonstrate 
that a reduction in HRSV viral load can be achieved by taking advantage of the infection-permissive 
protection of M2e antibody pretreatment against influenza A virus to induce CD8
+
 T cell mediated 
immunity by an influenza A virus vector expressing the HRSV F85-93 epitope. 
5.4 Discussion 
We evaluated the vaccine potential of a recombinant influenza virus encoding the H-2
d
 F85-93 CTL 
epitope of the HRSV F protein. We demonstrate that a single intranasal immunization with this virus 
induces a potent F85-93-epitope specific CD8
+ 
T cell response in mice. HRSV clearance was enhanced in 
mice immunized with PR8/NA-F85-93 virus but not in control, PR8/NA-HA518-526 and PBS immunized 
mice. Importantly, the enhanced clearance in PR8/NA-F85-93 immunized mice could not be explained 
by differences in replication efficacy of the recombinant viruses: PR8/NA-F85-93 and control PR8/NA-
HA518-526 virus replicate with similar efficacy in mice and induce similar bodyweight loss. 
It has been reported that an enhanced illness is observed upon overcompensation of the CTL 
response by the immunodominant K
d
M282-90 epitope (22). This is mainly due to a difference between 
quantity and quality of the M282-90 specific CTLs: less than 50% of the M282-90 specific CTLs produce 
effector cytokines (IFNγ, IL-2 and TNF-α) (23). In a side by side comparison, F85-93-specific CTLs have 
been shown to contain a higher frequency of cells capable of co-producing these effector cytokines, 
suggesting that F85-93 specific CD8
+
 T cells exhibit greater cytokine production capacity compared to 
their M282-90 counterparts. Based on these arguments we reasoned that inducing an F85-93 specific CTL 
response would result in at least comparable, if not greater levels of functional CTLs compared to 
M282-90-specific CTLs, whereas the F85-93-specific CTL responses would not be harmful to the mice. 
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Remarkably, we repeatedly observed that mice vaccinated with PR8/NA-HA518-526 generally had lower 
pulmonary HRSV titers than PBS treated mice, indicating that influenza induces a pathogen-
independent immune response that can partly protect against an HRSV infection. It is not clear 
whether this effect is a result of a nonspecific innate or adaptive immune response. Similar effects 
have been reported for several pathogens. For example, BCG, the live attenuated vaccine against 
tuberculosis, induces nonspecific protection against other infections (31). In this example nonspecific 
innate immune responses through epigenetic reprogramming of monocytes lie at the basis of the 
pathogen-independent protection (31). This innate imprinting or innate education has been defined 
as “the long term modification of a microenvironment, which will consequently lead to a nonspecific, 
but more protective, immune phenotype to a subsequent pathogen” (32). On the other hand it has 
been reported that in a model of G-protein primed mice an influenza infection can reduce the 
severity of G-protein vaccination induced enhancement of disease (illness, lung eosinophilia, and 
weight loss) upon an HRSV infection (33). This effect is most likely mediated by the adaptive 
immunity, as an activation of influenza specific T cells, possibly through the mechanism of bystander 
activation, is observed upon a secondary HRSV infection. Additionally, the formation of iBALT might 
contribute to nonspecific protection (34) (discussed more in detail below). 
To prevent influenza induced morbidity, we further optimized our vaccination strategy by passive 
administration of IgG2a monoclonal antibodies directed against M2e to control morbidity associated 
with PR8/NA-F85-93 virus infection. In contrast to vaccination with conventional HA-based influenza 
vaccines, M2e based vaccination with M2e-VLPs (virus-like particles) is not sterilizing (28, 29). 
Immunity induced by M2e-VLPs allows limited virus replication, and hence viral antigen processing 
and presentation to the host immune system, which leads to the induction of a functional influenza-
specific T-cell response (29). In agreement with previous results, we observed that passively 
transferred anti-M2e monoclonal antibodies protected the mice against weight loss following 
PR8/NA-F85-93 infection and allowed the induction of an F85-93-epitope specific CTL response, which 
correlated with reduced HRSV lung viral load upon a subsequent HRSV infection. Additionally, anti-
M2e antibody treatment was associated with reduced infiltration of immune cells into the lungs after 
PR8/NA-F85-93 infection. However, the formation of iBALT, a hallmark of influenza infection, was not 
affected. These tertiary lymphoid structures might contribute to protection, as they can initiate a 
localized immune response consisting of B and T cells (30, 34). A recent study demonstrated that 
iBALT induced by protein cage nanoparticles protects against multiple respiratory viruses, at least 
until 35 days after immunization with the nanoparticles (34). This is the first report of nonspecific 
protection evoked by iBALT. In our study we could confirm the presence of iBALT 26 days after 
PR8/NA-F85-93 virus infection; however we did not investigate whether this persists until the moment 
of HRSV infection, which is 51 days after the influenza A virus infection. If iBALT is still present upon 
HRSV infection, this might contribute to the nonspecific protection observed upon PR8/NA-HA518-526 
infection.  
The bodyweight loss caused by the influenza vaccine vector might be prevented or reduced by 
administering the virus as a live attenuated influenza vaccine (LAIV). Since 2003, LAIV (Flumist®) has 
been approved in the USA as an influenza vaccine for healthy persons aged 2 to 49 years (35). In 
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Europe, the European Medicines Agency has approved Fluenz® only for healthy individuals aged 2 to 
18 years (36). Compared to an inactivated influenza vaccine, LAIV has the advantage of inducing an 
immune response that more closely resembles the immune response induced by natural infection 
(37). Besides a local mucosal immune response, the LAIV also induces a systemic cellular immune 
response (38). An alternative strategy for producing live attenuated influenza virus was recently 
described by Mueller and colleagues (39). Using a computer algorithm, the A/PR/8/34 PB1, NP and 
HA genes were codon pair-deoptimized, while the wild type protein sequence was not affected. This 
leads to an in vivo attenuation of the virus in mice due to a less than optimal arrangement of codon 
pairs. Such deoptimized live attenuated viruses are highly unlikely to revert back to original virulence 
because that would involve hundreds of nucleotide mutations (39). 
To adapt the vaccination strategy for humans, one or several human CTL epitopes have to be 
introduced into the influenza virus. It has been shown that up to 58 aa can be incorporated into the 
stalk of the neuraminidase (40). In this way, several human epitopes can be included in the NA to 
generate a vaccine that covers most human HLA types. Alternatively, large fragments can be 
introduced in the NS1/NS2 gene fragment. Manicassamy et al. reported the production of an 
influenza virus containing GFP in the NS segment. This virus has the additional advantage of being 
attenuated in vivo (41).  
In conclusion, we describe a novel vaccine approach against HRSV that is based on the induction of a 
CTL immune response. Our results demonstrate that it is possible to take advantage of the infection-
permissive protection of M2e-specific antibodies against influenza A virus to induce CD8
+
 T cell 
mediated immunity by an influenza A virus vector expressing the HRSV F85-93 epitope. 
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5.6 Materials and methods 
Cell lines and viruses. Madin-Darby canine kidney (MDCK) cells, African green monkey kidney (Vero) 
cells, HEp-2 cells and HEK293T cells were cultured in DMEM supplemented with 10% FCS, non-
essential amino acids, L-glutamine, sodium-pyruvate and penicillin/streptomycin at 37°C in 5% CO2. 
HRSV-A2 (ATCC VR-1540) was propagated on HEp-2 cells and quantified by plaque-titration on Vero 
cells. Influenza viruses were grown on MDCK cells in serum-free cell culture medium in the presence 
of 2 µg/ml TPCK-treated trypsin (Sigma). Virus was pelleted from culture supernatant by overnight 
centrifugation at 25,000 x g.  
 
Construction of PR8/NA-F85-93 and PR8/NA-HA518-526. Recombinant viruses were rescued using the 
influenza A/Puerto Rico/8/34 based reverse genetics system (25). Using fusion PCR, the K
d
-restricted 
CTL epitope of the HRSV fusion protein (F85-93) and the K
d
HA518-526 CTL epitope of influenza A 
hemagglutinin were cloned into pHW196-NA plasmid by replacing the region encoding aa 65 to 71 of 
the NA coding sequence with a sequence encoding 15 aa containing the CTL epitope extended with 
the 3 naturally flanking amino acids both C- and N-terminally. To generate recombinant virus, 1 µg of 
each of the seven pHW-plasmids (pHW191-PB2, pHW192-PB1, pHW193-PA, pHW194-HA, pHW195-
NP, pHW197-M, pHW198-NS) was transfected together with one of the NA plasmids (pHW196-NA, 
pHW196-NA-F85-93 or pHW196-NA-HA518-526) in a HEK293T/MDCK cell co-culture using calcium-
phosphate co-precipitation in Optimem. After 36 h, TPCK-treated trypsin (Sigma) was added to a final 
concentration of 2 µg/ml. After 72 hours, the medium was collected. The presence of the virus in the 
medium was confirmed by hemagglutination of chicken red blood cells. After clonal selection by two 
rounds of limiting dilution, the virus was amplified on MDCK cells and the viral titer was determined 
by plaque assay. The presence of the epitope in the viral genome was confirmed by RT-PCR followed 
by sequence analysis. 
  
Influenza plaque assay. MDCK cells were seeded in complete DMEM in six-well plates at 5 x 10
5
 cells 
per well one day before infection. The next day, cells were washed once with serum-free medium 
and incubated with a ten-fold dilution series of the virus in 500 µl medium. After 1 h of incubation at 
37°C, medium was removed and replaced by an overlay of 0.8% Avicel RC-591 (FMC Biopolymer) in 
serum-free medium with 2 µg/ml TPCK-treated trypsin (Sigma). After 72 hours of incubation at 37°C, 
the overlay was removed, and the cells were fixed with 4% paraformaldehyde and permeabilized 
with 0.2% Triton X-100. Plaques were stained with an anti-M2e IgG1 mouse monoclonal (final 
concentration 0.4 µg/ml) followed by a secondary anti-mouse IgG HRP-linked antibody. TrueBlue 
peroxidase substrate (KPL) was used for visualization. 
 
HRSV plaque assays were carried out on Vero cells, seeded 1 day before infection at 20,000 cells per 
well in a 96-well plate. Cells were infected with a 3-fold dilution series of lung homogenate or BAL 
fluid, in Optimem. After 3 hours incubation at 37°C, the inoculum was removed and replaced with an 
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overlay of 0.8% Avicel RC-591 (FMC Biopolymer) diluted in cell culture medium containing 2% FCS. 
After 4 days of incubation at 37°C, the overlay was removed, cells were fixed with 4% 
paraformaldehyde and permeabilized with 0.2% Triton X-100. Plaques were stained using goat anti-
HRSV serum (AB1128, Chemicon International) followed by a secondary anti-goat IgG HRP linked 
antibody and visualized by the addition of TrueBlue peroxidase substrate (KPL).  
 
Neuraminidase activity assay. Forty microliters of virus diluted in PBS was added to 9 µL assay buffer 
(1 M NaAc, 10 mM CaCl2, 5% butanol) and 1 µl 5 mM 2′-(4-Methylumbelliferyl)-α-D-N-
acetylneuraminic acid substrate (MUNANA, Sigma) in a 96-well plate. Fluorescence was measured 
every 2 min in a cytofluometer (excitation at 360 nm, emission at 460 nm) for 3 h. The background 
(fluorescence measured in a sample containing 40 µl PBS combined with substrate and assay buffer) 
was subtracted from each measurement. Using a standard curve of free 4-methylumbelliferone, the 
amount of released 4-methylumbelliferone in the sample for each timepoint was calculated. The 
number of NA units in the sample was calculated by dividing the amount of free 4-
methylumbelliferone by the duration (in minutes). For relative activities, the highest amount of NA 
units during the 3 h (correlating to the highest turnover rate of the enzyme) was divided by the 
highest amount of NA units in the wild type NA sample. To confirm that equal quantities of virus 
were tested, the viral titer was checked by agglutination with chicken red blood cells and by plaque 
assay. 
 
Immunizations and HRSV challenge of mice. Eight-week-old female BALB/c mice were housed in 
specified pathogen free conditions and used in all experiments. Under mild isoflurane anesthesia the 
mice were immunized by intranasal administration with 5 x 10
3
 PFU PR8/NA-F85-93,  5 x 10
3
 PFU 
PR8/NA-HA518-526 virus or 1 x 10
3
 PFU PR8 wild type virus diluted in 50 µl PBS. Passive immunization 
experiments were performed by giving the mice while under slight isoflurane anesthesia a single 
intranasal (i.n.) dose of 50 µl of PBS containing 1 µg of monoclonal antibody. An IgG2a monoclonal 
antibody directed against M2e or an IgG1 monoclonal antibody directed against the ectodomain of 
the influenza B virus NB protein (NBe) were used for passive immunization before influenza A virus 
administration. Both antibodies were purified from hybridoma supernatants. 
Challenge with 1 x 10
6
 PFU HRSV-A2 was performed under slight isoflurane anesthesia by i.n. 
administration of 50 µL virus suspension diluted in PBS. Mice were killed on day four or five post 
challenge (as indicated). Lungs were removed and homogenized in 1 ml of HBSS containing 20% 
sucrose using a Heidolph RZR 2020 homogenizer. Homogenates were cleared by centrifugation 
(1,000 x g for 15 min at 4°C) and supernatant was used for quantitation by plaque assay. 
 
IFNγ enzyme-linked immunospot assay (ELISPOT). At various time points after immunization 
(mentioned in the figure legends) spleens were removed aseptically. Splenocytes were isolated and 
red blood cells were lysed in NH4Cl red blood cell lysis buffer. IFNγ ELISPOT assay was performed 
according to the manufacturer’s instructions (U-Cytech Biosciences). Briefly, maxisorp 96-well plates 
were coated overnight with anti-IFNγ monoclonal antibody at 4°C. The next day, plates were blocked 
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and 3 x 10
5
 cells were seeded per well in 100 µL culture medium (RPMI + 10% FCS + L-glutamin + 
penicillin/streptomycin) supplemented with H-2
d
-restricted HRSV-F protein-derived (KYKNAVTEL) 
restimulation peptide at a final concentration of 5 µg/ml. After 12 h of restimulation at 37°C, the cells 
were removed, the plates were washed, and IFNγ trapped on the plates was visualized using 
biotinylated polyclonal anti-IFNγ antiserum. The spots were counted using an inverted light 
microscope. 
 
Intracellular cytokine staining. For intracellular cytokine staining (ICS), 2 x 10
6
 splenocytes were 
seeded in 96-well suspension plates in 200 µL culture medium (RPMI + 10% FCS + L-glutamine + 
penicillin/streptomycin) supplemented with restimulation peptide at a final concentration of 5 
µg/ml. After 12 h of restimulation at 37°C with HRSV-F protein-derived KYKNAVTEL (F85-93) or NP 
derived TYQRTRALV (NP155-163) peptides, GolgiPlug (BD) was added at a final concentration of 1 µg/ml 
and the cells were incubated for another 4 h at 37°C. After restimulation, cells were incubated with 
anti-mouse CD16/CD32 antibody (BD) to avoid nonspecific staining of immune cells. Staining was 
performed with anti-CD8a-FITC, anti-CD3ε-PE (both from BD) and LIVE/DEAD® fixable Aqua Dead Cell 
stain (Molecular probes) for 30 min. Cells were then fixed with 2% paraformaldehyde, permeabilized 
with Perm/Wash buffer (BD), and stained with anti-IFNγ Alexa Fluor® 647 (BD) for 30 min. IFNγ
+
 CD8
+
 
T cells were quantified on an LSRII flow cytometer (BD, San Jose, CA) and analyzed with FACSDiva 
software (BD). 
 
Analysis of pulmonary cell infiltration. Five days after influenza virus infection, mice were killed with 
ketamine/xylazine and lungs were washed through the trachea with 3 ml of HBSS + 5 mM EDTA. The 
first 0.5 ml was collected separately, centrifuged for 5 min at 400 x g, and supernatant was used for 
viral quantification. The pelleted cells from the first BAL fluid collection were added to the rest of the 
BAL fluid. Cells were incubated with anti-mouse CD16/CD32 antibody (BD) to avoid nonspecific 
staining of immune cells and stained with anti-CD3ε-FITC, anti-CD4-PerCP, anti-CD11c-APC, anti-
CD11b-APC-Cy7 (all BD), anti-CD8a-PE-Cy7, anti-MHC-II-eFLUOR 450 (both eBiosciences), and CCR-3-
PE (R&D Systems). Bronchoalveolar lavage (BAL) immune cell composition was determined on an 
LSR-II flow cytometer (BD, San Jose, CA) by analyzing cellular autofluorescence and surface 
expression of CD3ε, CD4, CD8a, CD11b, CCR3, MHC-II, and CD11c, similar to the protocol described in 
Bogaert et al, (26) using FACSDiva software (BD). 
 
Analysis of induced bronchus-associated lymphoid tissue (iBALT) formation. Twenty six days after 
influenza infection, mice were terminally anesthetized and the lungs were removed. Lungs were 
grinded with the plunger of a syringe and passed through a 70-µM filter to produce single-cell 
suspensions. Red blood cells were lysed in NH4Cl red blood cell lysis buffer. They were incubated with 
anti-mouse CD16/CD32 antibody (BD) to avoid nonspecific staining of immune cells and stained with 
anti-IgM-PerCp-Cy5.5, anti-IgD-PE, anti-B220-Alexa Fluor® 700, anti-CD3ε-APC, anti-Fas-PE-Cy7, anti-
GL7-FITC (all BD) and LIVE/DEAD® fixable Aqua Dead Cell stain (Molecular probes) for 30 min. IgD
-
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IgM
-
 Fas
+
 GL7
+
 B-cells were quantified on an LSRII flow cytometer (BD, San Jose, CA) and analyzed 
with FACSDiva software (BD). 
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5.8 Additional data 
Construction of a recombinant influenza virus expressing the 
immunodominant M282-90 CTL epitope 
In BALB/c mice, the CTL epitope in the M2.1 protein (M282-90) is immunodominant over the other 
epitopes (1). Immune responses to the M282-90 epitope (SYIGSINNI) have been studied more 
extensively than those against the F85-93 epitope. However, a strong immune response to the 
immunodomant M282-90 epitope has been shown to be involved in enhancement of disease whereas 
an immune response to a subdominant epitope can make a significant contribution to viral clearance 
without exacerbating illness (2). Therefore, we were interested in comparing the immune responses 
to both epitopes, when inserted in the NA of a recombinant influenza virus.  
For the construction of recombinant PR8 virus containing the HRSV M282-90 CTL epitope (PR8/NA-
M282-90) we used the same strategy as previously described for PR8/NA-F85-93 and control PR8/NA-
HA518-526 virus (3): the region encoding aa 65 to 71 of the NA coding sequence was replaced with a 
sequence encoding 15 aa containing the CTL epitope extended with the 3 naturally flanking amino 
acids both C- and N-terminally. However, even after numerous attempts, we did not succeed in 
generating recombinant influenza virus containing the M282-90 epitope in the NA stalk (Figure 5.7).  
 
Figure 5.7 PR8/NA-M282-90 virus could not be rescued. Wild type PR8 virus, or recombinant  PR8/NA-
HA518-526 and PR8/NA-M282-90 were generated by transfecting 1 µg of each of the seven pHW-plasmids 
(pHW191-PB2, pHW192-PB1, pHW193-PA, pHW194-HA, pHW195-NP, pHW197-M, pHW198-NS) together 
with one of the NA plasmids (pHW196-NA, pHW196-NA-HA518-526, or pHW196-NA-M282-90) in a 
HEK293T/MDCK cell co-culture. A setup without NA (7 plasmids) was used as negative control. After 36 h, 
TPCK-treated trypsin (Sigma) was added to a final concentration of 2 µg/ml. The viral titer in the culture 
supernatant was determined with a TCID50 assay at 24 (blue), 48 (red) and 72 (green) hours post infection. 
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Sequence analysis did not reveal any abnormalities in the coding sequence of NA-M282-90, although 
we did note that an extra N-linked glycosylation site was created due to the introduction of the 
epitope. To analyse protein expression and enzymatic activity, the NA-M282-90 was cloned into a 
potent eukaryotic expression vector (pCAXL) containing a chicken β-actin/rabbit β-globin hybrid 
promoter and the human cytomegalovirus immediate early promoter enhancer. Note that this step 
was required because the pHW-plasmids, used for generating recombinant virus express only low 
levels of proteins in the cells, also for WT NA, which cannot be detected easily by western blot (data 
not shown). The pCAXL vectors containing the coding sequence of wild type NA, NA-M282-90, NA-F85-93 
or NA-HA518-526 were transfected to HEK293T cell cultures and the expression of the different NAs was 
analyzed by western blot (Figure 5.8). NA-M282-90 was expressed at similar levels as the other NAs. 
Next, to examine the enzymatic activity of NA-M282-90 we performed an NA-activity assay on the 
same samples. This assay revealed that NA-M282-90 did not possess any NA enzymatic activity 
(Figure 5.9), which explains why no recombinant PR8/NA-M282-90 virus could be recovered.  
 
Figure 5.8 NA-M282-90 is expressed and migrates slower in SDS-PAGE. HEK293T cells were 
transfected with a pCAXL expression vector containing wild type NA, NA-F85-93, NA-HA518-526 or NA-M282-90. A 
setup with an empty pCAXL expression vector was used as negative control. 48 hours after transfection the 
cells were harvested by a brief treatment with EDTA. After centrifugation for 10 min. at 400 x g the pellet 
was resuspended in 200µl PBS. A 40 µl sample of the cells was loaded on an SDS-PAGE and transferred to a 
nitrocellulose membrane via western blot. NA was detected using a monoclonal antibody directed against 
NA. 
 
Figure 5.9 NA-M282-90 is not enzymatically active. HEK293T cells were transfected with a pCAXL 
expression vector containing wild type NA (blue diamonds), NA-F85-93 (red squares), NA-HA518-526 (green 
triangles) or NA-M282-90 (purple circles). A setup with an empty pCAXL expression vector (black dashed line) 
was used as negative control. The enzymatic activity was measured using an NA-activity assay. 
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This lack of NA activity could be a consequence of the introduction of an extra N-glycosylation site in 
the NA stalk, which is present at the border between the M282-90 epitope and its naturally flanking 3’ 
amino acid ( 5’VLE SYIGSINNI TKO 3’). Indeed, analysis of the expressed NAs on western blot showed 
that NA-M282-90 migrates slightly slower compared to the other 3 NA-variants (Figure 5.8). The 3 
amino acids flanking the M282-90 epitope at the 5’ and 3’ end in the M2 protein were introduced in NA 
together with the epitope, to retain as much as possible the processing of the peptide as it was in the 
M2 protein. Removing these 3 amino acids at the 3’ end removes the glycosylation site but this might 
negatively affect the proper processing of the peptide and the presentation on MHC-I molecules, as 
has been reported for other epitopes (4-6). Also mutating these residues could impact the 
dominance pattern (4), making it difficult to draw conclusions when comparing this M282-90 epitope 
with the F85-93 epitope. Therefore it was decided to continue only with the PR8/NA-F85-93 virus. 
The absence of NA activity due to the introduction of an extra glycosylation site is remarkable. The 
NA stalk contains several glycosylations, which do not interfere with its enzymatic activity. In 
addition, NAs of different subtypes differ in the length of the stalk and the number of glycosylations, 
yet still as these different subtypes are found in nature; this difference does not affect the activity. 
Moreover, secreted stalkless NA, which only contains the globular head, is still enzymatically active 
(7). Therefore, a possible explanation for the absence of NA activity might be that the additional 
glycosylation interferes with the formation of an NA tetramer, which is the enzymatically active unit. 
Boosting the F85-93 CTL response by DNA vaccination. 
It was noted (in the first part of this chapter), that the number of F85-93 specific CTLS 50 days after 
PR8/NA-F85-93 infection was significantly lower in anti-M2e IgG treated mice compared to anti-NBe 
IgG treated mice (Figure 5.6, panel B). In addition, upon an HRSV infection the CTLs of anti-M2e 
treated PR8/NA-F85-93 infected mice were not associated with reduced viral lung replication, in 
contrast to the controlled replication observed in anti-NBe treated PR8/NA-F85-93 infected mice 
(Figure 5.6, panel C). Therefore, we were interested in analyzing the magnitude of the recall response 
during an HRSV infection. Mice were treated with anti-M2e antibodies or control anti-NBe antibodies 
one day before infection with PR8/NA-F85-93 or PR8/NA-HA518-526, and seven weeks later they were 
challenged with 1 x 10
6
 PFU of HRSV-A2. Five days after HRSV challenge the spleens of the mice were 
isolated and the splenocytes were in vitro restimulated with F85-93 peptide. The number of F85-93 
specific activated CD8
+
 T cells was determined by intracellular cytokine staining. We observed 
significantly lower numbers of activated F85-93 specific CTLs in anti-M2e treated PR8/NA-F85-93 infected 
mice compared to anti-NBe treated PR8/NA-F85-93 infected mice (Figure 5.7). This supports our 
previous observations that less CTLs are present in the anti-M2e treated PR8/NA-F85-93 infected group 
and that these mice are less well protected against an HRSV challenge. We hypothesized that, due to 
the less severe immune response, as a consequence of the anti-M2e treatment, memory CTLs are 
less well formed in the anti-M2e treated PR8/NA-F85-93 infected group. Boosting the immune 
response might solve this problem. 
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Figure 5.10 Treatment with anti-M2e antibodies reduces the number of activated F85-93-specific CD8
+
 
T cells in PR8/NA-F85-93-vaccinated mice upon HRSV infection. Mice were immunized with anti-M2e 
antibodies or control anti-NBe antibodies 1 day before infection with PR8/NA-F85-93 or PR8/NA-HA518-526, and 
7 weeks later were challenged with 1 x 10
6
 PFU of HRSV-A2. Five days after HRSV challenge, splenocytes 
were isolated and restimulated ex vivo with F85-93 peptide for 12 h. Percentage IFNγ positive CD8
+
 T cells was 
determined by flow cytometry. Statistical significance was determined by using a two-sided Mann-Whitney 
U test; ** p < 0.01. 
 
To test this hypothesis we performed a prime-boost experiment. A heterologous boost will be 
necessary since boosting the immune response with the same PR8/NA-F85-93 virus would lead to rapid 
neutralization and elimination of the virus due to the antibodies directed against the influenza HA 
and NA evoked by the first infection. We therefore chose to boost the immune response by DNA 
vaccination, using the pCAXL vectors containing the recombinant neuraminidases. The mice were 
primed as previously described. The anti-M2e treated PR8/NA-F85-93 infected group and the anti-NBe 
treated PR8/NA-F85-93 infected group were divided into two: one half received a boost by DNA 
vaccination with the pCAXL-NA-F85-93 plasmid and the other half of each group received a boost with 
pCAXL-NA-HA518-526 plasmid. The mice of the anti-M2e treated PR8/NA- HA518-526 infected group and 
the anti-NBe treated PR8/NA-HA518-526 infected group all received a boost with the pCAXL-NA-HA518-
526 plasmid. Five weeks after the boost, the mice were challenged with 1 x 10
6
 PFU of HRSV-A2. The 
numbers of F85-93 specific CTLs was determined one day before and 5 days after HRSV challenge. On 
the latter date also the lung HRSV titer was determined. We observed a clear effect of the DNA boost 
(however, not significantly different) in the mice that were treated with anti-NBe antibodies 
(Figure 5.11 A). Before as well as after challenge the anti-NBe treated PR8/NA-F85-93 infected mice 
that received a pCAXL-NA-F85-93 plasmid boost had higher CTL numbers than the anti-NBe treated 
PR8/NA-F85-93 that received an irrelevant boost with pCAXL-NA-HA518-526 plasmid. The effect of this 
boost on clearance of HRSV from the lungs is less clear (Figure 5.11  B). In most mice, the viral lung 
titer was below detection level on day 5 after challenge, except for one mouse in the anti-NBe 
treated PR8/NA-F85-93 infected pCAXL-NA-F85-93 boosted group. For the mice that received an anti-
M2e treatment the outcome is different. In these mice, it seems that the DNA boost did not have an 
effect, both on the level of CTL numbers (Figure 5.11 A) and the viral titer in the lung (Figure 5.11 B). 
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It should be noted that for the intracellular cytokine assay before challenge, the background level 
(i.e. the number of F85-93 specific CTLs in the PR8/NA-HA518-526 infected, pCAXL-NA-HA518-526 boosted 
groups) was high, making it difficult to draw conclusion from this assay. Since these are results from 
only one experiment, it would be necessary to repeat the experiment to conclude whether or not the 
DNA boost has a positive effect on the number of F85-93 specific CTLs and consequently on the 
reduction in lung viral titer after HRSV challenge. 
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Figure 5.11 Boosting with the pCAXL/NA-F85-93 vector does not enhance CTL numbers and protection 
against HRSV in anti-M2e treated PR8/NA-F85-93 immunized mice. Mice were immunized with anti-M2e 
antibodies or control anti-NBe antibodies 1 day before infection with PR8/NA-F85-93 or PR8/NA-HA518-526, and 
and received a boost with a pCAXL vector containg either NA/F85-93 or NA/HA518-526 2 weeks after the 
infection. 5 weeks after the boost, mice were challenged with 1 x 10
6
 PFU of HRSV-A2. (A) One day before 
HRSV challenge, splenocytes were isolated and restimulated ex vivo with F85-93 peptide for 12 h. Percentage 
IFNγ positive CD8
+
 T cells was determined by flow cytometry. (B) Lung HRSV titers were determined by 
plaque assay 5 days after HRSV challenge. Statistical significance was determined by using a two-sided 
Mann-Whitney U test; ** p < 0.01. 
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5.9 Additional materials and methods 
Production of recombinant influenza viruses was performed as described in the main text. 
Construction of pCAXL plasmids. Recombinant NAs were expressed using pCAXL plasmid, which is a 
derivative of pCAGGS. For ease of cloning, the restriction sites NheI, SacI, NotI and MluI were 
inserted in the multi cloning site of pCAGGS at restriction site XhoI. This modified vector was named 
pCAXL. The neuraminidase sequences were amplified from the pHW196, pHW196-NA-F85-93, 
pHW196-NA-M282-90 and pHW196-NA-HA518-526 plasmids and inserted in the pCAXL vector between 
the MluI and XhoI sites. 
 
Expression analysis of recombinant NAs 
For expression test, HEK293T cells were seeded in 6 well plates at 2 x 105 cells per well in complete 
DMEM medium (DMEM supplemented with 10% FCS, non-essential amino acids, L-glutamine, 
sodium-pyruvate and penicillin/streptomycin). 24h later the cells were transfected with 125µg of the 
pCAXL plasmids using calcium phosphate precipitation. After 48h cells were washed once with PBS 
and detached by a brief treatment with 200µL EDTA, which was removed by centrifugation (5 min at 
400 x g). Cell pellets were resuspended in 200 µL PBS. Expression of the recombinant proteins was 
analyzed using SDS-PAGE and western blot. NA was visualized using a mouse anti-NA antibody 
(isolated and produced in our lab).  
 
Neuraminidase activity assay on transfected cells. Cells were transfected and detached as described 
above under ‘Expression analysis of recombinant NAs’. A 40µL sample of the PBS containing the cells 
was added to 10µL of 1M NaAc, 10mM CaCl2, 5% butanol) and 5mM 2′-(4-Methylumbelliferyl)-α-D-
N-acetylneuraminic acid substrate (Sigma) in a 96-well plate. Fluorescence was measured every 2 
minutes in a cytofluometer (excitation at 360 nm, emission at 460nm) for 3h. 
 
Mice, vaccination and challenge. 
Vaccination and challenge were performed as described for the main text. For DNA vaccination LPS 
free plasmids were purified using EndoFree Plasmid Giga Kit (Qiagen). DNA was diluted in LPS free 
PBS to a concentration of 1 mg/ml. Mice were anesthetized by intraperitoneal injection of a 
ketamine and xylazine mixture (100 µg/g and 10 µg/g body weight, respectively) diluted in 150 µl 
PBS. Mice were immunized by intramuscular injection in the quadriceps of the hind legs (50 µl/leg). 
 
Intracellular cytokine staining was performed as described in the main text. 
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6.1 Introduction 
We have reported the construction of a recombinant influenza A virus carrying the H-2
d
 restricted 
CTL epitope of the HRSV fusion protein (F85-93), which induces an HRSV F85-93-specific CD8
+
 T cell 
response, that can reduce HRSV replication in BALB/c mice (1). To reduce morbidity associated with 
the live viral vector, we took advantage of the infection-permissive nature of the immune protection 
afforded by anti-M2e antibodies. This means that our aim was to control morbidity induced by the 
PR8/NA-F85-93 virus by co-administration of an M2e-specific IgG2a monoclonal antibody, without 
significantly compromising the F85-93-specific CD8
+
 T cell response. However, combining the anti-M2e 
antibodies with the PR8/NA-F85-93 virus complicates the vaccination strategy to a certain extent. In 
addition, it is highly unlikely that a live virus without a stable attenuated genotype would be 
accepted by FDA or another regulatory agency to be used as a prophylactic vaccine. Therefore, we 
explored strategies to make an attenuated variant of the PR8/NA-F85-93 virus. 
One way to make an attenuated virus is by reassorting with the cold adapted, temperature sensitive 
A/Ann Arbor/6/60 strain. This strategy is currently applied for the production of live attenuated 
influenza vaccine (LAIV). Since 2003, LAIV (Flumist®) has been approved in the USA as influenza 
vaccine for healthy persons aged 2 to 49 years (2). In Europe, the European Medicines Agency has 
approved Fluenz® only for healthy individuals aged 24 months to 18 years (3). Classical or reverse 
genetics based reassorting of a circulating human influenza strain with the A/Ann Arbor/6/60 master 
donor virus (MDV), results in a virus that contains the two surface glycoproteins neuraminidase and 
hemagglutinin of the circulating strain and the six internal gene segments of the MDV, thereby 
retaining its attenuated phenotype (4). Compared to an inactivated influenza vaccine, LAIV has the 
advantage of inducing an immune response that more closely resembles the immune response 
detected after natural infection (5). The LAIV is administered via a nasal spray, which induces an 
mucosal immune response, directly at the site of entrance of the respiratory pathogens. Besides this 
local mucosal immune response it also induces a systemic immune response, which includes the 
induction of a cellular immune response (6).  
Recently a computer aided, rational design strategy was developed for the attenuation of viruses (7). 
Besides a bias for codon usage, each species also has a certain bias for codon-pair usage, meaning 
that certain codon-pairs are used more or less frequently than statistically expected. The central idea 
of codon-pair deoptimization is to recode and synthesize a viral gene (or complete genome) in a way 
that preserves the wild type amino acid sequence while rearranging synonymous codons to create a 
suboptimal arrangement of codon pairs. This results in a slower rate of protein synthesis of such a 
protein. It has already been shown for polio virus and influenza virus that such codon-pair biased 
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viruses are attenuated in vivo, but are still capable of eliciting a protective immune response against 
a challenge with the wild type virus (7, 8). 
Modifying the gene carrying the coding information of the influenza non-structural protein 1 (NS1) 
can also result in an attenuated virus (9). The main function of the NS1 protein is the inhibition of the 
host type I interferon (IFN) mediated immune response. Modification of this gene, such as mutations, 
truncations or deletions results in a robust local immune response, which limits the viral replication 
and the associated disease. Interestingly, despite the significant reduction in viral replication, live 
attenuated viruses with truncated NS1 proteins still prime long-lived T- and B- cell responses (10). 
NS1 modified, attenuated viruses form a promising new vaccination strategy, which has been proven 
to be protective against influenza in mice, pigs, horses, chickens and macaques (9, 11). 
Reporter influenza viruses have been created by inserting the GFP coding sequence in the NA or NS 
gene segment (12-14). Such viruses express GFP in infected cells in vitro, as well as in vivo in animal 
models. These viruses are a useful tool for example for following the course of an influenza infection 
in animal models or for screening of influenza anti-viral drugs. However, it should be noted that 
these viruses are attenuated in vivo in the mouse model. 
Here we report the construction of two types of live attenuated PR8 viruses: one with codon-pair 
deoptimized NP and HA gene segments and a second virus with a truncated NS1 open reading frame 
that was furthermore expressing GPF. Our aim was to assess the induction of F85-93 specific T cell 
responses using these live viruses in naïve laboratory mice. The addition of GFP also allowed to 
detect the differences in the course of an influenza infection between mice infected with virus 
carrying full length NS1 and mice infected with attenuated viruses carrying a truncated NS1 
sequence. 
6.2 A codon-pair deoptimized variant of PR8/NA-F85-93 virus is 
slightly attenuated in vivo. 
Construction and in vitro characteristics of PR8/NA-F85-93 viruses carrying 
codon-pair deoptimized HA and/or NP genes. 
Mueller et al. previously reported the construction of an influenza virus carrying the codon-pair 
deoptimized gene sequences of HA, NP and/or PB1. They kindly provided us the pDZ-NP
min
 and pDZ-
HA
min
 containing the coding sequences for codon-pair deoptimized NP and HA derived from influenza 
A/Puerto Rico/8/34 (PR8) strain. Using the reversed genetics 8-plasmid system for the generation of 
reassortant influenza PR8 virus, we constructed viruses containing one or both codon-pair 
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deoptimized genes, together with NA-F85-93, NA-HA518-526 or wild type NA, combined with the five 
other wild type genes (PB2, PA, NP,  M and NS). This resulted in 9 different viable viruses (Table 6.1). 
 
Table 6.1 Overview of the constructed codon-pair deoptimized viruses 
Virus name NA NP HA 
PR8/NA-F85-93/NP
min
/HA
min
 NA-F85-93 NP
min
 HA
min
 
PR8/NA-F85-93/NP
min
 NA-F85-93 NP
min
 HA wt. 
PR8/NA-F85-93/HA
min
 NA-F85-93 NP wt HA
min
 
PR8/NA-HA518-526/NP
min
/HA
min
 NA-HA518-526 NP
min
 HA
min
 
PR8/NA-HA518-526/NP
min
 NA-HA518-526 NP
min
 HA wt. 
PR8/NA-HA518-526/HA
min
 NA-HA518-526 NP wt HA
min
 
PR8/NAwt/NP
min
/HA
min
 NA wt NP
min
 HA
min
 
PR8/NAwt/NP
min
 NA wt NP
min
 HA wt. 
PR8/NAwt/HA
min
 NA wt NP wt HA
min
 
 
The virus was collected after 3 days and transferred to culture flasks, for expansion on MDCK cells. 
We observed that the viruses containing one or two codon-pair deoptimized genes induced less 
cytopathic effect on the cells than similarly generated wild type PR8 virus. Remarkably, the MDCK 
cells did not detach from the culture flask, even though virus was present at high titers in the culture 
supernatant. This could indicate that the viruses are attenuated in vitro. After growth for 7 days on 
MDCK cells, the viral titer present in the supernatant of the cells was determined by plaque assay. 
The viruses containing both codon-pair deoptimized genes in combination with wild type NA or, NA-
HA518-526 seemed to grow slower than viruses containing only one codon-pair deoptimized gene. This 
however was not observed for PR8/NA-F85-93/NP
min
/HA
min
, which grew even to a higher titer than 
PR8/NA-F85-93/NP
min
 and PR8/NA-F85-93/HA
min
 (Figure 6.1). However, kinetics studies starting off with 
low MOI will be required to determine what the effect is of the codon-pair deoptimized genes on in 
vitro replication efficiency of the recombinant viruses.  
Plaque phenotypes revealed some effects of the deoptimization of NP and HA. For all 3 types of NA, 
viruses with NP
min
 and HA
min
 have much smaller plaque phenotypes than the corresponding viruses 
with wild type NP and HA proteins (Figure 6.2). Similar to the viral titers, this effect was most 
pronounced in the viruses expressing NA-HA518-526 or wild type NA. The virus with wild type NA and 
NP but with HA
min
 (PR8/NA wt/HA
min
) also had a smaller plaque size than wild type PR8 virus, which 
was not the case for virus with NP
min
 and HA wild type (PR8/NA wt/NP
min
) indicating that the smaller 
plaque size is most likely a result of the presence of HA
min
. 
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Figure 6.1 Plaque assay of codon pair deoptimized virus production. Recombinant A/Puerto 
Rico/8/34 viruses were generated using the reverse genetics 8 plasmid system. All viruses contain wild type 
PB2, PA, NP,  M and NS genes, combined with wild type or codon pair deoptimized (min) NP and/or HA in 
combination with NA-F85-93, NA-HA518-526 or wild type NA. Supernatant containing the virus was collected 3 
days after transfection and 1/25 was transferred to MDCK cells. Virus was collected 7 days later and a 
plaque assay was performed to determine the viral titer.  
 
  
Figure 6.2 Recombinant viruses with codon pair deoptimized NP or HA or both have smaller plaque 
phenotypes. Recombinant A/Puerto Rico/8/34 viruses were generated using the reverse genetics 8 plasmid 
system. All viruses contain wild type PB2, PA, NP,  M and NS genes, combined with wild type or codon pair 
deoptimized (min) NP and/or HA in combination with NA-F85-93, NA-HA518-526 or wild type NA as indicated in 
the borders of the figure. Virus was transferred to MDCK cells and after 1h of incubation an overlay of 0.8% 
avicel was added to the cells. After 2 days of incubation the plaque assay was developed. (N.D. : not 
determined) 
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In vivo attenuation study. 
Next, we investigated whether these viruses are attenuated in vivo, compared to PR8/NA-F85-93, 
which was used in previous in vivo studies (Chapter 5). Our hypothesis was that the presence of the 
codon-pair deoptimized genes would result in a virus that was more attenuated in vivo than PR8/NA-
F85-93 and that we might be able to completely abolish body weight loss caused by the influenza 
vector. Mice received an intranasal infection with doses ranging from 5 x 10
3
 PFU to 5 x 10
5
 PFU of 
PR8/NA-F85-93/NP
min
/HA
min
, PR8/NA-F85-93/NP
min
, or PR8/NA-F85-93/HA
mi
. Bodyweight was measured 
daily and compared to mice that received an intranasal infection with 5 x 10
3
 PFU or PR8/NA-F85-93.  
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Figure 6.3 Recombinant PR8 viruses expressing codon pair deoptimized NP and/or HA genes are 
not attenuated in vivo. Mice (n = 3 per group) received an intranasal infection with doses ranging from 5 x 
10
3
 PFU to 5 x 10
5
 PFU of PR8 virus with NA-F85-93  and NP
min
 or HA
min
 or both codon-pair deoptimized genes, 
as indicated in the figure legends. Bodyweight was measured daily and compared to mice that received an 
intranasal infection with 5 x 10
3
 PFU of PR8/NA-F85-93. (A) Relative body weight of mice infected with 5 x 10
5
, 
5 x 10
4
 or 5 x 10
3
 PFU of PR8/NA-F85-93/NP
min
/HA
min
. (B) Relative bodyweight of mice infected with 1.63 x 10
4
 
or 5 x 10
3
 PFU of PR8/NA-F85-93/NP
min
 or 5 x 10
3
 PFU PR8/NA-F85-93/HA
min
. (Group average +/- SD.) 
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We did not observe any in vivo attenuation of the PR8/NA-F85-93/NP
min
 or PR8/NA-F85-93/HA
min
 virus 
(Figure 6.3 A). On the contrary, PR8/NA-F85-93/NP
min
 infection even appeared to induce more 
morbidity than PR8/NA-F85-93 infection in mice, as both administered doses (1,63 x 10
4
 and 5 x 10
3
 
PFU) were lethal to the mice. The virus containing two codon-pair deoptimized genes (PR8/NA-F85-
93/NP
min
/HA
min
) was slightly attenuated compared to PR8/NA-F85-93 (Figure 6.3 B). Here, a dose of 5 x 
10
4
 PFU of PR8/NA-F85-93/NP
min
/HA
min
 results in a comparable mean bodyweight loss as when a 10-
fold lower dose (5 x 10
3
 PFU) is given of PR8/NA-F85-93. With a dose of 5 x 10
3
 PFU of PR8/NA-F85-
93/NP
min
/HA
min
 the mean bodyweight of the mice only dropped until 90% of the initial bodyweight. 
6.3 A GFP-reporter influenza virus that is attenuated in vivo 
One of the major functions of the influenza NS1 protein is the inhibition of the host type I IFN 
response. The NS1 protein consist of an N-terminal RNA binding domain (aa 1-73) followed by an 
effector domain (aa 74-207) and a short C-terminal region (+/- 20 aa) (15). It has been shown that 
viruses expressing NS1 proteins that are progressively truncated from the C-terminus replicate less 
efficiently and hence are attenuated in vivo (10). Remarkably, viruses expressing only the N-terminal 
RNA-binding domain are most attenuated, even though they replicate to higher titers in the lungs, 
compared to viruses with less truncated forms of NS1 (10). Despite the reduced replication of these 
viruses in vivo, a long-lived protective immune response is still induced in the mice. Again, the 
shortest versions of NS1 (aa 1-73) were capable of inducing the strongest T cell response, which 
correlates with their better replication efficiency in vivo (10). We therefore were interested in 
creating a virus containing such a truncated NS1(1-73). This cannot be achieved by just truncating the 
NS gene segment, since influenza virus also encodes NEP from the same gene segment: NS1 is 
produced from full length NS mRNA and NEP from a spliced mRNA. It has been previously shown that 
NS1 and NEP can be expressed as a single polyproteins, separated by a foot and mouth disease 
(FMDV) 2A autoproteolytic cleavage site (16). Cleavage at this 2A site occurs during translation, 
resulting in two separate proteins. We applied this strategy for the expression of NS1(1-73) and NEP. 
In addition, we were interested in creating a reporter influenza virus with this adapted NS gene 
segment. The GFP coding sequence was introduced between the NS1(1-73) and NEP coding 
sequences. An FMDV 2A autoproteolytic cleavage site was inserted between NS1(1-73) and GFP, 
while the latter was separated from NS2 by a porcine teschovirus-1 (PTV-1) 2A cleavage site 
(Figure 6.4). The coding sequence of an HA tag was fused to NS1, for ease of protein detection. 
Finally, a dimerization domain of Drosophila melanogaster kinesin motor protein (Dmd) was also 
added to NS1. This adapted NS gene segment was named NS1(1-73)-GFP-NS2. 
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Figure 6.4 Schematic representation of the promoters and coding sequences of the pHW-NS1(1-
73)-GFP-NS2 plasmid for the generation of reporter GFP influenza virus. A truncated NS1 gene (aa 1-73) is 
fused to an HA tag (HA) and a Drosophila melanogaster kinesin motor protein dimerization domain (Dmd). 
The GFP coding sequence was inserted between the coding sequence of truncated NS1 (1-73) and full 
length NS2. A foot and mouth disease (FMDV) 2A cleavage site is inserted between NS1(1-73) and GFP and 
a porcine teschovirus-1 (PTV-1) 2A cleavage site is inserted between GFP and NS2. The first methionine 
codon of the 3 proteins is indicated (ATG). Coding sequences are flanked by the NS non coding regions 
(NCR). These sequences are inserted in the pol I/pol II expression cassette in the pHW2000 
expressionvector of the reverse genetics 8 plasmid system. 
 
 
 
Figure 6.5 Characterization of the NS and NA segments of the recovered viruses by RT-PCR. RNA 
was extracted from virus particles after 1 passage on MDCK cells and cDNA was prepared in the presence 
(with RT) or absence (No RT) of reverse transcriptase. The cDNA was amplified by PCR using primers specific 
for the NS segment (A) or primers lining the insertion site in NA (B). Plasmids were used as positive control 
for the PCR (Lanes 1, 2, 8 and 9). 1 = plasmid pHW198-NS; 2 = plasmid pHW-NS1(1-73)-GFP-NS2; 3 = PCR 
containing no cDNA, only primers; 4 = PR8/NA-F85-93/ NS1(1-73)-GFP-NS2; 5 = PR8/NAwt/ NS1(1-73)-GFP-
NS2; 6 = PR8/NA-F85-93/ NSwt; 7 = PR8wt; 8 = plasmid pHW196-NA; 9 = plasmid pHW NA-F85-93. 
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Generation of a recombinant reporter influenza virus expressing GFP, 
that has a truncated NS1 gene. 
Using the before mentioned reversed genetics 8-plasmid system, we constructed reassortant A/PR8 
influenza virus containing the NS1(1-73)-GFP-NS2  gene segment with either wild type neuraminidase 
(PR8/NAwt./NS1(1-73)-GFP-NS2  virus) or NA-F85-93 (PR8/NA-F85-93/NS1(1-73)-GFP-NS2 virus). Several 
attempts to produce virus with the NS1(1-73)-GFP-NS2 gene segment in combination with NA/HA518-
526 failed. Both reassortant viruses were further subcloned by two rounds of limiting dilution. The 
presence of the NS1(1-73)-GFP-NS2 gene segment and of NA-F85-93 or wild type NA in the viral 
genome was confirmed by RT-PCR (Figure 6.5) and by sequence analysis of the RT-PCR product.  
In vitro characterization. 
To assess whether the deletion of a fragment of the NS1 gene, or the insertion of GFP affected the 
viral replication, we first performed a plaque assay to spot differences in plaque morphology. We 
noticed that the plaques of both PR8/NAwt./NS1(1-73)-GFP-NS2  virus and PR8/NA-F85-93/NS1(1-73)-
GFP-NS2 virus had a thinner halo than plaques of wild type PR8 virus (Figure 6.6), indicating that the 
changes made in the NS gene segment may have an effect on the in vitro viral fitness. Next, we 
compared the growth kinetics on MDCK cells of PR8/NAwt./NS1(1-73)-GFP-NS2 virus and PR8/NA-F85-
93/NS1(1-73)-GFP-NS2 virus with wild type PR8 virus. Cells were infected with a MOI of 0.001 and at 
indicated time points after infection the viral titer in the supernatant was determined by TCID50 
analysis. In this multi-cycle replication assay (due to the addition of trypsin to the culture), both 
recombinant viruses showed similar growth kinetics to wild type PR8 virus (Figure 6.7).  
To test whether GFP was expressed in the infected cells we performed fluorescent microscopy. 
MDCK cells were infected with either one of the GFP expressing viruses or wild type PR8 virus and at 
10h post infection the cells were stained for NP expression. We observed GFP signal in all NP 
expressing cells, indicating that GFP is expressed in all infected cells, both for PR8/ NA-F85-93/NS1(1-
73)-GFP-NS2, and PR8/NAwt./NS1(1-73)-GFP-NS2 (Figure 6.8). The FMDV 2A autoprotyolytic 
cleavage site inserted between the NS1 and GFP sequence and the PTV-1 2A cleavage site inserted 
between GFP and NS2 should ensure that 3 individual proteins are produced. We performed western 
blot analysis on PR8/NA-F85-93/NS1(1-73)-GFP-NS2 and PR8/NAwt./NS1(1-73)-GFP-NS2-infected cells 
to assess whether the cleavage between these 3 proteins is complete. Detection with an anti-GFP 
antibody revealed multiple bands on the blot: two major bands of approximately 50 kDa and 27 kDa 
and a smaller band around 25 kDa (Figure 6.9). The higher band most likely corresponds to the 
complete, uncleaved polyprotein, whereas the exact identity of the two lower bands is less clear. 
This indicates that, in contrast to what we expected, the cleavage at the 2A cleavage site is only 
partial, or doesn’t occur at all. Detection of the same blot with an anti-NS1 monoclonal only revealed 
a band in the wild type PR8 infected cells, since the epitope of this monoclonal lies in the C terminal 
region of the protein, which is removed in the viruses carrying the NS1(1-73)-GFP-NS2 gene segment. 
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An HA-tag was inserted behind the NS1 coding sequence to facilitate detection of this protein. 
However, even after multiple attempts, no protein could be detected with anti-HA antibodies (data 
not shown).  
For other GFP-carrying influenza reporter viruses it has been reported that the GFP-positivity is often 
lost during multiple rounds of replication (13). To assess the stability of the PR8/NA-F85-93/NS1(1-73)-
GFP-NS2 and PR8/NAwt./NS1(1-73)-GFP-NS2 the virus was passaged multiple times over MDCK cells. 
After each round of replication, during which virus replicated for approximately 3 days on the cells, a 
sample was taken from the medium. Some of these intermediate samples were subsequently used to 
infect cells, which, after 10 h of infection were fixed and analysed for the expression of GFP and NP 
by fluorescent microscopy. We did not observe an increasing number of NP positive, GFP negative 
cells, in later passages, compared to the starting virus, indicating that both PR8/NA-F85-93/NS1(1-73)-
GFP-NS2 and PR8/NAwt./NS1(1-73)-GFP-NS2 can stably transfer the GFP gene sequence to progeny 
virus during in vitro replication (Figure 6.10). 
 
 
 
Figure 6.6 Plaque assay of recombinant viruses. Plaques of recombinant PR8 viruses 
PR8/NAwt./NS1(1-73)-GFP-NS2 and PR8/NA-F85-93/NS1(1-73)-GFP-NS2 have a smaller halo than plaques of 
wild type PR8 virus in an influenza plaque assay. 
 
 
Figure 6.7 PR8/NAwt./NS1(1-73)-GFP-NS2 virus and PR8/NA-F85-93/NS1(1-73)-GFP-NS2 virus show 
similar in vitro growth kinetics as PR8 wild type virus. MDCK cells were infected in duplicate with a 
multiplicity of infection of 0.001 of wild typePR8 virus, PR8/NAwt./NS1(1-73)-GFP-NS2 virus and PR8/NA-F85-
93/NS1(1-73)-GFP-NS2 in a total volume of 10 ml. A 200µl sample was taken at 0, 4, 8, 12, 24 and 48 h post 
infection. The viral titer in the samples was determined by TCID50 assay. 
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Figure 6.8 GFP expression is observed in PR8/NA-F85-93/NS1(1-73)-GFP-NS2 and PR8/NAwt./NS1(1-
73)-GFP-NS2 infected cells. MDCK cells were infected with PR8/NA-F85-93/NS1(1-73)-GFP-NS2 (A), 
PR8/NAwt./NS1(1-73)-GFP-NS2 (B) or wild type PR8 (C) virus and at 10h post infection the cells were 
stained with anti-NP (red) and DAPI (blue). The GFP signal is shown in green. An overlay of the three colours 
is shown in the right panel. 
 
 
Figure 6.9 Expression analysis of NS1 and GFP in PR8/NA-F85-93/NS1(1-73)-GFP-NS2 and 
PR8/NAwt./NS1(1-73)-GFP-NS2 infected cells. MDCK cells were infected with wild PR8/NA-F85-93/NS1(1-
73)-GFP-NS2, PR8/NAwt./NS1(1-73)-GFP-NS2 or wild type PR8. After 11h of infection, cells were lysed and 
expression of GFP (A) and NS1 (B) proteins was analysed on western blot. Not infected cells were used as 
negative control. 1 = PR8/NA-F85-93/NS1(1-73)-GFP-NS2; 2 = PR8/NAwt./NS1(1-73)-GFP-NS2; 3 = wild type 
PR8; 4 = not infected MDCK cells. 
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Figure 6.10 PR8/NA-F85-93/NS1(1-73)-GFP-NS2 and PR8/NAwt./NS1(1-73)-GFP-NS2 can stably 
transfer the GFP gene sequence to progeny virus. PR8/NA-F85-93/NS1(1-73)-GFP-NS2 (A) and 
PR8/NAwt./NS1(1-73)-GFP-NS2 (B) were serially passaged over MDCK cells. Supernatant containing virus 
from passage 3, 7 and 9 was used to infect MDCK cells. After 10h of infection the cells were fixed, stained 
and analysed by fluorescent microscopy for the expression of with NP (red) and GFP (green). An overlay of 
both signals combined with nuclear DAPI signal (blue) is shown in the right panel. 
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Analysis of in vivo attenuation. 
We hypothesised that the replacement of a part of the NS1 gene by GFP would cause an in vivo 
attenuation of the influenza virus. To test this, BALB/c mice (n = 6 per group) received 1 x 10
3
, 1 x 10
4
 
or 1 x 10
5
 PFU of PR8/NA-F85-93/NS1(1-73)-GFP-NS2 or PR8/NAwt./NS1(1-73)-GFP-NS2. Body weight 
was measured daily during 14 days after challenge and weight loss was compared to mice that 
received 5 x 10
3
 PFU of PR8/NA-F85-93 or 1 x 10
3
 of wild type PR8 virus. A 10-fold higher inoculum dose 
of PR8/NAwt./NS1(1-73)-GFP-NS2 was needed to reach comparable morbidity as wild type PR8 virus 
(approximately 70% of initial bodyweight) (Figure 6.11 A). PR8/NA-F85-93/NS1(1-73)-GFP-NS2 virus 
however appeared to be at least 100-fold attenuated: here a dose of 1 x 10
5
 PFU reduced the mean 
body weight up to 80% of the initial body weight, whereas a dose of 5 x 10
3
 PFU of PR8/NA-F85-93 
already induces body weight loss up to 70% of the initial weight (Figure 6.11 B). These results confirm 
our hypothesis that both PR8/NA-F85-93/NS1(1-73)-GFP-NS2 and PR8/NAwt./NS1(1-73)-GFP-NS2 are 
attenuated in vivo.  
Analysis of the number of induced F85-93-epitope specific CTLs should clarify if the attenuation of the 
PR8/NA-F85-93/NS1(1-73)-GFP-NS2 virus also has an effect on the induction of an adequate CTL 
response. 
 
 
Figure 6.11 PR8/NA-F85-93/NS1(1-73)-GFP-NS2 and PR8/NAwt./NS1(1-73)-GFP-NS2 are attenuated in 
vivo in BALB/c mice. Mice (n = 6 per group) received 1 x 10
3
, 1 x 10
4
 or 1 x 10
5
 PFU of PR8/NA-F85-93/NS1(1-
73)-GFP-NS2 (A) or PR8/NAwt./NS1(1-73)-GFP-NS2 (B). Body weight was monitored daily during 14 days 
after challenge and weight loss was compared to mice that received 5 x 10
3
 PFU of PR8/NA-F85-93 (A) or 1 x 
10
3
 of wild type PR8 virus (B). 
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In vivo cell tropism of GFP reporter PR8 virus. 
Next we were interested in analysing the possibility to use these GFP-carrying viruses as in vivo 
reporter virus in mice. BALB/c mice (n = 2 per group) were infected with 10
4
 PFU of wild type PR8 
virus or 10
6
 PFU of PR8/NA-F85-93/NS1(1-73)-GFP-NS2 or PR8/NAwt/NS1(1-73)-GFP-NS2. Two days 
after infection the lungs of the mice were isolated and we identified the specific cell types infected 
by the virus by counting the number of GFP positive cells using multicolour flow cytometry. GFP 
positive cells could be detected in the lungs of mice infected with PR8/NA-F85-93/NS1(1-73)-GFP-NS2 
and PR8/NAwt/NS1(1-73)-GFP-NS2, while these cells were not present in mice infected with PR8 wt 
virus. For mice infected with either of the GFP viruses we found that on average 25% of the epithelial 
cells (CD45-) were GFP positive (Figure 6.12). For all types of immune cells (CD45
+
) analysed, 
including B cells, CD8
+
 T cells, CD4
+
 T cells, CD11c
+
 DCs and granulocytes we found that only minor 
fractions (mostly below 1%) were GFP positive; however, there was still a clear difference compared 
to the mice infected with PR8 wt virus. For all the immune cell types tested we noted that a smaller 
number of cells was GFP positive in PR8/NA-F85-93/NS1(1-73)-GFP-NS2 infected mice, compared to 
PR8/NAwt/NS1(1-73)-GFP-NS2 infected mice. This is likely because of the more attenuated 
phenotype of PR8/NA-F85-93/NS1(1-73)-GFP-NS2 in mice, compared to PR8/NAwt/NS1(1-73)-GFP-NS2 
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Figure 6.12 PR8/NA-F85-93/NS1(1-73)-GFP-NS2 or PR8/NAwt/NS1(1-73)-GFP-NS2 infection results in 
GFP expression in vivo in BALB/c mice. Mice (n = 2 per group) were infected with 10
6
 PFU of 
PR8/NAwt/NS1(1-73)-GFP-NS2 (black) or 10
6
 PFU of PR8/NA-F85-93/NS1(1-73)-GFP-NS2 (grey) or 10
4
 PFU of 
wild type PR8 virus (white). Two days after infection the lungs of the mice were isolated and the number of 
GFP positive cells was determined using multicolour flow cytometry. GFP expression was analysed in (A) 
immune cells (CD45
+
), including B cells, CD8
+
 T cells, CD4
+
 T cells, cd11c
+
 DCs and granulocytes and (B) 
epithelial cells (CD45
-
). 
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6.4 Discussion 
A live attenuated HRSV vaccine has the best chance of becoming accepted as a vaccine against HRSV 
in young children (17). Since the recombinant influenza virus we previously constructed (PR8/NA-F85-
93 virus; see chapter 5) is not attenuated in vivo, we searched for methods to generate an attenuated 
variant of this vaccine virus, that would be capable of inducing a strong CTL response against HRSV, in 
the absence of vector-induced disease. Here we explored the use of two different strategies to 
genetically attenuate the PR8/NA-F85-93 virus. 
The first strategy for generating attenuated viruses uses the technique of codon-pair deoptimization 
(7, 8). We created recombinant virus containing codon-pair deoptimized NP and/or HA gene 
sequences. In vitro these codon-pair deoptimized viruses behaved clearly different from wild type 
PR8 or PR8/NA-F85-93 virus, since we observed less cytopathic effect on MDCK cells and a distinct 
plaque phenotype. In addition, it was difficult to grow these viruses to high titers on MDCK cells. This 
was in contrast to the in vivo behaviour of the viruses: we only observed mild in vivo attenuation. 
Viruses containing only one codon-pair deoptimized gene (PR8/NA-F85-93/NP
min
 and PR8/NA- F85-
93/HA
min
) were not at all attenuated. The virus containing two codon-pair deoptimized genes 
(PR8/NA-F85-93/NP
min
/HA
min
) was 10 times more attenuated than the parent PR8/NA-F85-93 virus. This is 
in strong contrast to the results reported by Mueller et al., who showed that addition of one of the 
codon-pair deoptimized genes already had a 10- or 30- fold increase of the median lethal dose (LD50) 
for PR8-NP
min
 and PR8-HA
min
 respectively (8). It should be noted that the codon-pair deoptimized 
viruses in our experiment were not pelleted by a centrifugation step but were administered to the 
mice as diluted cell supernatant. It is not ruled out that soluble factors, produced by the infected cell 
could have an impact on the immune response of the host. From the in vivo attenuation study we 
concluded that addition of two codon-pair deoptimized genes (NP
min
 and HA
min
) confers a 10-fold 
attenuation, however the virus did not meet our expectations of an in vivo attenuated virus that no 
longer induces body weight loss at high titers. Therefore, one would likely need to include the codon-
pair deoptimized PB1 gene sequence (PB1
min
), since this gene reportedly confers a 500-fold 
attenuation on its own, according to Mueller et al., and even a 13 000-fold attenuation when 
combined with NP
min
 and HA
min
 (8). 
A second method used for attenuating the PR8/NA-F85-93 virus consisted of truncating the NS1 
protein of the virus. Truncations of NS1, which is responsible for inhibition of the host immune 
response, has been shown to attenuate the virus replication in vivo (10). Here we report the 
construction of two viruses containing a truncated NS1, consisting of the N terminal amino 73 aa of 
NS1. In addition, we introduced GFP and designed an expression strategy for GPF as well as for NEP 
that is independent of mRNA splicing (Figure 6.4). We indeed observed that a 10- and 20-fold higher 
dose PR8/NAwt./NS1(1-73)-GFP-NS2 and PR8/NA-F85-93/NS1(1-73)-GFP-NS2 respectively had to be 
given to the mice to achieve similar body weight loss as PR8/NA-F85-93, confirming our hypothesis that 
both PR8/NA-F85-93/NS1(1-73)-GFP-NS2 and PR8/NAwt./NS1(1-73)-GFP-NS2 would be attenuated in 
vivo. In contrast, we did not observe any in vitro attenuation: wild type PR8 virus and mutant NS1(1-
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73)-GFP-NS2 viruses showed similar growth characteristics on MDCK cells. This corresponds to 
previous observations by Wang et al. who found that carboxy-terminal truncations of NS1 did not 
affect virus replication in vitro but did result in attenuation in mice (18). In addition, the MDCK cells 
used stably express the V protein of parainfluenza virus type 5. This protein binds to the IFN-
inducible RNA helicase, mda-5, hereby inhibiting IFN signalling (19). This should allow more efficient 
growth of viruses which do not possess an IFN-antagonising protein, such as the described influenza 
A viruses with truncated NS1 proteins.  
Besides a truncated NS1 to attenuate the virus, PR8/NAwt./NS1(1-73)-GFP-NS2 and PR8/NA-F85-
93/NS1(1-73)-GFP-NS2 also contain an additional sequence in the NS gene segment, coding for GFP. It 
has been shown that insertion of GFP in the influenza genome results in a virus expressing GFP in 
infected cells. Such viruses can be employed as a reporter virus to follow the course of an infection 
(13). Here we show that also viruses with a truncated NS1 (PR8/NAwt./NS1(1-73)-GFP-NS2 and 
PR8/NA-F85-93/NS1(1-73)-GFP-NS2) can still be utilized as a reporter virus both in vitro and in vivo. We 
show that in vivo, non-immune cells (CD45-) are the major cell type that is infected by influenza, 
whereas only small fractions (on average less than 1%) of the different types of immune cells (CD45
+
) 
are infected. This is not surprising, since epithelial cells are the primary target cell for influenza 
viruses (20). Our results are somewhat different from those reported earlier: Manicassamy et al. 
observed for some immune cell types up to 10% of GFP positive, i.e. influenza infected cells when 
infecting mice with their NS1-GFP reporter virus (13). This difference might be a result of the 
truncated NS1 which is present in our PR8/NAwt./NS1(1-73)-GFP-NS2 and PR8/NA-F85-93/NS1(1-73)-
GFP-NS2 viruses, whereas a full length NS1 was present in the NS1-GFP reporter virus used by 
Manicassamy et al., most likely resulting in a more infectious virus. It should be noted that in our 
study only 1 timepoint after infection was measured. This does not provide any information about 
the progress of the infection, or for example if infected DCs have migrated from the lungs to the 
lymph nodes. A kinetics study, both in the lungs and the draining lymph nodes will give a more 
thorough understanding of the progress of the influenza infection. In addition, a side by side 
comparison of our virus with truncated NS1 with a GFP containing virus with wild type NS1 will allow 
a better understanding of the effects of the truncated NS1 on the immune system. 
When working with recombinant viruses, stability of the virus is an important issue that needs to be 
taken into account. Manicassamy et al. reported that in a multicycle in vitro assay after 12 h already 
5-10% of the virus was no longer GFP-positive (13). In addition, they observed that 5-30% of the virus 
present in the lungs of mice was GFP-negative, indicating that these viruses are likely to contain 
mutation or deletions in the GFP sequence. Similarly Kittel et al. reported the appearance of NS-GFP 
deletion mutants in high frequency after passage on MDCK cells, with complete loss of GFP positivity 
after several passages (12). These GFP-negative viruses can arise due to selective pressure for viruses 
containing mutations in the GFP sequence resulting in more fit viruses. We did not observe such 
selective pressure for GFP-negative viruses in vitro: after 10 consecutive passages over MDCK cells 
PR8/NAwt./NS1(1-73)-GFP-NS2 and PR8/NA-F85-93/NS1(1-73)-GFP-NS2 were still GFP positive. This 
difference might be an effect of the dimerization domain which was added to the PR8/NAwt./NS1(1-
73)-GFP-NS2 and PR8/NA-F85-93/NS1(1-73)-GFP-NS2 virus, and which has been reported to (partially) 
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restore the NS1 function (18). We did not yet asses the in vivo stability PR8/NAwt./NS1(1-73)-GFP-
NS2 and PR8/NA-F85-93/NS1(1-73)-GFP-NS2 in mice. 
We did not determine the in vitro or in vivo stability of the viruses containing codon-pair deoptimized 
genes. It is not excluded that mutations occur in these viruses, however, it is unlikely that these 
viruses can revert back to wild type virus, since this would theoretically involve hundreds of 
mutations. 
A live attenuated influenza virus carrying an HRSV CTL epitope, as described here may be used as a 
vaccine against influenza as well as HRSV. First, however, it needs to be explored whether these 
attenuated viruses still induce a potent CTL response in mice, which is comparable to the parent, not-
attenuated virus. Live attenuated vaccines are already being used for influenza vaccination. In 
addition, a live vaccine against HRSV has the highest possibility of being approved for use in young 
infants, compared to inactivated vaccines (17). The latter is discouraged for use in young infants after 
the dramatic results of the inactivated FI-RSV vaccine trial (21). Besides the FI-RSV vaccine, the only 
type of vaccine that has been tested in 1-2 months old infants are live inactivated HRSV vaccines (22, 
23). 
6.5 Materials and methods 
Cell lines and viruses. Madin-Darby canine kidney (MDCK) cells and HEK293T cells were cultured in 
DMEM supplemented with 10% FCS, non-essential amino acids, L-glutamine, sodium-pyruvate and 
penicillin/streptomycin at 37°C in 5% CO2. Influenza viruses were grown on MDCK cells in serum-free 
cell culture medium in the presence of 2 µg/ml TPCK-treated trypsin (Sigma).  
 
Construction of the plasmid pHW-NS1(1-73)/GFP/NS2. The plasmid pHW-NS1(1-73)/GFP/NS2 was 
constructed using the following strategy: the coding sequence of the HAtag/Dmd/FMDV-2A was 
ordered from Genscript and cloned into the pcDNA3 vector using the restriction sites NotI and XbaI. 
The coding sequence of the first 73 aa of NS1 was picked up by PCR from the pHW198-NS plasmid 
and cloned in front of the HAtag using BamHI and EspEI. This NS(1-73)-HAtag/Dmd/FMDV-2A was 
cloned into the pHW2000 plasmid using the sites BamHI and MunI. The Quantum SuperGlo GFP 
coding sequence (derived from Qbiogene vector pQBI25-fc1) was cloned behind the FMDV-2A 
cleavage site using BglII and EcoRI. The PTV-1 2A cleavage site was fused to the NS2 coding sequence 
(by fusion PCR) and cloned behind the GFP coding sequence using the EcoRI and BstEII restriction 
sites. 
 
Production of recombinant viruses. Recombinant viruses were rescued using the influenza A/Puerto 
Rico/8/34 based reverse genetics system (24). To generate recombinant virus, 1 µg of each of the 
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seven pHW-plasmids (pHW191-PB2, pHW192-PB1, pHW193-PA, pHW194-HA, pHW195-NP, pHW197-
M, pHW198-NS) was transfected together with one of the NA plasmids (pHW196-NA, pHW196-NA-
F85-93 or pHW196-NA-HA518-526) in a HEK293T/MDCK cell co-culture using calcium-phosphate co-
precipitation in Optimem. For generation of codon-pair biased viruses, the plasmids pHW193-PA and 
pHW194-HA were replaced by pDZ-NP
min
 and pDZ-HA
min
 (a kind gift from Dr. E. Wimmer) (8). The 
plasmid pHW198-NS was replaced by the plasmid pHW-NS1(1-73)-GFP-NS2 for production of 
attenuated GFP reporter viruses. 
After 36 h, TPCK-treated trypsin (Sigma) was added to a final concentration of 2 µg/ml. After 72 
hours, the medium was collected. The presence of the virus in the medium was confirmed by 
hemagglutination of chicken red blood cells. The virus was amplified on MDCK cells and the viral titer 
was determined by plaque assay. The presence of wild type or mutant NA and NS segments in the 
viral genome were confirmed by RT-PCR and sequence analysis. The sequence of the primers is 
available on request. 
 
In vitro growth kinetics. MDCK cells (seeded at 4 x 10
6
 cells per 9 cm dish) were infected in duplicate 
with a multiplicity of infection of 0.001 of wild type PR8 virus, PR8/NAwt./NS1(1-73)-GFP-NS2 virus 
and PR8/NA-F85-93/NS1(1-73)-GFP-NS2 in a total volume of 10 ml. After one hour of incubation the 
inoculum was removed and replaced by 10 ml of serum-free medium with 2 µg/ml TPCK-treated 
trypsin (Sigma). A 200µl sample was taken at 0, 4, 8, 12, 24 and 48 h after removal of the inoculum. 
The viral titer in the samples was determined by TCID50 assay. 
  
Influenza plaque assay. MDCK cells were seeded in complete DMEM in six-well plates at 5 x 10
5
 cells 
per well one day before infection. The next day, cells were washed once with serum-free medium 
and incubated with a ten-fold dilution series of the virus in 500 µl medium. After 1 h of incubation at 
37°C, medium was removed and replaced by an overlay of 0.8% Avicel RC-591 (FMC Biopolymer) in 
serum-free medium with 2 µg/ml TPCK-treated trypsin (Sigma). After 72 hours of incubation at 37°C, 
the overlay was removed, and the cells were fixed with 4% paraformaldehyde and permeabilized 
with 0.2% Triton X-100. Plaques were stained with an anti-M2e IgG1 mouse monoclonal (final 
concentration 0.4 µg/ml) followed by a secondary anti-mouse IgG HRP-linked antibody. TrueBlue 
peroxidase substrate (KPL) was used for visualization. 
 
Immunization mice. Eight-week-old female BALB/c mice were housed in specified pathogen free 
conditions and used in all experiments. Under mild isoflurane anesthesia the mice were immunized 
by intranasal administration with the indicated doses of recombinant or wild type PR8 virus diluted in 
50 µl PBS.  
 
Immunofluorescence. MDCK cells (seeded on glass coverslips at 2 x 10
4
 cells per well in a 24 well 
plate) were infected with a MOI 5 of PR8/NA-F85-93/NS1(1-73)-GFP-NS2, PR8/NAwt/NS1(1-73)-GFP-
NS2 or wild type PR8 virus. After 10h the cells were fixed with 4% paraformaldehyde, permeabilized 
with 0,2% Triton X-100 and stained with goat anti-influenza RNP, diluted 1/2000 (NR-4282; NIH 
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Biodefense and Emerging Infections Research Resources Repository, NAIAD). As secondary antibody 
Alexa Fluor® 568 rabbit anti-goat IgG was used. The coverslips were mounted with DAPI-containing 
vectashield (Enzo Life Sciences, VC-H-1200).  
 
Analysis of GFP expression using western blot. MDCK cells (seeded at 2 x 10
5
 cells per well in a 6 
well plate) were infected with a MOI 5 of PR8/NA-F85-93/NS1(1-73)-GFP-NS2, PR8/NAwt/NS1(1-73)-
GFP-NS2 or wild type PR8 virus. Not infected MDCK cells were included as negative control. 10h later, 
the cells were lysed on ice for 30 min. in 200 µl lysis buffer (20mM Tris pH8, 200mM NaCl, 0,5% 
NP40, 1 mM EDTA pH 8 with protease inhibitors (Complete; Roche Diagnostics N.V. Belgium)). 
Laemlli was added and the sample was boiled for 10 min. The proteins were separated using SDS-
PAGE and GFP was visualised by western blot, using a monoclonal mouse anti-GFP antibody (A11121; 
Molecular probes), followed by a sheep anti-mouse HRP-linked secondary antibody and detection 
using ECL western blotting substrate (Pierce; Cat. No. 32106) 
 
Flow cytometry. Two days after influenza infection, mice were terminally anesthetized and the lungs 
were removed. Lungs were grinded with the plunger of a syringe and passed through a 70-µM filter 
to produce single-cell suspensions. Red blood cells were lysed in NH4Cl red blood cell lysis buffer. 
Cells were incubated with anti-mouse CD16/CD32 antibody (BD) to avoid nonspecific staining of 
immune cells and stained with anti-CD4-PerCP, anti-B220-Alexa Fluor® 700, anti-CD11c-APC, anti-
CD11b-APC-Cy7 (all four BD), anti-CD8-PE-Cy7, anti-CD45-PE, anti-CD3-eFluor 450 (all three 
eBioscience) and LIVE/DEAD® fixable Aqua Dead Cell stain (Molecular probes) for 30 min. The 
number of GFP positive lung cells was determined on an LSR-II flow cytometer (BD, San Jose, CA) by 
analysing surface expression of CD45, CD3, CD4, CD8, B220, CD11b, and CD11c, similar to the 
protocol described in Bogaert et al, (25) using FACSDiva software (BD). 
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Summary, general discussion  
and future perspectives 
Prevention strategies for severe disease caused by human respiratory syncytial virus (HRSV) are 
urgently needed. The currently used preventive measure consists of monthly intramuscular injections 
of a monoclonal antibody (Palivizumab) directed against the F protein of HRSV. This intervention is 
associated with a significantly reduced number of hospitalisation days due to HRSV infections: per 
100 patients the total number of hospitalisation days is 36.4 for treated vs. 62.6 for non-treated 
patients (1, 2). However, the Palivizumab administration cannot be used for every individual (2). Due 
to the high costs of this treatment, it is only recommended for use in children that are at high risk for 
severe HRSV disease, such as premature babies and children with congenital heart and lung disease 
(3). Yet, in this high risk group, Palivizumab is not capable of preventing severe HRSV-associated 
disease in each treated patient (2). Therefore, the development of a safe and effective vaccine, that 
can prevent severe HRSV-associated disease would mean a major breakthrough. 
Since monoclonal antibodies directed against the fusion protein are a known correlate of protection, 
a logic strategy for preventing HRSV associated disease would be to induce such antibodies by an 
active vaccination protocol, a canonical strategy that has been used successfully in the past to control 
most (childhood) infectious diseases such as polio and hepatitis A and B virus infection. However, 
history has shown that for HRSV the situation is not just ‘as simple as it seems’. Vaccination of 
children using a formalin-inactivated HRSV (FI-RSV) vaccine, a strategy that had been applied with 
success for the development of other childhood vaccines, resulted in severe disease upon an HRSV 
infection in 80% of the vaccines and two children died (4). This severe disease was characterized by 
poor functionality of the induced antibodies and a CD4
+
 Th2 biased immune response (5, 6). Since 
these fatal clinical trials it became clear that an HRSV vaccine that induces IL-4 producing CD4
+
 T cells 
should be avoided in HRSV-naïve infants.  
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A virus-like particle based vaccine candidate for HRSV. 
A first vaccination strategy described in this thesis builds upon the knowledge that antibodies 
directed to the F protein are a known correlate of protection. We aimed at inducing a strong 
antibody response, by linking HRSV F protein derived peptides to the virus-like particle (VLP) carrier 
made up of hepatitis B virus core (HBc) proteins. We hypothesized that the highly repetitive structure 
in which the HRSV peptides can be presented at the surface of the HBc particle, would be an 
approach with a high chance of success for the induction of a strong antibody response. 
Furthermore, this approach might work in the presence or absence of T helper cells. In addition, 
since VLPs cannot replicate – they consist of structural proteins without a functional genome – this 
type of vaccine carrier is considered safer than replicating viral carries, which still (partly) retain the 
ability to cause disease. Vaccine safety is a prime factor when very young children are the target 
group. Therefore we explored the use of HBc-based VLPs as a candidate for a novel vaccination 
strategy against HRSV. This technique has been successfully used in the past by our lab for the 
development of a universal influenza A virus vaccine, based on the ectodomain of the matrix 2 
protein (7-10). Two types of peptides were coupled to the VLP by genetic fusion. First we chose small 
peptides derived from regions in the F protein with known binding sites of neutralizing antibodies. As 
a second antigen source, we linked larger protein fragments of the F protein, which likely would 
more closely mimic the natural conformation of full length F protein, to the HBc carrier. All chosen 
antigens were free of possible N-linked glycosylation sites. These HRSV-derived peptides or domains 
were genetically fused to the major immunodominant region (MIR) of HBc as well as at the N-
terminus of the HBc monomer. Unfortunately, none of the attempted strategies used to fuse the 
HRSV derived antigens to the HBc carrier resulted in a VLP that was soluble.  
Changing of the salt concentration or the pH of the buffer used for sonicating the bacteria in which 
the VLP is produced, did not result in a more soluble VLP product. This imposes severe problems for 
the upscaling of the production process and the subsequent purification of the VLP vaccine. A 
possible answer to the question why these HRSV peptides lead to insoluble VLPs might be found in 
the hydrophobicity of the used peptides. We noticed that the M2e peptide, which has been coupled 
with success to HBc VLPs is highly hydrophilic, whereas most of the HRSV peptides that we used are 
predicted to be extremely hydrophobic. These hydrophobic regions which are present at the surface 
of the VLP might result in a particle with low solubility in aqueous solutions. We attempted to 
enhance the solubility of the VLP product by fusing the M2e coding sequence behind the HRSV 
peptides at the N-terminus of HBc. But again this did not result in any highly soluble VLP product.  
An alternative virus-like particle based vaccine platform uses a modified alphavirus (Alphavax, North 
Carolina, USA). These so called virus replicon particles (VRPs) carry a modified viral RNA genome that 
carries the coding sequence of the heterologous antigen, resulting in abundant antigen expression in 
the infected cell upon vaccination with such a VRP vaccine (11). Both strategies, VLPs and VRPs have 
advantages compared to the other. A major advantage of the VRPs is that a non-human virus is used 
as basis for the VRP, such as Equine encephalitis virus, which ensures that no pre-existing vector 
immunity is present that can blunt the immune response in humans. An advantage of the VLPs is its 
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highly repetitive superficial exposition of the foreign antigen, which allows cross-linking of the B cell 
receptor and activation of the B cell completely independent of T cell help (12, 13) as well as 
presentation in a T cell depentant way, which allows affinity matuation and isotype switching. 
Since we did not succeed in producing particles that were satisfactorily soluble to proceed to in vivo 
testing in mice, the question whether this vaccination strategy could provide protection against HRSV 
remains unanswered. It is likely that, for preventing HRSV infection, the induction of a CD8
+
 T cell 
response by a vaccine will be required. Nevertheless, a vaccination strategy as described here, which 
only induces a robust antibody response, without a CD8
+
 T cell compartment, may also be beneficial. 
Due to adverse events that occured in the past, non-replicating vaccines for HRSV are unlikely to be 
accepted for use in young infants however, these vaccines can be used for vaccinating adults or older 
children. A strategy which has been proposed that might benefit from such an antibody-inducing 
vaccine is the “herd immunization” (14) strategy. This strategy is based on the observation that 
infants are often infected by a close relative, such as an older sibling, a parent or somebody else with 
whom he lives together. These older people, when infected with HRSV, often experience only mild 
symptoms and hence are not aware that they could be the source of infection for the infant. It has 
been shown, for viruses other than HRSV, that large scale vaccination of the people in a community 
decreases the chances of the non-vaccinated, in this case the infant, to become infected (14). 
Another strategy that would benefit from an antibody-inducing vaccine is the maternal vaccination 
strategy. It has been shown that HRSV-specific maternal antibodies, that have been transferred to 
the infant during pregnancy, correlate with a reduced number of HRSV cases during the first weeks 
after infant birth (15). Using a purified F protein vaccine (PFP-2) it was shown that vaccination of the 
mother during pregnancy enhances the antibody levels in the infant (16). Such a vaccination strategy 
might be useful in providing a significant amount of protection during the first weeks of life, when 
the child is still too young for vaccination. 
A live attenuated influenza virus as HRSV vaccine candidate. 
An increasing amount of data supports the idea that, for an efficient vaccine against HRSV, the 
induction of a T cell immune response will be mandatory. First, in early vaccine trials using FI-RSV 
vaccine children suffering severe HRSV induced disease had developed a weak CTL response (17). 
Second, in a model of vaccine enhanced disease in mice it has been shown that CTLs can inhibit the 
development of an undesired CD4
+
 Th2 immune response (17-19). Third, whereas in mice CTLs have 
been shown to be associated with enhancement of disease (20), in humans they have been shown to 
peak during convalescence (21), and hence are not the cause of observed lung damage. And last, in 
humans and mice CTLs have been attributed a role in clearance of HRSV from the lungs of infected 
patients or animals (20, 21). 
To explore the possibilities of inducing a CD8
+
 T cell response against HRSV using a live viral vector, 
we created a recombinant influenza virus carrying the HRSV F85-93 CTL epitope in the NA stalk 
(PR8/NA-F85-93 virus). Infection of mice with this virus showed that an HRSV specific CTL response was 
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efficiently induced and this in a dose dependent manner. We showed that upon a subsequent HRSV 
challenge these CTLs were capable of reducing the HRSV replication in the lungs of the mice, 
indicating that the CTLs induced by the vaccine can provide considerable protection against HRSV. 
Since the vaccine is a live virus that is capable of evoking disease, it is desirable to suppress the 
infectivity of this virus to eliminate vector-induced disease. To attain this, we pretreated the mice 
with a monoclonal antibody directed against the influenza M2e. In contrast to neutralizing 
antibodies, these anti-M2e antibodies are infection permissive, allowing at least one round of 
replication, which is required for efficient presentation of the CTL epitope and induction of a CTL 
response. Indeed we observed that even though anti-M2e antibody pretreatment completely 
abrogates weight loss caused by the vaccine vector, an HRSV specific CTL response is still efficiently 
induced. In addition, following an HRSV challenge these CTLs are capable of reducing HRSV 
replication in the lungs of the mice. 
Interestingly, we repeatedly observed that mice infected with a control influenza virus, that does not 
carry an HRSV CTL epitope have a reduced lung viral load compared to PBS treated mice, indicating 
that influenza can partly protect against an HRSV infection. This heterologous immunity, or the 
immunity that can develop to one pathogen after an encounter with a non-related pathogen, is a 
common feature that has been demonstrated for a variety of pathogens, including parasites, 
protozoa, bacteria and viruses (22). It has been observed between closely related species but also 
between unrelated pathogens and can lead to either diminishing or, as is the situation for an 
influenza infection followed by HRSV, enhancement of protective immunity. This heterologous 
immunity can be mediated either by effects of the innate immunity or by effects of the adaptive 
immune response. One possibility could be the existence of cross-reactive T cells between influenza 
and HRSV. Such cross-reactive CD8
+
 T cells have been reported between several pathogens, both in 
mice and in humans (summarized by Welsh et al. (22)). For example, in hepatitis C virus (HCV) naïve 
individuals T cells were found that reacted to stimulation with the HCV HLA-A2 restricted epitope 
NS31073-1081. It appeared that these T cells were memory T cells specific for the influenza A virus NA231-
239 epitope, which were able to cross react with the HCV NS31073-1081 epitope (23). Until now, no cross-
reactive epitope between HRSV and influenza has been reported. Alternatively, the heterologous 
immunity might be a result of bystander activation of CD8
+
 T cells. This has been observed in the 
model of HRSV-mediated disease enhancement in G-protein primed mice: here, a prior influenza 
infection can diminish the enhancement of disease, which is normally observed upon HRSV infection 
of G-protein primed mice (24). Also, epigenetic reprogramming of monocytes upon BCG vaccination 
has shown to result in a pathogen non-specific protection, which in this case is mediated by the 
innate immune system (25). It is not clear which arm of the immune response is involved in the non-
specific protection against HRSV. 
Noteworthy, only partial protection against HRSV by the recombinant influenza virus could be 
demonstrated, that is, at day 4 or 5 after HRSV challenge, the virus could still be recovered from the 
lungs. Possibly, the number of CD8
+
 T cells induced by vaccination is not high enough or the memory 
formation is not effective. However, it might be a property that is characteristic to the mouse model 
of HRSV. Indeed, to achieve sufficient infection in the mice, a high dose of HRSV (typically > 10
6
 PFU) 
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is needed. This is in contrast to a natural infection in humans, which likely originates from a rather 
small inoculum (26). It is possible that, in humans the CD8
+
 T cells induced by vaccination might be 
sufficient to clear the infection, before the virus reaches high titers. Alternatively, a boost vaccination 
has been shown to increase memory formation, which might result in a better protection (27). We 
performed such a boosting experiment, using DNA vaccination for the boost, however we did not 
observe an enhancement of the number of CD8
+
 T cells, when used in combination with anti-M2e 
pretreatment; whereas without the anti-M2e treatment, the effect of the boost was more clear. This 
is an interesting observation and suggests that the treatment with anti-M2e antibodies drives the 
CD8
+
 T cell response in the direction of terminally differentiated effector T cells, which cannot be 
boosted by a second antigen exposure.  
 
Combining the recombinant influenza virus with M2e pretreatment in humans would be an 
unpractical solution. This would require people to possess anti-M2e antibodies, either through active 
vaccination, or through passive administration of monoclonal antibodies as used in the mice study 
described above. Particularly in young infants an active influenza vaccination preceding the HRSV 
vaccination would extend the period that the child is highly susceptible to HRSV, which is not 
recommended. Passive administration of monoclonal antibodies would be a faster option, however 
such a vaccination strategy remains complex and has not been used for other pathogens. Currently it 
seems rather unlikely that anti-M2e treatment followed by vaccination with the recombinant 
influenza virus would be an acceptable vaccination strategy for HRSV in infants. Therefore a more 
practical strategy for reducing vector induced morbidity would be to attenuate the vector. In this 
thesis we explored two different strategies for producing an attenuated influenza virus. The first 
strategy consisted of a virus with codon-pair deoptimized HA and NP genes (28). While preserving 
the wild type amino acid sequence, codon pair deoptimization results in a virus with sub-optimal 
codon-pairs, causing slower protein synthesis of the deoptimized genes and as a consequence, 
reduced viral replication. Such an attenuated recombinant influenza virus with codon-pair 
deoptimized HA and NP and with the HRSV F85-93 CTL epitope in the NA stalk was only mildly 
attenuated in mice. However, addition of a third codon pair deoptimized gene, such as PB1 has been 
reported to dramatically increase the attenuation of the virus in vivo (29). 
A second strategy used for attenuating the influenza viral vector is by truncating the NS1 protein. 
Viruses with C-terminally truncated NS1 proteins have been shown to be attenuated in vivo in 
multiple animal models (30, 31). In addition, we added a GFP coding sequence to the NS1 gene 
sequence, not so much to attenuate the virus, but rather to follow the course of the infection with 
this recombinant vector both in vitro and in vivo. We generated such a recombinant influenza virus 
with the HRSV F85-93 CTL epitope in the NA stalk and a truncated NS1 followed by the GFP coding 
sequence. We succeeded in rescuing this virus and demonstrated that it was viable, stable and 
attenuated approximately 10-fold compared to parental virus in vivo in mice. A live attenuated 
influenza virus carrying an HRSV CTL epitope, as we described may be used as a vaccine against 
influenza as well as HRSV. First, however, it needs to be explored whether these attenuated viruses 
still induce a potent CTL response in mice, which is comparable to the parent, not-attenuated virus.  
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As with any new technology, before the PR8/NA- F85-93 virus can be used as a live vaccine for the 
human population, some issues need to be resolved. Stringent safety requirements must be met for 
viruses that, in their natural state, have the potential to infect humans. Since the PR8/NA-F85-93 virus 
does not contain any attenuating element, it is rather unlikely that this virus will be accepted in this 
form for human use, even in M2e immune humans. Attenuating elements will be required, certainly 
for use in young infants. Even though LAIV are already being used for influenza vaccination, they 
have not been accepted for children younger than 2 years old (32). This implies that before a 
recombinant influenza virus, carrying any foreign protein, whether derived from HRSV or from a 
different pathogen, will be accepted as childhood vaccine, outstanding safety will need to be proven. 
However, “if” an attenuated recombinant influenza virus expressing HRSV CTL epitopes could be 
generated that meets the safety criteria and induces sufficient protective immunity, such a vaccine 
has a high chance of being accepted for use in young infants (26): after the fatal FI-RSV trials, only 
live vaccines have been approved for testing in young infants of 1-2 months old (33, 34). 
An additional drawback of influenza virus as vaccine vector is its limited coding capacity, implying 
little space for foreign antigens. To use influenza as vector for inducing HRSV CTL immunity in 
humans, several human epitopes need to be included to generate a vaccine that covers most human 
HLA types. The number of residues that can be inserted in the NA stalk is limited (35, 36) and other 
strategies are required to accommodate large foreign sequences. Replacing a complete gene 
segment by a series of human CTL epitopes could be promising strategy (37, 38). This strategy only 
requires the inclusion of the appropriate segment specific packaging signals and providing the 
deleted gene in trans. Additionally, this strategy could (partly) overcome safety concerns (as 
mentioned above) since the deletion of an essential gene renders the virus replication defective in 
humans. 
The first recombinant influenza virus expressing foreign antigens has been described more than 20 
years ago, however, since then, no recombinant influenza virus expressing foreign epitopes has 
advanced to clinical testing. This is an indication that the use of influenza as live viral vector is a tough 
challenge. Alternatively, other viruses could be used, that are more likely of becoming accepted as 
recombinant vectors. Recombinant viruses such as Adenovirus, Vaccinia virus and Modified vaccinia 
virus Ankara are currently already being tested in clinical trials as vaccine against various pathogens 
including HIV, influenza virus, Plasmodium falciparum and Mycobacterium tuberculosis amongst 
others (39). The main advantage of influenza virus over these other viral vectors is the antigenic 
variability of influenza viruses, which can be of particular importance when a vaccination requires 
one or multiple boosts. If the same virus is used for boosting as for the priming immunization, the 
vaccine can be neutralized rapidly by antibodies directed to the viral surface proteins that were 
generated during the priming vaccination. When using influenza as viral vector, this can be simply 
overcome by boosting with a vaccine strain with a different neuraminidase and hemagglutinin 
subtype than the vaccine strain that was used for priming. 
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The future HRSV vaccine: will it ever be found? 
More than 60 years of vaccine research has not lead to a suitable vaccine candidate against HRSV. 
Why is it so difficult to find a vaccine that protects against HRSV? There are several factors that 
complicate the development of a vaccine. First, the lack of a good animal model, that faithfully 
reproduces the disease in humans is a major drawback. HRSV animal studies can give us a good clue 
of what ‘might’ happen in humans, however they rarely provide the complete picture, and often, 
different results are observed in animals than in humans. A good example is the fact that CD8
+
 T cells 
can contribute to disease in the mouse model (20), whereas this has not been seen in humans (40). 
Since the development of a single animal model that completely mimics the human situation is a 
utopia, testing the vaccine candidates in multiple animal models is the only possibility. A second 
factor complicating HRSV vaccine development is linked to the main target group of the vaccine, i.e. 
infants of 1-2 months old. The immune system in these young children is less well developed as in 
adults, and is mainly biased in the Th2 direction, which should be avoided for HRSV vaccines. It 
should be noted however, that this Th2 bias is more pronounced in mice, and is less explicit in human 
new-borns. Rather the CTL response in new-borns is diminished in magnitude compared to adults 
and, when formulated correctly a Th1 response can be evoked (41). In addition, at very young age, 
most infants still possess maternally derived anti-HRSV antibodies, that may shield off vaccines, and 
hence prevent efficient vaccination (42). However, this does not mean that vaccination at this young 
age is excluded: in Belgium, as in many other countries, vaccination is started at the age of 6 weeks 
(43). In accordance with the WHO guidelines for vaccination (44), at the age of 6 to 8 weeks old 
children receive vaccines against Rotavirus, Polio, Diphtheria, Tetanus, Haemophilus influenzae, 
Pertussis and Hepatitis B (43). In addition, children born from infected mothers may receive a 
Hepatitis B or BCG vaccine as early as 24h after birth (45, 46). These data indicate that it is possible to 
vaccinate children during the first two months of life. A third and maybe the biggest factor 
complicating HRSV vaccine development is the complexity of the virus itself and the immune 
response it induces. HRSV has developed many strategies to evade the innate immunity of the host. 
For example, the non-structural proteins, NS1 and NS2 collaborate to inhibit expression of IFN-
associated genes through IRF3 and Stat2 (47, 48). Also, HRSV inhibits TLR signalling through MyD88 
and MAVS and it interferes with RIG-I signaling (49, 50). Many other examples exist, and a thorough 
understanding of these processes and their consequences for immunity is needed to be able to 
design a safe HRSV vaccine. In addition, HRSV does not evoke long term protective immunity. A 
better understanding of memory formation after HRSV infection is needed to design vaccines that 
efficiently induce memory formation. And last, we need to understand the processes related to the 
enhancement of disease, associated with the FI-RSV vaccine. Only when the origin of this 
exacerbation is completely understood, we can rationally design vaccines without this complication. 
When we look back at the past vaccine attempts against HRSV, we can roughly categorize them into 
three groups. A schematic representation is given in figure 7.1. On one side of the spectrum we find 
the non-replicating vaccines, with the FI-RSV at the extreme end. This vaccine caused exacerbation of 
disease and hence is not suitable as an HRSV vaccine. In the same group, but a bit more to the right, 
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we find the subunit vaccines, which in some cases were also found to induce enhanced disease, 
however, not as bad as the FI-RSV vaccine. On the other end of the spectrum we find the second 
group of vaccines, i.e. the live attenuated HRSV vaccines. The first generations of these vaccines 
suffered from safety issues: when not sufficiently attenuated, these vaccine viruses could still cause 
disease. These two groups form the extremes of the spectrum, which are considered not suited as an 
HRSV vaccine candidate. In between these two categories, we find a big group with a variety of 
different types of vaccine strategies (such as recombinant viral vectors, virus-like particles, non-
replicating viral vectors etc.) of which it is less clear where exactly on the scale they should be placed. 
The narrow green zone in the middle, between the inactivated and the live vaccines represents the 
“ideal” HRSV vaccine, that has not been discovered yet. This ideal vaccine should induce an antibody 
response and a T cell response, and provide long term memory, without the risk of enhancement of 
disease. Although, due to the different immune status of various age groups, one vaccine that will be 
suitable for every individual will be rather unlikely. It is likely that specific vaccines for each of these 
age groups will need to be developed. Future will tell if it is possible to develop a safe and effective 
HRSV vaccine. 
 
Figure 7.1 Schematic representation of the vaccine candidates for HRSV. 
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Samenvatting, algemene discussie  
en toekomstperspectieven 
Er is dringend nood aan preventieve maatregelen tegen het humaan respiratoir syncytieel virus 
(HRSV). De enige beschikbare preventieve maatregel op dit moment bestaat uit een maandelijkse 
intramusculaire injectie van een monoclonaal antilichaam (Palivizumab) gericht tegen het HRSV F 
eiwit. Deze maatregel zorgt voor een significante reductie in het aantal hospitalisatie dagen als 
gevolg van een HRSV infectie: het totaal aantal hospitalisatie dagen voor 100 patiënten wordt 
gereduceerd van 62,6 dagen naar 36,4 dagen als gevolg van de palivizumab behandeling (1, 2). De 
behandeling met palivizumab kan echter niet gebruikt worden voor alle kinderen (2). Door de hoge 
kostprijs wordt de behandeling enkel geadviseerd voor kinderen die een hoog risico lopen op 
complicaties als gevolg van een HRSV infectie, zoals prematuur geboren baby’s, of kinderen met 
aangeboren hart en long afwijkingen (3). Maar zelfs in deze hoge risico groep kan een Palivizumab 
behandeling niet elk kind beschermen tegen ernstige ziekte als gevolg van een HRSV infectie (2). 
Daarom zou de ontwikkeling van een veilig en doeltreffend vaccin, dat zware ziekte als gevolg van 
een HRSV infectie kan verhinderen, een grote doorbraak betekenen. 
Aangezien het algemeen geweten is dat antilichamen gericht tegen het HRSV F eiwit correleren met 
bescherming, zou een logische strategie om HRSV infecties te verhinderen eruit kunnen bestaan om 
zulke antilichamen op te wekken door middel van een actief vaccinatie protocol; een strategie die in 
het verleden met succes is toegepast voor het onderdrukken van de meeste (kinder-)ziektes zoals 
bvb. deze veroorzaakt door het polio virus of het hepatitis A en B virus. De geschiedenis heeft ons 
echter geleerd dat de situatie voor HRSV “niet zo simpel is als het lijkt”. Vaccinatie van kinderen met 
een formaline-geïnactiveerd HRSV (FI-RSV) vaccin - een strategie die reeds met succes was toegepast 
voor het ontwikkelen van andere vaccins – leidde tot ernstige ziekte ten gevolgen van een HRSV 
infectie in 80% van de gevaccineerde kinderen met zelfs 2 doden tot gevolg (4). Kenmerkend voor 
deze zware ziekte was de zwakke neutraliserende activiteit van de opgewerkte antilichamen en de 
aanwezigheid van Th2 CD4
+
 immuun cellen (5, 6). Sinds deze fatale klinische studies was het duidelijk 
dat een HRSV vaccin dat IL-4 producerende CD4
+
 T cellen opwekt absoluut moet vermeden worden 
bij HRSV-naïeve baby’s.  
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Een virus-achtig partikel vaccin-kandidaat tegen HRSV. 
Een eerste vaccinatie strategie maakt gebruik van het feit dat antilichamen gericht tegen het HRSV F 
eiwit bescherming kunnen bieden tegen een HRSV infectie. Het doel was om een antilichamen op te 
wekken door korte peptiden van het HRSV F eiwit te koppelen aan een dragermolecule, nl. een virus-
achtig partikel (VLP) opgebouwd uit monomeren van het hepatitis B virus kern eiwit (HBc). Hierbij 
was onze hypothese dat de sterk repetitieve structuur waarin de HRSV peptiden gepresenteerd 
worden aan het oppervlak van het VLP een goede strategie zou vormen die een grote kans maakte 
voor het opwekken van een sterk antilichaam-gemedieerd immuun antwoord. Deze strategie zou 
bovendien kunnen werken zowel in aan- als afwezigheid van helper T cellen. Aangezien VLP-
gebaseerde vaccins niet meer in staat zijn te  vermenigvuldigen – het vaccin bestaat nl. enkel uit 
structurele eiwitten zonder een functioneel genoom – worden deze algemeen als veiliger aanzien 
dan virale dragers die nog de mogelijkheid bezitten om te repliceren en bijgevolg nog (gedeeltelijk) in 
staat zijn om ziekte te veroorzaken. Vaccin veiligheid wordt beschouwd als een belangrijke factor 
wanneer jonge kinderen de doelgroep vormen. Daarom onderzochten we de mogelijkheden van een 
HBc-gebaseerd VLP vaccin als kandidaat voor een nieuwe HRSV vaccinatie strategie. Deze techniek 
werd in verleden reeds met succes toegepast in onze onderzoeksgroep voor het ontwikkelen van een 
vaccin tegen influenza A virus, gebaseerd op het ectodomein van matrix 2 eiwit (7-10). Voor het 
HRSV vaccin werden twee soorten peptiden gekoppeld aan het VLP door middel van genetische 
fusie. Ten eerste werd gekozen voor korte peptiden afkomstig van regio’s in het F eiwit die epitopen 
bevatten van reeds gekende neutraliserende antilichamen. Als tweede bron van antigen gebruikten 
we grote fragmenten van het F eiwit welke mogelijks de natuurlijke conformatie van het complete F 
eiwit beter benaderen. De gekozen antigenen bezitten geen N-gekoppelde glycosylatieplaatsen. Deze 
peptiden of domeinen afgeleid van HRSV werden genetisch gefusioneerd zowel aan de 
immunodominante lus (MIR) van HBc als aan het N-terminale uiteinde van de HBc monomeer. Helaas 
resulteerde het koppelen van ieder van deze peptiden aan HBc in een onoplosbaar VLP product.  
Wijzigen van de zoutconcentratie of de pH van de sonicatiebuffer waarin de bacteriën gesoniceerd 
werden bood geen oplossing en resulteerde niet in een meer oplosbaar product. Dit zorgt voor 
moeilijkheden bij het opschalen van het productieproces en de zuivering van het vaccin. Een 
mogelijke verklaring voor deze onoplosbaarheid kan liggen in de hydrofobiciteit van de gebruikte 
peptiden. Het M2e peptide, dat reeds met succes aan HBc VLPs werd gekoppeld is sterk hydrofiel, 
terwijl de meeste HRSV peptiden die gebruikt werden eerder een hydrofoob karakter vertonen. 
These hydrofobe gebieden die zich aan het oppervlak van het VLP bevinden kunnen ervoor zorgen 
dat het partikel moeilijk oplosbaar is in waterige vloeistoffen. In een poging om de oplosbaarheid te 
verhogen plaatsten we de coderende sequentie van M2e na deze van het HRSV peptide aan de N-
terminus van HBc. Opnieuw resulteerde dit niet een product dat goed oplosbaar was. 
Een alternatieve strategie maakt gebruik van een gemodificeerd alfavirus als drager. Deze virus 
replicon partikels (VRPs) bezitten een gemodificeerd RNA genoom dat de coderende sequentie van 
een heteroloog antigen draag, wat bij vaccinatie met dit partikel resulteert in overvloedige expressie 
van dit antigen in de geïnfecteerde cel (11). Beide strategieën, VLPs en VRPs hebben hun voordelen 
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ten opzichte van de andere. A groot voordeel van de VRP strategie is dat wordt gebruik gemaakt van 
een niet-humaan virus, zoals een Equine encephalitis virus, hetgeen ervoor zorgt er geen immuniteit 
bij de mensen aanwezig is die het effect van het vaccin kan onderdrukken. VLPs echter bezitten de 
mogelijkheid om een immuun antwoord op te wekken in afwezigheid van helper T cellen. Een 
voordeel van VLPs is het sterk repititieve patroon waarin vreemde antigenen worden gepresenteerd 
aan het immuun systeem wat zorgt voor rechtstreekse crosslinking van B cel receptoren en de 
activatie van de B cel zonder de hulp van T cellen (12, 13) alsook voor T cel afhankelijke 
immuunstimulatie wat zorgt voor affiniteitsmaturatie en isotype swith.  
 
Aangezien we er niet in geslaagd zijn om partikels te produceren die geschikt waren om te testen in 
vivo in muizen, kunnen we geen antwoord geven op de vraag of deze vaccinatie strategie 
bescherming kan bieden tegen een HRSV infectie. Het is echter niet ondenkbaar dat het opwekken 
van een CD8
+
 T cel immuun antwoord noodzakelijk is om een HRSV infectie tegen te gaan. Toch biedt 
ook een vaccin zoals dit hier voorgesteld, dat enkel een antilichaam-gemedieerd immuun antwoord 
opwekt zonder een CD8
+
 T cel component, mogelijkheden. Ook al is het onwaarschijnlijk dat niet-
levende vaccins zullen geaccepteerd worden voor gebruik in jonge kinderen, toch kunnen deze 
vaccins gebruikt worden voor het vaccineren van volwassenen en oudere kinderen. Een strategie 
waarvoor dit soort antilichaam-inducerende vaccins een voordeel kan bieden is de zogenaamde 
“kudde vaccinatie” strategie (14). Deze strategie is gebaseerd op de vaststelling dat babies vaak 
geïnfecteerd worden door de naaste familie, zoals een oudere broer of zus, een ouder of iemand 
anders met wie hij samen woont. Doordat deze oudere personen vaak slechts milde symptomen 
vertonen bij een HRSV infectie zijn ze er zich niet van bewust dat ze een bron van infectie kunnen zijn 
voor de baby. Voor andere virale infecties werd reeds aangetoond dat het vaccineren van een grote 
populatie de kansen op infectie van niet-gevaccineerden, in dit geval de baby, drastisch doet 
afnemen (14). Een andere strategie waarvoor een antilichaam-opwekkend vaccin zinvol kan zijn is de 
maternale vaccinatie strategie. Er werd reeds aangetoond dat de overdracht van HRSV-specifieke 
antilichamen van de moeder naar de baby tijdens de zwangerschap correleert met een verlaagde 
kans op HRSV infectie van de baby tijdens de eerste weken na de geboorte (15). Bovendien werd in 
een klinische studie bevestigd dat vaccinatie van zwangere vrouwen met een gezuiverd F eiwit vaccin 
kandidaat (PFP-2) zorgde voor een verhoogd niveau aan HRSV-specifieke antilichamen bij hun baby 
(16). Deze vaccinatie strategie kan interessant zijn om de baby gedurende de eerste weken van zijn 
leven, wanneer het kind nog te jong is voor vaccinatie, een zekere mate van bescherming te bieden 
tegen een HRSV infectie. 
Een levend verzwakt influenza virus als HRSV vaccin kandidaat. 
Een als maar toenemende hoeveelheid data steunen het idee dat het opwekken van een T cel 
immuun antwoord essentieel zal zijn voor het ontwikkelen van een doeltreffend HRSV vaccin. Ten 
eerste heeft men vastgesteld dat de FI-RSV gevaccineerde kinderen die zwaar ziek werden ten 
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gevolge van een HRSV infectie nauwelijks een CTL immuun antwoord hadden opgewekt (17). Ten 
tweede werd aangetoond dat CTLs in een muismodel van vaccinatie-geïnduceerde ziekte-verergering 
de ontwikkeling van zware ziekte konden verhinderen (17-19). Ten derde werd aangetoond dat de 
piek in het CTL immuun antwoord bij de mens voorkomt tijdens het herstel van de ziekte en niet 
tijdens die piek van de ziekte, zoals bij muizen (20, 21). Als laatste heeft men zowel bij de muis als bij 
de mens kunnen aantonen dat CTLs noodzakelijk zijn om het virus volledig te elimineren uit de 
longen van geïnfecteerde dieren of patiënten (20, 21). 
 
Om na te gaan of het mogelijk is een CD8
+
 T cel immuun antwoord op te wekken door middel van 
een levende virale vector hebben we een recombinant influenza virus gemaakt dat het HRSV F85-93 
cytotoxische T lymfociet (CTL) epitoop draagt in de stam van het neuraminidase eiwit. Wanneer 
muizen met dit virus geïnfecteerd werden werd op een CTL immuun antwoord opgewekt dat dosis-
afhankelijk was. Bij een daaropvolgende infectie met HRSV waren deze CTLs in staat om de 
vermenigvuldiging van het virus in de longen af te remmen, wat aantoont dat de opgewekte CTLs 
een zekere mate van bescherming kunnen bieden tegen een HRSV infectie. Aangezien het vaccin 
bestaat uit een levend virus dat nog in staat is om ziekte te veroorzaken is het wenselijk om de 
infectiviteit van dit virus te onderdrukken en zodoende de vector-geïnduceerde ziekte te voorkomen. 
Dit werd bereikt door de muizen voorafgaand aan de vaccinatie te behandelen met een monoklonaal 
antilichaam dat gericht is tegen het influenza M2e. In tegenstelling tot neutraliserende antilichamen 
zijn deze anti-M2e antilichamen infectie-permissief, hetgeen noodzakelijk is voor de correcte 
presentatie van het CTL epitoop op MHC-I moleculen en het opwekken van een CTL immuun 
antwoord. Terwijl het gewichtsverlies ten gevolge van de influenza infectie volledig kon worden 
onderdrukt, werd nog steeds een HRSV specifiek CTL immuun antwoord opgewekt. Bovendien zijn 
deze CTLs nog steeds in staat om de vermenigvuldiging van HRSV in de longen van de muis te 
onderdrukken bij een HRSV infectie. 
 
We stelden herhaaldelijk vast dat muizen die gevaccineerd werden met een controle influenza virus 
dat geen HRSV CTL epitoop bevat, eveneens in mindere mate in staat waren om de 
vermenigvuldiging van HRSV in de longen te onderdrukken, in vergelijking met muizen die PBS 
toegediend kregen. Dit zou erop kunnen wijzen dat een influenza infectie gedeeltelijk kan 
beschermen tegen een HRSV infectie. Dit soort heterologe immuniteit, nl. de bescherming tegen één 
pathogeen die opgewekt wordt door een infectie met een ander niet verwant pathogeen werd reeds 
herhaaldelijk waargenomen tussen verscheidene pathogenen zoals parasieten, protozoa, bacteriën 
en virussen (22). Dit fenomeen werd reeds waargenomen zowel tussen verwante als niet verwante 
pathogenen en kan leiden tot hetzij een vermindering hetzij een verbetering van de bescherming, 
zoals hier wordt waargenomen voor een influenza infectie gevolgd door een HRSV infectie. Deze 
heterologe immuniteit kan een gevolg zijn van processen van hetzij het aangeboren immuun 
antwoord, hetzij het adaptief immuun antwoord. Het bestaan van kruis-reagerende T cellen tussen 
influenza en HRSV zou een mogelijke verklaring kunnen zijn voor de geobserveerde bescherming. Het 
bestaan van dit soort kruis-reagerende CD8
+
 T cellen werd reeds aangetoond tussen verschillende 
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pathogenen, zowel van muis als van mens oorsprong (samengevat in Welsh et al. (22)). Bijvoorbeeld, 
in hepatitis C virus naïeve personen werden T cellen waargenomen die reageerden bij stimulatie met 
het HCV HLA-A2 gerestricteerde NS31073-1081 epitoop (CVNGVCWTV). Verder onderzoek toonde aan 
dat het hier influenza A virus NA231-239 (CVNGSCFTV) specifieke geheugen T cellen betrof, die in staat 
waren te kruis-reageren met het HCV NS31073-1081 epitoop. (23). Tot op heden werden nog geen kruis-
reagerende T cellen waargenomen tussen influenza en HRSV. Een alternatieve verklaring voor de 
heterologe bescherming die werd waargenomen zou omstaander CD8
+
 T cel activering kunnen zijn. 
Dit werd eerder reeds waargenomen in een model van HRSV-gemedieerde verergering van ziekte in 
muizen geprimed met het HRSV G eiwit: hier zorgde een voorafgaande influenza infectie ervoor dat 
de G-eiwit afhankelijke ziekteverergering, die normaal wordt waargenomen bij een influenza infectie 
van G-eiwit geprimede muizen, werd onderdrukt (24). Bescherming tegen niet-verwante pathogenen 
werd eveneens waargenomen na een BCG vaccinatie. Dit is een gevolg van het aangeboren immuun 
systeem en wordt veroorzaakt door epigenetische herprogrammering van monocyten (25). Het is 
niet duidelijk welke arm van het immuun systeem verantwoordelijk is voor de niet-specifieke 
bescherming tegen HRSV, ten gevolge van een influenza infectie.  
We konden met het recombinant influenza virus slecht gedeeltelijke bescherming tegen HRSV 
aantonen: op dag 4 of 5 na infectie kon nog steeds HRSV uit de longen van de muizen geïsoleerd 
worden. Mogelijks is dit te verklaren doordat het aantal CD8
+
 T cellen dat gegenereerd werd door de 
vaccinatie niet voldoende hoog was, of doordat geheugen T cellen niet efficiënt gegenereerd 
worden. Anderzijds is het ook mogelijk dat dit een inherente eigenschap is van het HRSV muis-model: 
om voldoende infectie te bereiken worden muizen met een hoge dosis HRSV geïnfecteerd (vaak > 10
6
 
PFU), hetgeen in sterk contrast is met een menselijke HRSV infectie, die vaak ontstaat van een klein 
inoculum (26). Het is mogelijk dat bij de mens de CD8
+
 T cellen gegenereerd door vaccinatie met het 
PR8/NA-F85-93 virus in staat zijn om het virus te elimineren alvorens het hoge titers bereikt. Tevens 
werd reeds aangetoond het genereren van geheugen T cellen kan bevorderd worden door een 
booster vaccinatie, hetgeen mogelijks tot betere bescherming kan leiden (27). Wij voerden zo’n 
booster vaccinatie uit door middel van DNA vaccinatie maar we stelden vast dat dit niet resulteerde 
in een verhoging van het aantal CD8
+
 T cellen bij muizen die een anti-M2e behandeling kregen. Enkel 
bij muizen die niet met anti-M2e antilichamen behandeld werden was een effect van de boost 
vaccinatie merkbaar. Dit is een interessante vaststelling die suggereert dat de behandeling met M2e 
immuun serum de CD8
+
 T cellen duwt in de richting van terminale differentiatie, welke niet meer kan 
geboost worden door een tweede blootstelling aan antigeen.  
 
De combinatie van een recombinant influenza virus met een voorafgaande M2e behandeling is een 
eerder onpraktische oplossing voor een HRSV vaccin bij de mens. Hiervoor zou de te vaccineren 
persoon anti-M2e immuniteit moeten bezitten, verkregen door hetzij actieve influenza vaccinatie of 
door middel van passieve toediening van anti-M2e antilichamen zoals in de muizenstudie werd 
gebruikt. In het bijzonder bij jonge kinderen is een actieve influenza vaccinatie voorafgaand aan de 
HRSV vaccinatie niet aangewezen, aangezien dit de periode dat het kind extreem vatbaar is voor 
HRSV infecties zou verlengen. Het passief toedienen van monoclonale antilichamen zou een snellere 
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mogelijkheid zijn. Deze strategie werd tot op heden echter nog niet toegepast voor een menselijk 
vaccin waardoor het eerder onwaarschijnlijk lijkt dat de combinatie van een anti-M2e 
voorbehandeling gevolgd door een vaccinatie met het recombinant influenza virus zal aanvaard 
worden als HRSV vaccin voor jonge kinderen. Daarom zou afzwakking van de vector een alternatieve 
oplossing kunnen bieden voor het onderdrukken van de vector-gemedieerde ziekte. In deze thesis 
werden twee strategieën voor het verzwakken van influenza virus onderzocht. In een eerst strategie 
werd een influenza virus gegenereerd met een codon-paar gedeoptimaliseerd HA en NP gen (28). Bij 
codon-paar deoptimalisatie wordt de wild type aminozuur sequentie van de eiwitten behouden, 
echter door de niet-optimale codon paren verloopt synthese van deze eiwitten op een trager tempo 
met verminderde virus vermeerdering tot gevolg. Een recombinant influenza virus met het HRSV F85-
93 CTL epitoop in de NA stam en een codon-paar gedeoptimaliseerd HA en NP gen was echter slechts 
matig verzwakt in muizen. Doch er werd eerder reeds aangetoond dat toevoegen van een derde 
codon-paar gedeoptimaliseerd gen, bvb. PB1, de in vivo afzwakking van het recombinant virus 
drastisch verhoogt (29). 
Een tweede strategie die resulteert in een afgezwakte influenza virale vector is het inkorten van het 
NS1 eiwit. Men heeft reeds aangetoond dat influenza virussen met NS1 eiwitten ingekort langs de 
cytoplasmatische zijde verzwakt zijn in meerdere diermodellen (30, 31). Bijkomend hebben we de 
coderende sequentie van GFP toegevoegd aan het NS1 gen, dit niet zozeer als additioneel 
afzwakkend element, maar hoofdzakelijk om het verloop van een infectie met dit recombinant virus 
zowel in vivo als in vitro te kunnen volgen. Zo’n verzwakt recombinant influenza virus werd gecreëerd 
met een verkort NS1 gevolgd door de GFP coderende sequentie, in combinatie met een 
neuraminidase eiwit met het HRSV F85-93 CTL epitoop in de stam. We slaagden erin dit virus te 
generen en konden aantonen dat dit virus leefbaar is, stabiel is in vitro en ongeveer tienvoudig 
verzwakt is ten opzichte van niet verzwakt PR8/NA-F85-93 virus in muizen. Een levend verzwakt 
influenza virus dat een HRSV CTL epitoop draagt, zoals hier werd beschreven, kan gebruikt worden 
als een vaccin tegen zowel HRSV als influenza. Eerst zal echter moeten nagegaan worden of deze 
verzwakte virussen nog steeds een CTL immuun antwoord opwekken tegen HRSV dat van 
vergelijkbare grootte orde is als bij het niet-verzwakt virus.  
Zoals bij elke nieuwe technologie, zullen eerst een aantal zaken opgehelderd moeten worden 
alvorens het PR8/NA- F85-93 virus zal kunnen gebruikt worden als levend vaccin in de menselijke 
populatie. Virale vectoren die in hun normale toestand de mogelijkheid bezitten om mensen te 
infecteren moeten voldoen aan sterke veiligheidsvereisten. Aangezien het PR8/NA- F85-93 virus geen 
verzwakkingselementen bezit is het eerder onwaarschijnlijk dat dit virus onder deze vorm zal 
geaccepteerd worden voor gebruik in mensen, zelfs in M2e immune mensen. Elementen die het virus 
afzwakken zijn noodzakelijk, zeker wanneer het vaccin bestemd is voor gebruik bij jonge kinderen. 
Levend verzwakte influenza virussen worden reeds gebruikt als vaccin tegen influenza, maar niet bij 
kinderen onder de leeftijd van 2 jaar (32). Dit toont aan dat, voordat een recombinant influenza 
virus, als drager van een vreemd antigeen, hetzij van HRSV afgeleid, hetzij van een ander pathogeen, 
kan gebruikt worden als vaccin bij kinderen, er zal moeten aangetoond worden dat het vaccin 
extreem veilig is. Echter, “als” een verzwakt recombinant influenza virus, dat HRSV CTL epitopen 
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presenteert, kan gevonden worden dat voldoende veilig is en een sterk immuun antwoord opwekt, 
heeft zo’n vaccin een grote kans om geaccepteerd te worden als vaccin voor jonge kinderen (26): 
immers, de enige vaccins die na de fatale klinische proeven met het FI-RSV vaccin werden gebruikt bij 
kinderen jonger dan 2 maand waren levende verzwakte virussen (33, 34). 
Een bijkomend nadeel van het gebruik van influenza virus als vaccin drager is zijn beperkte 
coderende capaciteit, wat inhoudt dat er weinig ruimte is voor het aanbrengen van vreemde 
antigenen. Om influenza virus te gebruiken als vector voor het opwekken van een HRSV CTL immuun 
antwoord bij de mens moeten meerdere menselijke CTL epitopen aangebracht worden in het virus 
die kunnen herkend worden door de meerderheid van de HLA subtypes. Het aantal residuen dat kan 
worden aangebracht in de NA stam is echter beperkt (35, 36). Andere strategieën zullen nodig zijn 
om grote inserties toe te laten. Het vervangen van een volledig influenza gen door een reeks 
menselijke CTL epitopen is een mogelijkheid (37, 38). Hiervoor hoeft men enkel de nodige inpak 
signalen van het influenza gen-segment aan te brengen en het verwijderde gen te voorzien in trans. 
Bovendien omzeilt men zo (gedeeltelijk) de veiligheidsproblemen, omdat de deletie van een 
essentieel gen ervoor zorgt dat het influenza virus zich niet meer kan vermeerderen in mensen. 
Het eerste recombinante influenza virus dat vreemde antigenen draagt werd reeds meer dan 20 jaar 
geleden beschreven, maar tot op heden is nog geen recombinant influenza virus getest voor gebruik 
bij mensen. Dit toont aan dat het gebruik van influenza virus als levende virale drager een moeilijke 
uitdaging is. Als alternatief zouden andere virussen kunnen gebruikt worden die een grotere kans 
hebben om aanvaard te worden voor menselijk gebruik. Recombinante virussen als Adenovirus, 
Vaccinia virus en Modified vaccinia virus Ankara worden momenteel reeds getest in klinische 
proeven als vaccin tegen o.a. HIV, influenza virus, Plasmodium falciparum en Mycobacterium 
Tuberculosis (39). Het grote voordeel van influenza virussen tegenover deze andere virussen voor het 
gebruik als virale vector is de antigenische variabiliteit die influenza virussen bezitten. Dit is vooral 
van belang wanneer één of meerdere boost vaccinaties nodig zijn. Indien hetzelfde virus wordt 
gebruikt voor de boost vaccinatie als tijdens de eerste vaccinatie kan het vaccin snel geneutraliseerd 
worden door antilichamen gericht tegen de oppervlakte eiwitten van het vaccin virus, die werden 
opgewekt tijdens de eerste vaccinatie. Wanneer mijn influenza gebruikt als virale vector kan dit 
probleem vermeden worden door te boosten met een vaccin stam die een verschillend 
neuraminidase en hemagglutinine eiwit bezit als de stam die werd gebruikt voor de eerste vaccinatie. 
Het toekomstige HRSV vaccin: zal men het ooit vinden? 
Meer dan 60 jaar aan onderzoek heeft nog niet geleid tot de ontwikkeling van een geschikt kandidaat 
HRSV vaccin. Waarom is het zo moeilijk om een vaccin te ontwikkelen dat beschermt tegen een HRSV 
infectie? Er zijn verschillende factoren die de ontwikkeling van een HRSV vaccin bemoeilijken. Een 
eerste groot nadeel is het ontbreken van een goed diermodel dat de ziekteverschijnselen van een 
HRSV infectie in mensen waarheidsgetrouw kan nabootsen. HRSV dierenproeven kunnen ons 
aanwijzingen geven van wat er mogelijks kan gebeuren bij mensen, maar ze geven ons zelden het 
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volledige plaatje, en vaak worden er verschilleden resultaten waargenomen in dieren ten opzichte 
van mensen. Een goed voorbeeld hiervan is dat CD8
+
 T cellen bij muizen bijdragen tot de pathologie 
(20), terwijl dit nog niet werd waargenomen bij mensen (40). Aangezien het ontwikkelen van één 
enkel diermodel dat alle ziekteverschijnselen bij een humane HRSV infectie volledig kan nabootsen 
een utopie is, blijft het testen van vaccins in meerdere diermodellen de enige overgebleven 
mogelijkheid. Een tweede factor die de ontwikkeling van een HRSV vaccin bemoeilijkt houdt verband 
met de belangrijkste doelgroep voor dit vaccin, nl. pasgeboren baby’s van 1 à 2 maanden oud. Het 
immuun systeem in deze jonge kinderen is nog onderontwikkeld vergeleken met volwassenen en het 
immuun antwoord dat wordt opgewekt is hoofdzakelijk gestuurd in de Th2 richting, hetgeen moet 
vermeden worden voor HRSV vaccins. Hierbij moet wel opgemerkt worden dat deze dominantie van 
het Th2 immuun antwoord meer uitgesproken is bij jonge muizen dan bij baby’s. Bij deze laatste 
wordt vooral vastgesteld dat het CTL immuun antwoord minder groot is vergeleken met 
volwassenen, maar onder de juiste omstandigheden is het mogelijk om een Th1 immuun antwoord 
op te wekken (41). Tevens bezitten jonge kinderen vaak nog maternale anti-HRSV antilichamen, die 
mogelijks vaccins kunnen afschermen van het immuun systeem en zo efficiënte vaccinatie 
verhinderen (42). Dit betekent echter niet dat het onmogelijk is kinderen te vaccineren op jonge 
leeftijd: in België wordt, net als in vele andere landen, gestart met vaccinatie vanaf de leeftijd van 6 
weken (43). De richtlijnen van het WHO schrijven voor dat kinderen op de leeftijd van 6 à 8 weken 
mogen gevaccineerd worden tegen rotavirus, polio, difterie, tetanus, Haemophilus influenzae, 
kinkhoest en hepatitis B (44). Bovendien kunnen kinderen van de moeder geïnfecteerd is met 
hepatitis B of Mycobacterium tuberculosis een vaccin krijgen tegen deze ziekte zodra ze 24 uur oud 
zijn (45, 46). Deze gegevens tonen aan dat het mogelijk is om kinderen reeds in de eerste twee 
maanden van hun leven te vaccineren. Een derde en misschien wel belangrijkste factor die de 
ontwikkeling van een HRSV vaccin bemoeilijkt is het HRSV virus zelf en het immuun antwoord dat het 
opwekt. HRSV heeft meerdere strategieën ontwikkeld om te ontkomen aan het aangeboren immuun 
systeem van de gastheer. Zo werken de niet-structurele eiwitten, NS1 en NS2, samen om expressie 
van interferon-geassocieerde genen te verhinderen door interacties met IRF-3 en Stat2 (47, 48). 
Bovendien verhindert HRSV signalering via TLRs door interacties met MyD88 en MAVS en verstoort 
het signalering via RIG-I (49, 50). Er bestaan vele andere voorbeelden en het doorgronden van deze 
processen en de gevolgen die ze hebben op het immuun antwoord is noodzakelijk voor de 
ontwikkeling van een veilig HRSV vaccin. Bovendien wekt HRSV geen langdurig immuun antwoord op. 
Daarom is een beter begrip van de vorming immunologisch geheugen na een HRSV infectie 
noodzakelijk voor de ontwikkeling van vaccins die efficiënt langdurige immuniteit opwekken. 
Tenslotte is het noodzakelijk om de processen die verantwoordelijk zijn voor de verergering van de 
ziekte na een FI-RSV vaccinatie te doorgronden. Alleen wanneer de oorzaak van deze 
ziekteverergering duidelijk is zal het rationeel ontwerpen van een vaccin zonder deze complicatie 
mogelijk zijn.  
Wanneer we terugkijken naar alle reeds geprobeerde vaccin strategieën tegen HRSV kunnen we deze 
ruwweg indelen in drie categorieën. Een schematische voorstelling is weergegeven in figuur 7.2. 
Langs één zijde van het spectrum vinden we de geïnactiveerde vaccins, met het FI-RSV vaccin aan het 
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extreem linkse uiteinde. Omwille van de ziekteverergering die door dit vaccin werd veroorzaakt is het 
niet geschikt als HRSV vaccin. In dezelfde groep, maar iets meer naar rechts, vinden we de 
geïnactiveerde subunit vaccins, waarvan bij sommigen eveneens ziekteverergering werd vastgesteld, 
evenwel niet zo extreem als bij het FI-RSV vaccin. Aan de andere zijde van het spectrum vinden we 
de tweede groep vaccins, nl. de levend verzwakte HRSV vaccins. De eerste generatie van deze vaccins 
hadden te kampen met veiligheidsproblemen: indien niet voldoende verzwakt was het vaccin nog in 
staat om ziekte te veroorzaken. Deze 2 groepen vormen de uiteinden van het spectrum en zijn niet 
geschikt als HRSV vaccin. Tussen deze twee groepen vinden we de derde groep die bestaat uit allerlei 
vaccinatie strategieën (zoals recombinante virale vectoren, virus-achtige partikels, virale vectoren die 
niet meer in staat zijn te vermeerderen enz.) waarvan het minder duidelijk is waar exact ze op de 
schaal moeten geplaatst worden. De smalle groene zone, centraal gelegen tussen de geïnactiveerde 
vaccins en de levende verzwakte virussen stelt het “ideale” HRSV vaccin voor, dat tot op heden nog 
niet werd gevonden. Dit ideaal vaccin moet naast een antilichaam immuun antwoord een T cel 
immuun antwoord opwekken en langdurige bescherming garanderen, zonder risico op 
ziekteverergering. Hierbij moet wel opgemerkt worden dat, omwille van de verschillen in 
immunologische staat van de verschillende leeftijdsgroepen het eerder onwaarschijnlijk is dat één 
vaccin bescherming zal kunnen bieden aan iedereen. Waarschijnlijk zal voor elke leeftijdsgroep een 
verschillend vaccin moeten ontwikkeld worden. De toekomst zal uitwijzen of het mogelijk is om een 
veilig en doeltreffend HRSV vaccin te vinden. 
Figuur 7.2 Schematische weergaven van kandidaat HRSV vaccins. 
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Dankwoord 
Eindelijk, het is af! Ik kan het afronden van dit doctoraat niet beter vergelijken als met een zware 
beklimming, te voet of met de fiets, zoals ik er al wel enkele gedaan heb: het is lastig, onderweg stel 
je jezelf de vraag ‘waarom’ je dit precies doet, je twijfelt, maar er zijn anderen die je overhalen toch 
door te zetten en de opluchting eens je de top bereikt is onbeschrijflijk. Ik ben een aantal mensen 
dan ook terecht een bedankje verschuldigd voor de hulp en steun om deze ‘top’ te bereiken. 
Bedankt Xavier, om me de kans te geven te doctoreren in je labo. Ik heb het altijd fijn gevonden dat 
ik het beste van 2 werelden, influenza en RSV, kon combineren. Ook je suggesties bij het lezen van 
deze thesis werden steeds geapprecieerd. Professor Fiers, bedankt voor uw wetenschappelijk advies. 
Ik heb bewondering hoe u nog steeds met zoveel overgave de wetenschap volgt. 
Natuurlijk wil ik iedereen van het labo bedanken. De persoon die ik de dikste merci verschuldigd ben 
is toch wel Bert. Het schrijven van dit doctoraat heb ik dan misschien wel in m’n eentje gedaan, maar 
al het werk dat eraan vooraf gegaan is toch mede dankzij jouw: je kwam steeds weer met nieuwe 
ideeën… en als ik soms dacht dat de resultaten van een experiment niet goed waren zag jij er meestal 
toch het positieve van in. Ik bewonder hoe je met duizend-en-één dingen bezig bent, met alle project 
mee denkt en altijd weer met nieuwe ideeën op de proppen kan komen. Ik weet niet waar ik zou 
gestaan hebben zonder jouw. Echt bedankt! En dan is er Judith, mijn maatje ☺, bij wie ik altijd 
terecht kan voor een babbel, al dan niet wetenschappelijk. De vele gezellige babbels over Grey, 
vakantie en nog zo veel meer waren ideaal om mijn gedachten te verzetten. Maar ook 
wetenschappelijk gaf je soms net die ene tip die ik nodig had. Samen met Tine was het daar best 
gezellig in onze hoek. Jammer dat je nu verhuisd bent … Als er iemand in het labo is die altijd klaar 
staat om te helpen (ook al is het al bijzonder druk) dan is het Tine wel. Ik was altijd blij als jij het zag 
zitten om wat mee te helpen met longen, milten, muizen wegen en zo veel meer. En  Koen, jij 
stoorde je niet te erg aan ons vrouwenhoekje hé. Bij jouw kon ik dan weer terecht voor een babbel 
over een iets minder vrouwelijk thema: de koers en de hellingen van de vlaamse ardennen. Ik 
bewonder je doorzettingsvermogen: een jaar lang je controles optimaliseren, het is niet iedereen 
gegeven. Hopelijk levert het verdere onderzoek van de screen een positief resultaat op. Silvie, elke 
keer als ik een diepvries dicht doe moet ik aan jouw denken, hoe zou dat komen? Van jouw precisie 
kan ik nog wel iets leren. Bedankt ook voor de vele gezellige momenten. Michel, de encyclopedie bij 
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wie ik altijd terecht kon voor info over statistiek, facs, T-cellen en zo veel meer. Jij hebt me de 
kneepjes van het T-cel werk geleerd. Ik herinner me nog toen we onze eerste elispots deden. We 
hebben toen allebei tot vrij laat bezig gezeten in TC, al was het bij jouw nog een pak later (of zal ik 
zeggen vroeger) dan bij mij. Lang leve de gigantische muisexperimenten. Samen met Bert ook een 
beetje het ‘vuil brein’ van het labo. Ettelijke keren heb ik, toen ik weer eens een smerig lachske 
vanuit jullie richting hoorde, me afgevraagd waarover dat precies ging. Best dat ik het niet altijd 
verstaan heb, denk ik ;-). Aan de ‘verre’ overkant van het labo hebben we dan nog Kenny en Anouk, 
een onafscheidelijk duo. Ik moet bekennen, heel in het begin dacht ik dat jullie een koppel waren: 
elkaar constant plagen, precies een verliefd stel :-p . Kenny, (of is het Kelly?) door jouw is het 
allemaal begonnen. Door de thesis bij jouw had ik de smaak te pakken en wou ik absoluut verder 
doen. Bedankt ook voor je hulp en advies de afgelopen jaren. Anouk, nog zo iemand als Tine, die 
continu bereid is te helpen. Wat zou het labo zijn zonder jouw…  en de koffie/koekskes? Bij mij was 
het niet zo zeer de koffie, maar eerder de witte chocotofs die verslavend waren ☺. We delen ook de 
liefde voor onze favoriete assay: de NA-assay ;-) . Lei, I think you’re the next in line. Good luck with 
your project. When is that first manuscript coming up? Iebe, KiJoon en Liesbeth, bedankt voor de 
fijne momenten samen en veel succes met jullie projecten.  
En dan zijn er nog die vele ex-collega’s. ‘t is opmerkelijk hoeveel namen er in die afgelopen 5,5 jaar 
gepasseerd zijn: Miguel, Farzaneh, Itati, Wouter, Francis, Marina, Fred, Mostafa, Karim, Petra, Els, 
Jonas. Bedankt allemaal voor de vele fijne jaren. En uiteraard Vero en Kimberly: toen jullie weggingen 
was het toch niet meer hetzelfde als ervoor, precies alsof jullie een stukje gezelligheid van het labo 
hebben meegenomen. De vele fijne momenten die we samen beleefd hebben zal ik niet vergeten. De 
‘ladies night’ is een goede traditie die we zeker moeten verder zetten. Wanneer is de volgende?  
Van in het DMBR is er nog één persoon die ik een serieus bedankje verschuldigd ben: Pieter, de LSR-
master! Bedankt voor de vele uren meten en analyseren van mijn stalen. Het was een luxe om een 
plaat aan jouw te kunnen afgeven en nadien een exelletje met resultaten terug te krijgen. Ik heb dit 
pas echt ingezien toen je weg was.  
En dan is er “de bende van de fysica”: Brecht, Christine, Geert, Charlotte, Luc, Ward; en Hanne en 
Bea om samen met mij de eer van de niet-fysici hoog te houden. Bedankt allemaal voor de vele 
memorabele momenten. De etentjes, de weekendjes, de fietsvakantie, de reis naar Nepal, de 
gezelschapspelletjes, de sing-star en let’s dance avonden … waren ideaal om mijn gedachten te 
verzetten, zeker de laatste paar maanden. Ik kijk er met plezier naar terug en hoop dat we dit nog 
verder kunnen blijven doen, ook nu sommigen uit Gent wegtrekken… En om af te sluiten nog eentje 
voor de fysici om over na te denken: In moleculaire biologie is delen en vermenigvuldigen hetzelfde! 
Leg dat maar eens uit met de wetten van de fysica ☺. 
Thuis zijn er ook nog een paar mensen die een bedankje verdienen. Te beginnen met mama en papa. 
Bedankt voor jullie jarenlange onvoorwaardelijke steun. Altijd bleven jullie mij steunen, ook toen 
mijn verblijf in ‘hotel mama’ wat langer leek te duren dan jullie gehoopt/gepland hadden. Ik 
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apprecieer nog altijd dat één van jullie mij ’s avonds mijn avondeten kwam brengen, of mij kwam 
ophalen met de auto, omdat ik tot laat in de avond bezig was met mijn cellen. Ook aan Ben en Ruth, 
bedankt om er te zijn. Ben, ik heb er altijd van genoten om samen met jou over het zwemmen te 
babbelen. Jammer dat ik er heb moeten mee stoppen. En zus, aan jouw ben ik nog mijn excuses 
verschuldigd: sorry voor al de keren dat mijn wekker op zaterdagochtend is afgegaan, terwijl ik er 
niet was, en jij bijgevolg om 7u op een zaterdag moest opstaan. Ik zal het nooit meer doen ;-). Ook 
Oma en Opa, en de rest van de familie, bedankt voor de vele gezellige familie-momenten en de 
Banjaarden. 
Dan is er nog één iemand die ik niet mag vergeten: mijn schattie. Jij bent degene die ervoor gezord 
heeft dat ik de top van de berg bereikt heb, zowel letterlijk als figuurlijk: zonder jouw had ik de top 
van de Gokyo Ri nooit bereikt, maar ook het einde van dit doctoraat heb ik aan jouw te danken. Jouw 
aanmoedigende woorden, als ik het even niet meer zag zitten, brachten mij er steeds weer boven op. 
Maar daarvoor heb ik je dan ook gekozen ☺ . Ik hoop dat we samen nog veel toppen mogen 
beklimmen… . Dikke kus! 
 
Aan iedereen: Bedankt! 
 
    Sarah
